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SUMMARY.
INTRODUCTION.
Breathlessness and fatigue are the characteristic symptoms of chronic heart failure (CHF). 
Their quantification during submaximal exercise may be of value in the evaluation of 
patient disability and the impact of drug treatment Since these symptoms are commonly 
experienced during the submaximal levels of exercise involved in everyday activities, it 
was deemed appropriate to assess subjective scales during submaximal exercise and to 
compare physiological variables with these subjective scales to establish if any 
relationship existed between them.
Exercise testing in cardiology is commonplace and encompasses a variety of exercise 
protocols and subjects with wide ranging fitness capability. A new exercise protocol 
(STEXT protocol) has been developed which accommodates a wide range of fitness levels 
within a relatively short time period. Thus, it was considered appropriate to evaluate the 
symptomatic and physiological responses to this protocol.
This thesis is based on a series of studies which were designed to investigate the role of 
exercise testing in cardiology. The primary aims of the three studies reported in this thesis 
were to examine the reproducibility and (where appropriate) sensitivity to change of 
subjective scales for breathlessness and general fatigue. The sensitivity of the subjective 
scales was assessed using beta blockade to promote a sensation of breathlessness and 
general fatigue. In addition, an examination of a possible link between physiological 
variables and the subjective scales was carried out. The impact of beta blockade on 
physiological variables was also examined.
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STUDY ONE.
A COMPARISON OF THE REPRODUCIBILITY AND SENSITIVITY TO 
CHANGE OF VISUAL ANALOGUE, BORG CR10 AND LIKERT SCALES.
The main aims of this study were to:
1) assess which subjective scale if any, is most reproducible and sensitive to 
change in the assessment of symptoms.
2) determine the magnitude of the visit and therapy effects of the subjective 
scales and physiological variables
3) compare the subjective scales with the physiological responses to exercise.
Twenty three physically active male subjects (mean S.D. age 30.3. ± 6.5 years) were 
recruited. Gas collection was continuous throughout all exercise tests and heart rate was 
recorded every minute. The subjects were given an incremental VO2  max test and a 
submaximal economy test so that relative intensities could be calculated. The subjects 
were studied on four occasions. Three subjective scales were used - (1) Visual analogue 
(VAS) (continuous scale) (2) Borg CR10 scale (12 fixed points) and (3) Likert scale 5 
fixed points). Four identical submaximal tests were given (2 minutes at 60% VO2  max 
and 6 minutes at 70% VO2  max). Two tests were undertaken to assess reproducibility of 
scores obtained with each subjective scale. Two other tests were undertaken to assess 
sensitivity of each scale to a change in symptom perception. Here a double blind 
treatment with propranolol 80 mg (to increase the sensation of breathlessness and general 
fatigue during exercise) or matching placebo was given. All four tests were allocated 
using a Latin rectangle design and took place within 7 days of each other. The subjective 
scale scores were measured at 2, 6 and 8 minutes of exercise.
Reproducibility was defined as the proportion of total variance (i.e. between plus within 
subject variance) explained by the between subject variance given as a percentage. 
Sensitivity was defined as the effect of the active drug therapy over the variation within 
subjects.
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RESULTS.
SUBJECTIVE SCALES.
Overall the VAS performed best in terms of reproducibility for breathlessness and general 
fatigue. For sensitivity the VAS was best for breathlessness and the Borg CR10 scale was 
most sensitive for general fatigue, e.g. the Table SI shows the values for reproducibility 
and for sensitivity with 95% confidence intervals for each subjective scale for 
breathlessness at 6 minutes:
Table SI.
Reproducibility and Sensitivity with 95% Confidence Intervals for each Subjective 
Scale for Breathlessness at 6 minutes.
Scale Reproducibility Sensitivity
VAS 74% (59-86)* 2.7* (2.4, 3.0)
Borg CR10 42% (33-66) 2.0 (1.6, 2.4)
lik e r t 55% (38-80) 2.6 (2.2, 3.0)
VAS significantly different from Borg CR10.
PHYSIOLOGICAL VARIABLES.
The VO2  max (mean S.D.) of the subjects was 56.9 (4.9) ml.kg'^min- .^ On the placebo 
trial the relative percentage of maximum was 70.8%. A generalised linear model was 
used to examine if there were any systematic effects for the following: visit, within subject 
between subject and therapy effect. There were no significant differences among the "non 
therapy interventions". There were significant therapy effects for the following variables:
VE - after three minutes the active treatment was significantly higher than the other three 
"interventions".
VO2  - the active treatment was significantly lower than the other three "interventions" 
until the last 2 minutes.
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VCO2  - in minutes 1 and 2 the VCO2  was significantly lower than the other 3 
"interventions" and at minute 8 was significantly higher than the other 3 "interventions".
Frequency of breathing - after 2 minutes the frequency of breathing was significantly 
higher than the other three "interventions".
Heart rate - heart rate was significantly lower for the active treatment compared with the 
other 3 "interventions" at all timepoints during exercise.
VE/VO2  and VE/VC02 - the active treatment was significantly higher than the other 3 
"interventions" for both these variables at all timepoints during exercise.
RER - the active therapy raised the RER at all timepoints throughout exercise compared 
with the other 3 "interventions".
Tidal volume - the only significant results were at 2 and 6 minutes when the active therapy 
was significantly higher than replicate 2.
RELATIONSHIP BETWEEN PHYSIOLOGICAL VARIABLES AND 
BREATHLESSNESS AND GENERAL FATIGUE.
It was decided that the best way to indicate which perception of symptom was best related 
to each physiological variable was to evaluate individual subject correlations based on all 
observations for each subject. Once these correlations were evaluated, the correlations 
across all the subjects was taken as an overall measure of the relationship between 
variables.
For VE, VO2 , VCO2  and heart rate and all the subjective scales, correlations were above 
0.9. For the other physiological variables, (apart from VE/VCO^ and the subjective
scales, correlations were above 0.75. There was no significant difference in some 
physiological variables, (eg VE, VO2 , VCO2  and frequency of breathing) between 6 and 8 
minutes. Despite this stability in the physiological variables, the scores for the subjective 
scales increased. These findings suggest that there is not a direct association between the 
perception of symptoms and physiological variables.
CONCLUSION.
In conclusion, this study suggests that subjective scales can reproducibly measure 
symptoms during exercise and detect the effect of a drug intervention. The VAS and Borg 
CR10 scales appear to be the best subjective scales for this purpose. The active 
treatment had a lowering effect on heart rate and increased several respiratory variables 
including ventilation, frequency of breathing, RER and VCO2  VE/VO2 , and VE/VCO2  
at some or all timepoints. At some timepoints VO2  and VCO2  were reduced. Some 
physiological variables had very high correlations with the subjective scales 
(breathlessness and general fatigue).
As the VAS and Borg CR10 scales performed best in this study, it was decided to evaluate 
the reproducibility of these scales in patients with chronic heart failure.
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SYMPTOMATIC AND PHYSIOLOGICAL RESPONSES TO SUBMAXIMAL 
EXERCISE IN CHRONIC HEART FAILURE.
A large number of exploratory tests were conducted to determine a range of
appropriate relative intensities and to devise a method of selecting relative intensities.
Thereafter, a pilot study was carried out
CHF PILOT STUDY.
Six subjects with CHF (NYHA I & n) were studied. Each undertook 2 baseline
maximal incremental treadmill tests. Submaximal tests were undertaken 1, 2 ,4  and 6
weeks later. Each consisted of 6 minutes at 3 workrates (65%, 73% and 83% of peak
VO2 ). During each stage of the submaximal test, patients recorded their symptoms of
breathlessness and general fatigue rising computer automated VAS and Borg CR10
scales. Reproducibility was defined as the proportion of total variance (i.e. between
plus within subject variance) explained by the between subject variance given as a
percentage. Reproducibility coefficients for the three workrates are given in Table
S2.
Table S2.
Reproducibility coefficients for the Visual Analogue (VAS) and Borg CR10 
Scales (Breathlessness and General Fatigue) at three relative intensities.________
Relative Intensity
Breathlessness 
VAS BorgCRlO
General
VAS
Fatigue
Borg
(%Peak V 02) 
65% 78% 43% 55% 39%
74% 63% 65% 67% 60%
83% 82% 72% 81% 71%
There were no significant differences between the scales for breathlessness or general 
fatigue at any timepoint.
The subjective scales used were found to be as reproducible in patients with CHF as 
they were in treadmill familiar normal volunteers (see previous study). 
Reproducibility was best at higher workrates. Overall the VAS tended to be the more 
reproducible scale. The fairly prolonged procedure employed to determine 
appropriate workrates was considered to be a disadvantage. It was decided to use the 
VAS and Borg CR10 scales linked to a constant workrate treadmill protocol.
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STUDY TWO.
SYMPTOMATIC AND PHYSIOLOGICAL RESPONSES TO SUBMAXIMAL 
EXERCISE IN CHRONIC HEART FAILURE CHRONIC HEART FAILURE.
The aims of this study were to:
1) determine the reproducibility of VAS and Borg CR10 scales in CHF 
patients.
2) determine a method of establishing a constant workrate test which 
resulted in a symptom limited endpoint between 8 and 17 minutes and 
thus be of value in a clinical setting.
3) identify the relative intensities of the patients during the constant work 
rate test.
4) examine the relationship between the physiological variables and 
subjective scales during the constant work rate tests.
Ten patients with CHF (NYHA I&II) were studied. Based on 2 maximal incremental 
treadmill tests an individual protocol using a constant workrate at a submaximal 
intensity was derived using a diagrammatic aid. The projected treadmill time was 
between 8 and 17 minutes. Tests were carried out 1, 2 ,4 and 6 weeks after the 
maximal tests. Every two and a half minutes during the submaximal tests patients 
recorded their symptoms of breathlessness and general fatigue using computer 
automated VAS and Borg CR10 scales. Gas collection was continuous and heart rate 
was monitored at the end of each minute. Reproducibility was defined as the 
proportion of total variance (i.e. between plus within subject variance) explained by 
the between subject variance given as a percentage.
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RESULTS.
SUBJECTIVE SCALES.
Table S3 shows the reproducibility coefficients with 95% confidence intervals for 
each subjective scale for breathlessness and general fatigue.
Table S3.
Reproducibility Coefficients and 95% Confidence Intervals for Visual Analogue 
and Borg Scales for Breathlessness and General Fatigue.
REPRODUCIBILITY.
Breathlessness
Time
Scale 2.5 Min 5.0 Min 7.5 Min 10.0 Min
VAS 82%
(58,91)
83%
(61,92)
68%
(36,83)
66%
(22,78)
Borg CR10 51%
(16,73)
48%
(13,70)
46%
(11,69)
38%
(-0.57)
General Fatigue
Time
Scale 2.5 Min 5.0 Min 7.5 Min 10.0 Min
VAS 77% 86% 83% 81%
(51,89) (66,93) (60,92) (48,82)
Borg CR10 51% 77% 64% 46%
(17,73) (50,89) (32,81) (6,64)
Confidence intervals are in brackets beneath each estimate of reproducibility.
There were no significant differences between the scales for breathlessness and 
general fatigue at any timepoint.
PHYSIOLOGICAL VARIABLES.
The peak VO2  (mean S.D) of the patients was 20.6 + (4.2.) ml.kg"^ .min"^ . The 
mean relative intensities for VO2 , VE and heart rate were 89.3%, 92.5% and 98.5%
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respectively. The mean (S.D.) endurance time (seconds) for tests 1 ,2  3 and 4 were 
609 (159), 715 (218), 615 (295) and 713 (214) respectively. A reproducibility 
coefficient of 51% was calculated for endurance time for all constant workrate tests. 
This figure increased to 76% when the first test of subject 6 is excluded. Subject 6 
increased his endurance time from 7 minutes to 17 minutes from test 1 to test 2.
RELATIONSHIP BETWEEN SUBJECTIVE SCALES AND 
PHYSIOLOGICAL VARIABLES.
The highest correlations were between heart rate and the subjective scales (around 
0.8). Correlations for all the subjective scales and the respiratory physiological data 
(except VO2 ) were not particularly good and indicate a fairly poor relationship 
between these variables.
CONCLUSION.
It can be concluded that, overall, the VAS tended to be more reproducible than the 
Borg CR10 scale over the four submaximal tests. The method of selecting the 
workrate for the submaximal test (to elicit an endurance time of between 8-17 
minutes) was appropriate for most patients. The CHF patients exercised at very high 
relative intensities during the submaximal tests. The relationship between the 
respiratory physiological variables and the subjective scales was generally quite poor.
The use of the above exercise protocol with the VAS can offer a useful means of 
evaluating symptoms in CHF and potentially their response to treatment.
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STUDY THREE.
AN EVALUATION OF THE STEXT PROTOCOL.
There is no common exercise protocol for all categories of cardiac patients. A 
protocol with an exponential rise in energy cost (STEEP) was devised to encompass 
the anticipated energy cost range of cardiac patients so that treadmill times did not 
exceed 15 minutes. The STEEP protocol was extended to 18 minutes to 
accommodate the anticipated higher fitness levels in a population study of 2000 West 
of Scotland normal subjects (MONICA Study). This extension was called the STEXT 
protocol. The STEEP protocol has also been adopted by a number of clinicians and 
researchers. It has also been proposed to use the STEXT protocol to evaluate drug 
treatment in a group of angina subjects. No evaluation of the reproducibility or 
sensitivity to change of the physiological variables or subjective scales has been 
undertaken.
It was decided to assess the STEXT protocol using a drug trial format i.e. the number 
and timing of the tests simulated a possible drug trial time scale and sequence of 
events. Propranolol was selected to induce an increase in the perception of 
breathlessness and general fatigue.
The main aims of this study were to:
1) assess which subjective scale (VAS or Borg CR10) if any, is decidedly 
more reproducible and sensitive to change in the assessment of 
symptoms.
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2) determine the magnitude of the visit and therapy effects of the 
subjective scales and the physiological variables.
3) assess the reproducibility of maximal physiological values.
4) compare the subjective scales with the physiological responses to 
exercise.
Twelve healthy males (mean S. D.) (age 32.8 ±  8.9) who took part in regular exercise 
were recruited. The subjects performed a treadmill exercise test (STEXT) on 8 
occasions. Pairs of tests were carried out (48 hours apart) at weeks 0 ,2 ,6  and 10. At 
weeks 6 and 10 subjects were given placebo or 80 mg of propranolol 12 and 2 hours 
before testing (to increase the sensation of breathlessness and general fatigue during 
exercise). During the test, subjective scales for breathlessness and general fatigue 
were presented using computer automated scales at 2 mins 10 seconds and every 2 
minutes thereafter until the end of the test when the subjects responded to record their 
symptoms at maximum. VAS and Borg CR10 scales were used. Six subjects 
received a VAS/Borg CR10 sequence and six a Borg CR10/VAS order of 
presentation.
RESULTS.
SUBJECTIVE SCALES.
Reproducibility was defined as the proportion of total variance (i.e. between plus 
within subject variance) explained by the between subject variance given as a 
percentage. At the first two timepoints reproducibility was low for both scales for 
breathlesness and general fatigue. Thereafter, to maximum, reproducibility for 
breathlessness and general fatigue was generally between 75-85%. These values 
compare favourably with the previous study using steady state exercise with normal
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subjects. There were no significant differences between the scales. The VAS and 
Borg CR10 scales were generally significantly sensitive between the fifth and seventh 
timepoints. Sensitivity ratios (treatment effect/variation within subjects) were low 
compared with the "steady state" study and ranged between 0.02 to 1.7. There were 
no significant differences between the scales for sensitivity.
MAXIMAL PHYSIOLOGICAL VALUES.
The VO2  max (mean S.D.) of the subjects was 56.5 ±  5.8 ml.kg.~l m ^ -l There 
were no differences among the 6  non-propranolol tests for the maximal physiological 
variables. Reproducibility coefficients ranged between 43% to 96%. Generally 
reproducibility was considered to be good. Examples of reproducibility coefficients 
were 79% for exercise time and 76% for VO2  max. Both propranolol tests showed 
significant decreases for heart rate, VO2  VCO 2 VE, and endurance time.
SUBMAXIMAL PHYSIOLOGICAL VARIABLES.
There was a therapy effect for the following variables:
VE - on the "active" therapy there was a significant decrease in VE at minute 8  and a 
significant increase in VE at minutes 14 and 15.
VC>2 - VO 2 was significantly decreased throughout the entire exercise protocol on 
the "active" therapy.
VCO2  - VCO 2 was significantly lowered at minute 8  and significantly increased 
at minute 15 on the "active" therapy.
Frequency of breathing/tidal volume - frequency of breathing and tidal volume were 
significantly increased at minutes 14 and 15 on the "active" therapy.
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Heart rate - heart rate was lowered throughout the entire exercise protocol on the 
"active" therapy.
VE/V(> 2  - VE/VO 2 was significantly increased from minutes 10 - 15 on the 
"active" therapy.
VE/VCO2  - VE/VCO 2  was significantly increased from minute 12-15 on the 
"active" therapy.
RER - RER was significantly raised at minute 1 and from minutes 10-15 on the 
"active" therapy.
RELATIONSHIP BETWEEN THE PHYSIOLOGICAL VARIABLES AND 
SUBJECTIVE SCALES.
The correlations for VE and VCO2  were all over 0.8 for both the VAS and Borg 
CR10 scales (breathlessness and general fatigue). Apart from VE/VO2  and 
VE/VCO2  all other correlations were over 0.7.
CONCLUSION.
This study suggests that subjective scales can reproducibly measure symptoms during 
incremental exercise and detect the effect of drug intervention. It is concluded that 
maximal physiological variables were reproducible over a projected drug trial time 
period. The maximal physiological variables and the submaximal physiological 
variables were affected by the intervention of propranolol. VO2  max, VCO2  max, 
VE max, maximum heart rate and endurance time were among the variables 
significantly reduced after propranolol. For the latter submaximal stages of the test, 
there were significant increases in VE, frequency of breathing, tidal volume, VE/VO2  
and RER. On the "active" therapy, there was a significant decrease in VO2  
throughout the test with beta blockade. The relationship between some physiological 
variables and the subjective scales was good. The STEXT test could be used to 
evaluate aerobic fitness reproducibly.
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CHAPTER 1 
SECTION ONE.
INTRODUCTION
1.1.1. SYMPTOMS AND EXERCISE TESTS.
In most cardiac conditions patients have symptoms during exercise. Quantification of 
symptoms during exercise is therefore valuable in assessing both the patient's condition 
and the efficacy of drug intervention. Exercise testing has been applied to various 
categories of cardiac patients to help evaluate current status, predict prognosis and to 
monitor the effect of drug treatment
In this thesis a series of studies were designed to investigate the role of exercise testing 
using subjective scales in the assessment of cardiac patients.
1.1.2. HEART FAILURE.
In pathophysiological terms Braunwald, (1988) describes heart failure as "an inability of 
the heart to deliver blood (oxygen) at a rate commensurate with the requirements of the 
metabolising tissues despite normal or increased ventricular filling pressures (or can only 
do so at the expense of increased ventricular filling pressures - 'diastolic dysfunction')". 
The underlying pathophysiology in chronic heart failure (CHF) is complicated and it is not 
surprising that many physicians find CHF difficult to define. However, CHF in most 
patients is associated with depressed systolic function of the left ventricle (LV) secondary 
to myocardial damage or necrosis which has resulted from myocardial infarction, 
infection, toxic, metabolic or idiopathic causes. The response of the body to heart failure 
involves a number of compensatory mechanisms which include LV hypertrophy and 
dilatation, changes to central hemodynamics, and neuroendocrine stimulation (a collective 
term for a variety of processes including activation of the renin-angiotensin system and the 
sympathetic nervous system leading to peripheral haemodynamic changes involving raised 
peripheral resistance and redistribution of blood flow).
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Chronic heart failure is a relatively common condition in Western society and the 
prevalence of CHF continues to rise (McMurray et al; 1993). The prognosis of heart 
failure is poor, with around a 50% survival rate over a five year period. As CHF results 
from several factors, there is no single treatment for CHF. The introduction of a variety of 
new drugs has prompted renewed efforts to develop new techniques for the demonstration 
of drug efficacy and long term evaluation of patients.
The three main aims of therapy in chronic heart failure are to improve the quality of life 
by making the patient feel better, to enable the patient to be more active and to extend 
survival. While measurement of the effect on mortality is unambiguous, assessment of 
quality of life is more problematic. There is no obvious marker or gold standard by which 
changes in patient status can be readily and accurately assessed. Questionnaires have been 
used to assess the quality of life in several categories of cardiac patients with varied 
success.
1.1.3. EXERCISE TESTS.
Traditionally, cardiologists have used a maximum exercise tolerance test to:
1 ) categorise the severity of heart failure.
2 ) predict prognosis and provide information on the question of
transplantation.
3) assess efficacy of treatment.
The reason for carrying out maximum exercise tests is the hope that CHF patients can 
attain a representative "maximum" which reflects the true limits of the cardiovascular 
system. However, the researcher is often uncertain that a CHF patient has in fact 
produced a maximum effort. Maximum tests are influenced by the motivation of the 
subject and the skill and experience of the test administrator. Some studies have 
highlighted the need to conduct several tests to establish a representative baseline for peak 
oxygen consumption (Elbom et al; 1990).
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An added limitation to the use of maximal tests in the assessment of heart failure is the 
poor correlation between left ventricular function with exercise time and Peak VO % A 
possible explanation for this finding is that maximum oxygen uptake is limited not only by 
cardiac output but also by the delivery of oxygenated blood to the working skeletal 
muscles and the utilisation of oxygen by the working skeletal muscles. A further 
disadvantage of maximum tests in CHF is that they do not relate to the degree of activity 
in everyday life.
Attempts to circumvent these problems have included the measurement of respiratory gas 
exchange during exercise tests (Wasserman, 1990). However, the controversy 
surrounding the ventilatory threshold leaves its usage open to debate. The use of a 
respiratory exchange ratio (RER) value of 1.0 or an extrapolation to maximum using gas 
exchange measurements relies on the patient reaching a RER of 1.0 (Buller and Poole- 
Wilson, 1988). An exercise test which reflects the normal life of CHF patients and can 
evaluate symptoms, may be of great value in the long term monitoring of CHF patients. 
Many clinicians agree that some form of sub-maximal exercise test is desirable.
Since dyspnoea and general fatigue on exertion are limiting symptoms in CHF (Weber et 
al; 1986). It would be of great value to be able to quantify them in order to assess patient 
status and evaluate interventions. Previous research has demonstrated that different 
methods of testing have resulted in a variety of responses. While frusemide and captopril 
produced an increase in total treadmill time in a maximal test, frusemide had a more 
beneficial effect on some sub-maximal indices (Cowley et al., 1986). However, an 
appropriate test methodology involving sub-maximal exercise and subjective scales has 
yet to be established. Furthermore, the test protocol must be shown to be simple, 
reproducible and sensitive to change.
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1.1.4. SUBJECTIVE SCALES AND SUBMAXIMAL TESTS.
A variety of scaling systems have been used to assess dyspnoea, perceived exertion and 
fatigue but it is unclear how the results of studies which have used one scaling system 
relate to possible use with CHF patients. Furthermore, the selection of work intensity for 
submaximal tests in CHF patients is a subject of intense debate. Some leading 
cardiologists have recognised the need for a sub maximal test which relates to everyday 
activities and is conducted within a "reasonable" timescale. However, they concede that 
there is little data relating submaximal performance to clinical status or information 
available on an appropriate submaximal intensity (Franciosa, 1984, Poole-Wilson, 1989a). 
Thus, it is important to establish which scales should be used to measure symptoms and to 
determine the intensity and duration of exercise which is most appropriate for evaluation 
of symptoms. Poole-Wilson, (1989a), on page 355 outlines the need for a "new" exercise 
test, "There is a need for a simple exercise test which can be used to evaluate symptoms of 
patients with chronic heart failure and to test the efficacy of new drugs as they become 
available. The test must be simple, cheap, reproducible and sensitive. Exercise tests 
which relate to everyday activities of patients appear promising."
1.1.5. ASSESSMENT OF THERAPEUTIC RESPONSE.
Studies involving the evaluation of therapeutic agents is commonplace in cardiology. 
These studies have incorporated a variety of exercise protocols and sometimes subjective 
scales are used. Therapeutic interventions often involve a run-in period and fairly 
extended periods of time between exercise tests. Thus, the evaluation of exercise tests and 
subjective scales should attempt to mirror the time scales and procedures of drug trials.
1.1.6. STEEP PROTOCOL.
A new exercise protocol, the STEEP protocol (Northridge et al; 1990) which is currently 
in use in a number of hospitals, has been included in the evaluation of therapeutic agents. 
In addition, this protocol is currently being used to assess cardiorespiratory fitness in a 
medical screening project in 2000 people in the West of Scotland. The STEEP protocol
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has been extended to accommodate the anticipated wide range of fitness levels in a cross 
section of the population. The extended protocol has been called the STEXT protocol. 
No evaluation of this protocol has been carried out to date with the use of subjective 
scales. An appraisal of the protocol using two subjective scales under similar conditions to 
a drug trial would provide information on the reproducibility of measurement. In addition, 
the effect of beta blockade on exercise function could be used to measure sensitivity and 
therefore may indicate which subjective scale is more sensitive to intervention.
1.1.7. THESIS CONTENT.
This thesis has been subdivided into three parts:
PART ONE.
The reproducibility and sensitivity to change of three subjective scales in normals.
PART TWO.
Symptomatic and physiological responses to a submaximal exercise test in chronic heart 
failure patients.
PART THREE.
An evaluation of the STEXT protocol in normal subjects.
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CHAPTER 2 
SECTION ONE.
REVIEW OF LITERATURE
CHRONIC HEART FAILURE.
2.1.1. AETIOLOGY.
In the Framingham study hypertension was the major aetiological factor in 75% of CHF 
cases with coronary heart disease accounting for only 10% of cases (McKee et al; 1971). 
However, recent studies indicate that coronary artery disease is the major cause of CHF 
(Teerlink et al; 1991).
2.1.2. PREVALENCE.
The Framingham study reported that the incidence rate of CHF was 3 per 1000 for both 
sexes aged between 35-64 years and 10 per 1000 for those aged 65-94 years. (McKee et 
al; 1971). Using these figures it was calculated that there were 400,000 new cases in the 
USA in 1983. For the same year 2.3 million cases of CHF were estimated for the USA. 
In a survey of three London family general practices with a combined population of 
30,204, 117 patients (0.4%) had CHF. The prevalence rate was only 0.06% for those 
under 65 years but increased to 2.8% for those over 65 years (Sutton,1990). The study of 
McMurray et al; (1993) demonstrated that CHF is an increasingly common and costly 
cause of admission to hospital in the U.K. The authors concluded that in-patient mortality 
was very high and that CHF is a major health problem.
2.1.3. MORBIDITY AND MORTALITY.
CHF is responsible for a dramatic impairment in the quality of life. Jessup, (1986) stated 
that CHF is characterised by general fatigue and dyspnoea which results in limited 
physical work capacity. Other problems associated with CHF are socio-economic 
limitations, emotional concerns and adverse side effects (Rector and Cohn, 1993). The 
Framingham study reported that the probability of dying within five years of onset of CHF 
was 62% for males and 48% for females (McKee et al; 1971). Several studies have
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confirmed the poor prognosis for CHF patients and indicate higher mortality rates with 
increasing clinical severity (SOLVD, 1990; Gillum, 1990).
2.1.4. IMPLICATIONS.
Better treatment of patients who suffer from the clinical manifestations of CHD may 
increase the incidence of CHF. As the general population will become "older" and the 
incidence of CHF is associated with age, it is likely that the incidence of CHF will 
continue to rise.
2.1.5. PATHOPHYSIOLOGY.
Many complex and interrelated pathophysiological mechanisms are involved in CHF. 
Systolic impairment and/or diastolic dysfunction are characteristics of CHF. The inability 
of the left ventricle to contract with sufficient power to expel the venous return is often 
associated with the inability to relax with sufficient speed and adequate compliance during 
diastole to allow optimal filling (Braunwald, 1988). The consequences of ventricular 
dysfunction are an increase in ventricular volume, slower ventricular filling and a fall in 
ejection fraction. In CHF a number of adaptive mechanisms take place to maintain pump 
function. The development of hypertrophy is a common compensatory mechanism which 
is not well understood. Chronic pressure or volume overload on the ventricle results in 
myocardial hypertrophy and depresses contractility and performance of the heart. 
Myocardial hypertrophy is considered to be a compensatory process which normalises 
wall tension (Kiowski, 1989). Salt and water retention increases the circulatory volume. 
This leads to an increased filling pressure in the affected ventricle. The increased preload 
helps maintain cardiac performance. However, the adaptive mechanism are finite and 
adverse events produce the syndrome of chronic heart failure. Increased ventricular wall 
stress and myocardial oxygen consumption, reduced cardiac output and the stimulation of 
neuroendocrine responses are all unfavourable responses to heart failure. Cardiac output 
is reduced in CHF but blood flow to the brain and heart is maintained whereas blood flow 
to the skin, skeletal muscles and splanchnic regions is reduced. The compensatory 
mechanisms which result from the fall in output from the failing heart - some
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vasoconstrictive and others leading to salt and water retention eventually become a major 
problem in themselves. A decrease in cardiac output promotes a response from the kidney 
which leads to an expansion of extracellular fluid volume and ultimately to circulatory 
congestion and oedema. A decline in cardiac output results in vasoconstriction which 
tends to maintain perfusion pressure but increases aortic impedance and eventually 
impairs ventricular function. It is suggested that the compensatory response seen in CHF 
is an ancient reflex with the purpose of maintaining blood pressure (Harris, 1987).
2.1.6. CENTRAL HEMODYNAMICS.
The three major determinants of stroke volume have traditionally been considered to be 
contractility, preload and afterload.
2.1.6. (a) CONTRACTILITY.
Physiologically, contractility refers to a muscle's ability to shorten independently of its end 
diastolic length and the load opposing shortening (and in vivo, heart rate). Decline in 
contractile function in CHF has been attributed to infarction or cardiomyopathic 
processes. However, it has been demonstrated that surviving muscle may show abnormal 
contractile responsiveness (Braunwald, 1988). Beta adrenoreceptor down-regulation may 
limit the normal inotropic response to catecholamines (Hammond, 1993). A variety of 
other abnormalities may also be responsible for injury or even destruction of normal 
muscle and thus contribute to reduced cardiac function. Reductions in the maximal 
velocity of shortening of unloaded myocardium and a decrease in the development of 
maximal isometric force are characteristics of depressed cardiac performance (Braunwald, 
1988).
2.1.6. (b) PRELOAD.
The preload is determined by end diastolic fibre length and end diastolic volume (EDV). 
The principal variable which influences EDV is the rate of venous return to the heart. An 
increase in the end diastolic volume will enhance the contractile potential of the ventricle 
according to the Frank Starling mechanism (i.e. lengthening of the sarcomeres to an
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optimal level of thick and thin element overlap enhances contraction). The extracellular
fluid volume expansion, venoconstriction, a reduced venous capacity and a decreased
ventricular compliance contribute to an increased preload in CHF. In CHF, the left 
ventricular function curve is depressed which results in little increase in cardiac output 
despite an increase in preload. Pulmonary oedema occurs when end diastolic pressure 
reaches a critical level.
2.1.6. (c) AFTERLOAD.
The load applied after the onset of muscle contraction is referred to as the afterload. The 
afterload is primarily influenced by the aortic pressure during ejection. Increases in aortic 
pressure raises the level of the afterload. Stroke volume is inversely proportional to the 
afterload - an increase in aortic pressure produces a decrease in stroke volume. Aortic 
impedance is largely determined by systemic vascular resistance but other factors which 
include large artery compliance and blood viscosity also have a bearing on aortic 
impedance. In CHF small changes in afterload can have a marked effect on cardiac 
output Unlike the normal ventricle, a small increase in systemic vascular resistance can 
cause a marked decrease in cardiac output whereas a slight fall in afterload can greatly 
increase cardiac output. When there is a marked reduction in contractility, and no preload 
reserve is available, any increase in afterload results in a significant decrease in the 
velocity of shortening (Katz, 1987).
2.1.7. NEUROENDOCRINE RESPONSE.
Impaired ventricular function and the associated fall in cardiac output results in a relative 
hypoperfusion of various organs which prompts a neuroendocrine response. This 
neuroendocrine response incorporates a variety of processes and includes the activation of 
the renin-angiotensin-aldosterone system (RAA), the sympathetic nervous system, 
vasopressin, atrial natriureic factor (ANF) and prostaglandins (Poole-Wilson, 1989b). The 
main aims of the neuroendocrine response are the maintenance of blood pressure by 
constriction of the systemic arteries and veins and an expansion of blood volume (Van 
Gilst and De Graeff, 1990). Abnormal baroreflex function may be responsible for much
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of the neurohumoral activation (Marin-neto et al; (1991). The increase in blood volume is 
brought about by the retention of salt and water as a result of increased aldosterone 
secretion and stimulation of the antidiuretic hormone. Higher circulating concentrations 
of angiotensin II contribute to excessive vasoconstriction of the peripheral arteriolar 
resistance vessels and those and increase in afterload. In addition, vasoconstriction is 
augmented by an increase in vascular resistance as a result of increased salt and water 
retention. Angiotensin n  (a potent sodium retainer) is a powerful stimulus to adrenal 
secretion of aldosterone, leading to salt retention. The above vasoconstrictor mechanisms 
are countered to a certain extent by ANF and vasodilator prostaglandins which tend to 
lower vascular resistance and promote salt and water excretion. It is important to stress 
that a significant considerable part of the neuroendocrine response is as a result of diuretic 
therapy and not CHF per se (Goldsmith et al; 1989).
2.1.8. SYMPATHETIC NERVOUS SYSTEM.
A major compensatory mechanism in CHF is an increase in sympathetic activity as 
evidenced by increased plasma concentrations and urinary excretion of norepinephrine 
(Richards, 1989). Increased sympathetic drive augments myocardial contractility. 
Enhanced sympathetic activity moves the Starling curve upward and to the left and 
thereby increases the rate and force of each cardiac contractionat any fibre length. 
Increased sympathetic activity also results in an increase in cardiac output and peripheral 
perfusion. Desensitisation of vessels and the myocardium to agonists is a characteristic of 
CHF (Colucci et al; 1989).
2.1.9. RAISED PERIPHERAL RESISTANCE.
Increased peripheral resistance and changes in the distribution of the cardiac output at rest 
and during exercise characterise CHF. Alteration in the distribution of the cardiac output 
and increased peripheral resistance cannot be solely attributed to a neuroendocrine 
response. Changes within the microvasculature of the endothelial cells or smooth muscle 
are associated with a reduction in blood flow to skeletal muscle during exercise. Vascular
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"stiffness" is increased by vessel wall sodium content and arterial compliance is reduced 
(Poole-Wilson, (1989b).
2.1.10. PERIPHERAL HAEMODYNAMICS AND REGIONAL BLOOD 
FLOW.
Alterations in cardiac output distribution and increased peripheral resistance are 
implicated in the reduced muscle blood flow during exercise which result in decreased 
exercise performance, general fatigue and dyspnoea. The kidney does not receive an 
adequate blood flow which leads to fluid retention.
2.1.11. SKELETAL MUSCLE ABNORMALITIES.
A variety of skeletal muscle abnormalities have been described in CHF. Alterations in 
fibre type, changes in muscle metabolism and muscle enzyme activity and reductions in 
muscle strength and endurance have been found (Drexler, 1992). A lowered rate of 
muscle protein synthesis in the early stages of heart failure and an increased rate of protein 
breakdown in the advanced stages of CHF have been reported.
2.1.12. THE LUNGS.
The lower ejection fraction which characterises CHF results in an increased pressure and 
volume in the pulmonary arteries and veins. The pulmonary capillary volume and total 
lung water are also increased. These changes result in large discrepancies in the 
ventilation perfusion ratio in the lung.
2.1.13. TREATMENT.
The main aims in the treatment of heart failure are:
1 ) relief of symptoms.
2 ) reduction in the incidence of morbid events.
3) increase in longevity.
The pharmacological treatment of heart failure has traditionally centred on two areas:
1 ) the use of diuretics and vasodilator drugs to reduce salt and water
retention, and unload the heart (Van Zweiten, 1990).
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2 ) enhancement of cardiac contractile force with the use of inotropic 
drugs.
Diuretic treatment is the most effective drug which provides symptomatic relief for CHF 
patients. Diuretics act by promoting renal excretion of salt and water and by blocking 
tubular reabsorption of sodium and chloride. Diuretics and sodium restriction result in the 
activation of the renin angiotensin system which promotes the formation of angiotensin (a 
potent vasoconstrictor) and an increase in afterload.
ACE Inhibitors (ACEIs) (eg captopril, enalapril) have a number of effects including a 
lowering of systemic vascular resistance, increased cardiac output, decreased blood 
pressure, improved renal perfusion and an increase in blood flow to exercising skeletal 
muscle. ACEIs have been shown to be effective in prolonging life in patients with all 
grades of heart failure, and increase exercise tolerance (Firth, 1988). The increase in 
exercise capacity is delayed until after some weeks of therapy, and is believed to be the 
result of an increase in skeletal muscle blood flow following vasodilation (Riegger, 1991).
Positive inotropic drugs strengthen the contractile force of the heart independent of load 
alterations (Schlepper et al; 1989). Digoxin is an inotropic drug which inhibits sodium- 
potassium ATPase; Intracellular sodium is exchanged for extracellular calcium. These 
higher intracellular levels of calcium allow increased binding of contractile proteins actin 
and myosin resulting in enhanced contractility. Digoxin enhances baroreceptor function 
and decreases sympathetic nervous system activity which results in an increased limb 
blood flow (Braunwald, 1988).
Dobutamine is a selective agonist of the beta 1 receptor which increases intracellular 
cyclic AMP which results in increased calcium availability for contraction. Amrinone and 
milrinone are phosphodiesterase inhibitors which inhibit phosphodiesterase and therefore
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prevent the breakdown of cyclic AMP, the accumulation of which results in increased 
contractility.
Several types of vasodilators (eg. hydralazine, flosequinan) are potential therapeutic 
agents used in heart failure. Flosequinan causes both arterial and venous dilatation while 
hydralazine has a predominantly arterial effect. Arteriolar vasodilators reduce the after- 
load which results in an increased cardiac output. Alpha adrenergic blockers (eg prazosin) 
and direct smooth muscle relaxants (eg hydralazine) are examples of arteriolar 
vasodilators. Venodilators (eg isosorbide mononitrate) reduce pre-load by reducing 
venous return and lead to a fall in pulmonary arterial pressure. It might be expected that 
an increased cardiac output and a concomitant decrease in systemic vascular resistance 
would result in a reduction in symptoms. However, haemodynamics at rest, during 
exercise or during acute drug therapy have been shown not to give an accurate prediction 
of the patients' symptomatic response. While some vasodilator s have been shown to alter 
haemodynamics acutely, a lack of chronic response has been attributed to the development 
of drug tolerance.
A few drugs which have a simultaneous inotropic effect and vasodilator effect and are 
termed inodilators. Dopamine and dopexamine are examples of inodilator drugs which 
improve contractile performance by the stimulation of cardiac beta and possibly alpha 1 - 
adrenoreceptors. Stimulation of dopaminergic receptors in the blood vessels and the 
kidney cause vasodilation and enhanced renal perfusion. Dopamine is not such an 
effective inotrope as dobutamine but the selective action of dopamine on dopaminergic 
receptors enhances renal perfusion.
2.1.14. CLINICAL MANIFESTATIONS.
Appropriate methods are necessary to enable the clinician to evaluate the efficacy of 
treatment on patient symptoms.
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2.1.15. CLASSIFICATION OF CHF PATIENTS
Peak VO2  has been used to assess functional status of CHF patients but is not routinely 
used in hospitals as measurement of peak VO2  is expensive, time consuming and requires 
experienced personnel. The New York Heart Association (NYHA) classification system 
(Braunwald, 1988) has been used to classify the severity of CHF by assessing the severity 
of symptoms experienced in everyday life. The assessment criteria rely heavily on the 
physician's subjective appraisal of how compromised the patient is and relate how the 
patient's symptoms correspond to ''ordinary activity". The severity of heart failure is 
usually graded to the level of physical activity at which breathlessness and general fatigue 
appear. Cowley et al; (1991) have described the NYHA scale as an attempt to quantify a 
clinical description but concluded that it is a crude measure of disability and that a much 
better way of measuring patients’ functional ability is to use some form of exercise test.
The value of the NYHA classification has been questioned due to the subjectivity of 
measurement and limited reproducibility of measurement (Smith, 1985, Goldman et al; 
1982). Furthermore, the NYHA lacks the sensitivity to detect small but clinically 
important changes (Van den Broek et al; 1992). As the NYHA classification system 
categorises patients on a subjective impression of the degree of functional compromise, it 
may be that a decrease in physical activity may be interpreted as an improvement because 
the new activity level could result in fewer symptoms being reported (Goldman et al; 
1982).
Traditionally assessment of therapy effects has centred around clinical measures. The 
limitations of these measures have been recognised and quality of life assessment has 
emerged as an important outcome measure. Eriksson et al; (1988) have reported that 
quality of life measures demonstrated that CHF patients on drug treatment were more 
adversely affected than those who were not treated. The results from a study entitled 
"Quality of Symptom Control - The Patient Perspective", suggest that the physician may 
not fully appreciate the actual impact that CHF has on a patient's lifestyle. Brice, (1993)
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has found that there are differences between patient, physician and spouse perspectives on 
the impact of heart failure. He indicated that physicians appear to focus on the symptoms 
of heart failure, which many patients tend to avoid provoking through adjustments in 
lifestyle and restriction of everyday activities.
Weber et al; (1984) classified CHF patients according to the peak VO2  attained in an 
exercise test. This stratification has been shown not to correspond with the NYHA 
classification and it is doubtful if the severity of cardiac dysfunction can be assessed by an 
incremental exercise test.
Limitations in the current tests employed to classify CHF patients and monitor changes in 
status highlight the need for other tests to be developed.
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CHAPTER 2 
SECTION TWO
SYMPTOMS IN CHRONIC FAILURE.
2.2.1. BREATHLESSNESS AND FATIGUE IN CHF.
Dyspnoea and fatigue characterise CHF. The causes of these symptoms are multiple and 
may be interrelated. CHF patients have a peak VO2  of less than 25 ml.kg‘1. min* 
(Franciosa et al; 1979). Thus, participation in normal daily activities may force them to 
function so close to maximum that fatigue results. Lipkin et al; (1986a) have shown that 
the symptom which ultimately terminated exercise was dependent on the type of exercise 
protocol employed. In a "fast" protocol, all subjects stopped exercising as a result of 
breathlessness whereas in a "slow" protocol 23 out of 25 subjects terminated the exercise 
due to fatigue. The sensation of breathlessness was associated with a higher ventilation, 
peak lactate and a lower pH during the "fast" protocol compared with the "slow" protocol.
A variety of abnormalities which may affect exercise capacity and have a bearing on 
symptoms in CHF patients have been reported. An examination of these abnormalities 
may provide information on how these factors relate to general fatigue and breathlessness.
2.2.2. HAEMODYNAMIC FACTORS.
Attempts have been made to explain the severity of symptoms by examining exercise 
capacity and haemodynamic variables. Cardiac output is chronically reduced in CHF at 
rest and exercise. The inability to increase cardiac output to meet O2  requirements has 
been cited as the reason for the decrease in physical work capacity and a possible reason 
for fatigue in CHF (Weber et al; 1986). A poor relationship has been found between 
indices of systolic ventricular function, symptomatic status and exercise capacity 
(Franciosa etal; 1981). Szlachcic et al; (1985) showed no association between the change 
in ejection fraction from rest to peak exercise and exercise capacity. Correlations between
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indices of left ventricular function and exercise capacity have been consistently low, 
ranging from -0.10 to 0.24 (Myers and Frolicher, 1991).
Right ventricular ejection fraction (RVEF) has been shown to correlate with exercise 
capacity (Baker et al; 1984). This finding suggested an important role of the RV in 
determining the exercise capacity of CHF patients. There is evidence of an interaction 
between right and left ventricles in LV dysfunction. Baker and her colleagues speculate 
that RV overload displaces the interventricular septum into the LV which alters the 
geometry and distensibility of the LV. In a recent study with 109 patients, Deedwania et 
al; (1993) found that LVEF and RVEF were poor predictors of exercise tolerance. The 
authors suggested that earlier studies that showed RVEF to be have a good correlation 
with exercise tolerance, could be explained by the fact that there were few subjects in 
these studies.
Abnormal pulmonary haemodynamics is a characteristic of CHF. Exercise capacity has 
been increased in some but not all studies which have lowered pulmonary and right sided 
cardiac pressures by chronic pharmacological means (Massie et al; 1984). Furthermore, 
pulmonary arterial hypertension resulting from backward transmission of elevated left 
heart and pulmonary capillary pressures may lower RV function.
2.2.3. NEUROHUMORAL ABNORMALITIES.
Reduced exercise capacity in CHF can be partly attributed to abnormalities in 
neurohumoral mechanisms. Although catecholamine concentrations are thought to be 
higher in CHF, it may be there is a reduced sympathetic response during exercise (Francis, 
1987). Reduced beta receptor density and sensitivity have been shown in CHF and 
contribute to the chronotropic incompetence (Collucci et al; 1989). Baroreceptor reflex 
changes have been observed in animals with heart failure which may also contribute to 
chronotropic incompetence and lowered systolic pressure during exercise which may be 
linked to peripheral perfusion abnormalities (Higgens et al; 1972).
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2.2.4. PERIPHERAL ABNORMALITIES, BLOOD FLOW
ABNORMALITIES.
Abnormalites of the peripheral circulation have been cited as one of the major causes of 
fatigue in CHF. It has been demonstrated that CHF patients have a greater than normal 
exercise A-VO2  difference which has been interpreted as a compensatory response to 
reduced skeletal muscle blood flow. It has been shown that in CHF patients, the 
exercising muscle has a more rapid depletion of creatine phosphate and a decrease in pH 
compared with normals (Wilson et al; 1985). Impairment of blood flow to the exercising 
muscle is one possible reason for this response which would result in an imbalance 
between energy requirements and oxygen substrate delivery.
Although A-VO2  difference was greater in CHF patients than normals, Rubin et al; (1982) 
found that peak VO2  was 40% lower which indicated that despite the higher A-VO2  
difference this compensatory measure was inadequate to make up for the reduced blood 
flow. The Rubin and Brown, (1984) study and others (Wilson et al; 1984) suggest that the 
reduced exercise capacity in CHF is mainly due to limited oxygen availability to the 
skeletal muscles. Zelis and Flaim (1982) found that the more severe the CHF, the greater 
the impairment of regional distribution in cardiac output in CHF. Wilson et al; (1984) 
showed that CHF patients stopped exercising because of fatigue when skeletal muscle 
underperfusion reached a critical level and that this level of exercise intolerance was a 
direct function of the degree of impairment of skeletal muscle blood flow. The reduced 
skeletal muscle perfusion is one possible reason for the lower exercise capacity in CHF as 
a close relationship has been established between the early onset of anaerobic metabolism, 
metabolic acidosis and impaired work capacity in CHF patients (Sullivan et al; 1989). 
Cowley et al; (1986) found a significant correlation between the maximum exercise 
duration of CHF patients and calf blood flow after exercise and at rest. In addition, the 
CHF patients had a higher VE and decreased VO2  compared with controls which is 
suggestive of an earlier onset of anaerobic metabolism.
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A number of reasons for impaired skeletal muscle blood flow have been suggested but the 
underlying mechanisms remain unclear. Arterial vasodilation during exercise has been 
shown to be lower in CHF relative to normals (Zelis and Flaim, 1982). It is thought that 
sodium and water retention is implicated in this impaired vasodilatory response (Zelis and 
Flaim, 1982). Sullivan et al; (1989) found that a lower proportion of the cardiac output 
was delivered to the skeletal muscles during exercise in CHF patients compared with 
normals. Even although the cardiac output was reduced, the CHF patients maintained a 
normal mean arterial pressure as a result of a higher than normal vascular resistance. 
Conversely, Wilson et al; (1986) concluded that there was no vasodilatory abnormality. 
Wilson et al; (1986) reported that reduced arterial blood pressure response in patients was 
the most likely mechanism responsible for underperfusion in nonedematous patients. A 
reduction in sympathetic drive and vasoconstrictor tone in CHF patients during exercise 
have been suggested reasons for arterial hypotension and skeletal muscle underperfusion 
(Wilson et al; 1993). Excessive sympathetic tone in CHF could impair vasodilation 
during exercise. However, it has been shown that acute blocking of alpha adrenergic tone 
does not always produce an increase in leg blood flow. Increases in plasma angiotensin as 
a result of renin-angiotensin-aldosterone stimulation has several effects including a 
probable increase in sodium and water content in the vascular walls and a resultant 
increase in vascular "stiffness.”
The deconditioned state in CHF has been implicated in the reduced skeletal muscle blood 
flow (Sinoway et al; 1988). Chronic high flow states may promote endothelial changes 
which result in a facilitated release of endothelial derived relaxing factor whereas the 
opposite has been shown in CHF (Miller et al; 1986, Kaiser et al; 1988). Poole-Wilson et 
al; (1989b) stated that the cause of the increased resistance in vessels supplying the limbs 
is unknown. They cited the example of the changes in forearm resistance after heart 
transplantation (Sinoway et al; 1988) which does not return to normal for at least 4 weeks 
and concluded that changes are not directly linked to central haemodynamics. Some
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studies indicate that peripheral vessels are deconditioned. After 4-6 months of aerobic 
training CHF patients showed an increase in peak leg blood flow and a fall in leg vascular 
resistance with no change in mean arterial pressure (Sullivan et al; 1988). These findings 
suggest an increase in vasodilatory capacity and/or a decrease in sympathetic 
vasoconstrictor activity.
2.2.5. SKELETAL MUSCLE ABNORMALITIES.
The impairment of nutritive flow to the exercising muscle is not the only possible cause of 
fatigue in CHF. Indeed, Wilson et al; (1993) found in their study that a substantial number 
of patients developed exertional fatigue due to skeletal muscle abnormalities rather than 
due to a reduction in skeletal muscle blood flow. Sullivan et al; (1990) concluded that 
intrinsic abnormalites in skeletal muscle have a potentially important role in the 
development of early lactic acidosis and fatigue. They showed that CHF patients’ skeletal 
muscle abnormalities included fibre atrophy, a decrease in the percentage of type one 
fibres, an increase in type two fibres and a decrease in oxidative enzymes. A metabolic 
abnormality whereby skeletal muscle oxidative enzymes may be significantly reduced 
could be responsible for a reduced exercise capacity (Drexler et al; 1987) and may occur 
as a result of deconditioning (Cohen-Solal, 1989). Similarly, skeletal muscle atrophy and 
the associated muscle weakness may have a role in fatigue in CHF (Poole-Wilson and 
Buller, 1988). Histological abnormalities have been shown in the quadriceps muscles of 
CHF patients which have been related to reduced strength levels compared with normals 
(Lipkin et al; 1986a). The ’early’ recruitment of fast twitch fibres during exercise in CHF 
patients would result in the production of lactate at a lower workrate in CHF patients.
The lower pH and increased levels of inorganic phosphate in the exercising skeletal 
muscle observed in some CHF patients compared with normals are likely causes of fatigue 
in CHF patients (Massie et al; 1987), Wiener et al; 1986). Significantly, the CHF patients 
with lower pH values at submaximal exercise were found to be the more symptomatic 
patients. Massie et al; (1987) concluded that intracellular pH may be a major determinant
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of fatigue. Astrand and Rodahl, (1986) discussed the possibility that hydrogen ions alter 
the binding of calcium ions to muscle regulatory proteins and therefore reduce the 
contractile force. They hypothesise that a decrease in pH could reduce the myofibrillar 
ATP ase activity which would decrease the rate of ATP turnover and cross bridge cycling. 
CHF patients have a reduced work capacity and for a given workrate will be working 
closer to maximum and initiate anaerobic metabolism at a lower workload than normals.
2.2.6. DISPROPORTIONATE INCREASE IN VENTILATION.
Reduced skeletal muscle blood flow and the resultant muscle underperfusion promotes 
anaerobic glycolysis which leads to intramuscular lactate accumulation and lactate release 
into the blood (Karlson and Jacobs, 1982). Reddy et al; (1988) found that light isometric 
forearm exercise in CHF patients represented an anaerobic contraction with lactate 
production. They concluded that the subsequent increase in CO2  production was 
responsible for a disproportionate increase in minute ventilation during recovery which 
may partly account for the perception of breathlessness in CHF patients. Other possible 
reasons for an increased blood lactate level in CHF patients during exercise include the 
possibility of early recruitment of fast twitch fibres and reduced liver blood flow resulting 
in diminished hepatic metabolism. Lipkin et al; (1986a) concluded that the sensation of 
breathlessness was associated with a rapid rise in plasma lactate concentration and a fall in 
pH. Compared with a "slow” exercise protocol, they found greater plasma lactate levels 
during a "fast" protocol which coincided with a higher level of breathlessness. The 
sensation of breathlessness was accompanied by increases in VE during the "fast" protocol 
which may indicate that breathlessness is linked to VE. Thus, the sensation of 
breathlessness was associated with an increase in plasma lactate levels and a fall pH 
stimulating a hyperventilatory response. This apparently plausible explanation for 
breathlessness and fatigue does not necessarily imply a cause and effect. Patients with 
McArdle's syndrome cannot produce lactate yet demonstrate a non linear increase in 
ventilation (Hagberg et al; 1989). Recently, it has been suggested that increased plasma 
potassium levels could result in a disproportionate increase in ventilatory drive via the
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carotid bodies which are potassium sensitive (Busse et al; 1991, Paterson et al; 1990). 
Exercise is associated with a rapid increase in plasma potassium. Barlow et al., (1994) 
showed that the exercise induced rises in arterial plasma potassium and VE at given 
submaximal workrates were greater in CHF than subjects with normal LV function. The 
authors concluded that the close correlation between VE and potassium supported the 
hypothesis that potassium may serve as a humoral signal in the drive to breathe. Wilson et 
al; (1988) used dichloroacetate to decrease lactate formation by increasing pyruvate 
oxidation. The findings from this study suggest that intramuscular lactate is not 
responsible for muscular fatigue as there was no change in exercise capacity between the 
control situation and the dichloroacetate administration. Thus, it is possible to decrease 
blood lactate levels without enhancing muscle perfusion. The authors postulated that the 
production of the diprotonated acidic form, of inorganic phosphate (H2 PO4 ) may cause 
muscular fatigue. Wilson et al; (1988) also noted that respiratory gases did not change 
despite changes in blood lactate. Thus, the possible linkage between changes in blood 
lactate levels and ventilation appear to have limitations.
2.2.7. "EXCESSIVE” VENTILATION.
During exercise CHF patients demonstrate increased ventilation (termed "excessive 
ventilation" by Rubin and Brown, 1984) compared to normals. The size of this 
abnormality is closely linked to the degree of chronic heart failure (Weber et al; 1982). 
Weber et al; (1982) have shown that as peak VO2  declines in CHF patients, the ventilation 
rate for any given work rate becomes higher. Fink et al; (1986) confirmed that excessive 
ventilation responses are frequent in CHF and reported that the VE/VCO2  ratio (at a 
VCO2  of 1 litre per minute) ranged from 27-71 and exceeded the 33 or less observed in 
non-CHF individuals. They found that the VE/VCO2  rat*° ^  not correlate with peak 
exercise pulmonary artery wedge pressure.
VCO2  is closely related to VE in normals and CHF patients. However, in CHF patients, 
the slope of the VE/VCO2  relationship is increased and the slope correlates with the
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decrease in peak VO2  (Buller and Poole-Wilson, (1990). Furthermore, the same authors 
have found that for any given rate of CC>2 production the respiratory rate is higher in CHF 
patients. Poor lung compliance may contribute to the increased respiratory rate. This 
occurs with the accumulation of interstitial fluid and may activate the (J) receptors which 
may cause tachpynoea and promote the sensation of breathlessness (Karlsberg et al; 1979). 
However, there is a poor relationship between decreased lung compliance and the degree 
of dyspnoea (Paintal, 1969). Furthermore, only small increases in pulmonary blood 
volume and pulmonary extravascular fluid have been found with CHF patients (Hayward 
and Knot, 1955). Franciosa et al; (1984) found exercise intolerance in CHF patients was 
associated with an increase in pulmonary capillary wedge pressure. They suggested that 
therapeutic interventions might decrease symptoms by lowering wedge pressures. The 
findings of Lipkin et al; (1986a) suggest that a high pulmonary capillary wedge pressure is 
not the major factor associated with the sensation of breathlessness in CHF. They found 
that there was no difference in the maximum pulmonary capillary wedge pressure at the 
end of "slow" and "fast" protocols but the patients reported a much higher incidence of 
breathlessness during the "fast" protocol. Thus, symptoms were altered by changing the 
protocol but the pulmonary capillary wedge pressure remained the same. Furthermore, 
Fink et al; (1986) found that an acute decrease in intrapulmonary pressures with 
vasodilator or inotropic therapy did not decrease exercise ventilation during exercise in 
CHF patients. In a comparison of pulmonary artery pressure changes during maximal 
treadmill and cycle exercise and daily activities, Gibbs et al; (1990) found that symptoms 
and pulmonary artery pressure during treadmill and cycle exercise were not the same as 
during every day activities. The main symptom which limited maximal exercise was 
breathlessness.
2.2.8. DEAD SPACE.
Rubin and Brown, (1984) postulated that VE is increased in CHF during exercise by two 
mechanisms:
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1 ) the fraction of dead spaceAidal volume is increased, decreasing ventilatory 
efficiency and requiring greater VE to maintain eucapnia.
2 ) alveolar hyperventilation.
Both factors combine to increase ventilatory equivalents for C> 2 and CO2 . Rubin and 
Brown, (1984) have postulated that the increase in alveolar ventilation may be as a result 
of elevated venous pressures stimulating pulmonary receptors which trigger 
hyperventilation but they concede that it is likely that metabolic acidosis promotes 
hyperventilation by stimulating peripheral chemoreceptors. It has been suggested that 
ventilation perfusion mismatch could explain the increase in ventilation in CHF patients 
(Rubin et al; (1982) i.e. areas of high perfusion and low ventilation (ie. increase in 
physiological shunting) and areas of normal ventilation but low perfusion (ie. increased 
dead space ventilation). It has been shown that dead space is increased in CHF patients. 
Total physiological dead space consists of the anatomical component (conducting 
airways) and alveolar dead space ie. the alveoli which are ventilated and not perfused. 
While anatomical dead space is not increased in absolute terms, Weber et al; (1982) have 
postulated that anatomical dead space is increased relatively in CHF patients as increased 
respiratory rates at smaller tidal volumes could be a contributory factor. Sullivan et al; 
(1988) concluded that the increase in VE was due to elevations in the dead spaceAidal 
volume (Vd/Vt) ratio and was not related to lactate production or increased pulmonary 
vascular pressures. Sullivan et al; (1988) found that cardiac output was inversely related 
to Vd/Vt and VE/VCO2  and they postulated that decreased lung perfusion may accentuate 
ventilation perfusion mismatching and increased pulmonary dead space. They also 
reported no differences in VE/VCO2 , Vd/Vt or alveolar ventilation/volume of CO2  
produced (Va/VCC^) in patients with normal wedge pressures versus patients with 
increased pressures.
Weber et al; (1982) have shown that for any given rate of CO2  production, CHF patients 
\  demonstrate a higher respiratory rate. The greater the decrease in peak VO2  the higher the 
\  respiratory rate for any given workrate. The increased respiratory rate may result in a
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greater respiratory effort to ventilate the dead space. Buller and Poole-Wilson, (1990) 
concluded that two thirds of increase in ventilation in CHF patients was due to an increase 
in physiological dead space ventilation and a significant ventilation perfusion mismatch. 
The cause of the increased alveolar ventilation is unknown. Buller and Poole-Wilson,
(1990) attributed the other third increase in ventilation to changes in breathing pattern. 
Sullivan et al; (1988) have shown that the primary mechanism for an increased respiratory 
rate in CHF is an abnormal increase in physiological dead space per breath. They have 
postulated that an abnormally low cardiac output results in a ventilatory perfusion 
mismatch.
2.2.9. ARTERIAL OXYGEN SATURATION.
A fall in arterial oxygen saturation might be expected if a respiratory limitation was 
implicated in the reduced work capacity in CHF. Several studies have shown that arterial 
oxygen desaturation is normal in CHF patients (Rubin et al ;1982). Mancini et al; (1991) 
confirmed the ventilatory abnormalities associated with CHF (i.e.increased ventilation and 
respiratory rate compared to normals) but noted that there was respiratory muscle 
deoxygenation which may be due to respiratory muscle underperfusion. Mancini et al;
(1991) reported that there was no arterial oxygen desaturation but concluded that 
breathlessness in CHF may be partly as a result of respiratory muscle undeperfusion.
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CHAPTER 2 
SECTION THREE.
USE OF EXERCISE TESTS IN CHRONIC HEART FAILURE.
2.3.1. REASONS FOR EXERCISE TESTS.
Exercise testing in CHF has been widely used for a variety of reasons;
1 ) to indicate the functional capacity of patients.
2 ) to predict prognosis.
3) to assess drug intervention.
4) to categorise the severity of heart failure.
The assessment of CHF patients has usually been carried out using incremental protocols 
to a symptom limited maximum. Assessment of CHF patients using a maximum test has 
problems:
1 ) some patients stop before a "true maximum" has been reached.
2 ) it has been shown that exercise time can be increased by giving 
encouragement
3) if a maximum test is used, at least two tests should be performed as 
a single test will probably underestimate exercise capacity (Elbom 
etal: (1990).
4) it has been suggested that maximum tests do not simulate everyday 
life (Cowley et al; 1991).
2.3.2. WHICH TEST? WHAT FOR?
While exercise testing is widely used to evaluate CHF patients, there is no agreement on 
the most appropriate protocol. In addition, there is no consensus on the interpretation of 
the results. Gibbs et al; (1991) have shown that walking and stair climbing elicit different
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haemodynamic responses to maximum tests and concluded that this may restrict the use of 
maximum tests in the assessment of CHF patients.
Problems associated with maximum tests have led to attempts to circumvent some of these 
difficulties. Weber and Janciki, (1985) concluded that the severity of heart failure could be 
graded by the appearance of anaerobic metabolism (by examining mixed venous lactate 
levels during incremental exercise). They found that the anaerobic threshold as 
determined by mixed venous lactate showed a good correlation with non invasive 
ventilatory values. Lactate levels were very reproducible. They concluded that the 
anaerobic threshold (AT) (lactate and ventilatory) may be useful markers of severity of 
heart failure.
The use of the ventilatory threshold (VT) has been explored as a cardiorespiratory 
measure but has limitations. A variety of criteria have been used to determine VT and 
various methods have resulted in different values (Cohen Solal et al; 1991). Cohen Solal 
et al; (1991) examined the use of VT using 5 different graphical methods to determine VT. 
They found that VT could only be determined between 72-88% in CHF patients using the 
5 methods and concluded that the reproducibility of VT was less than the peak VO2  in the 
same group of CHF patients. However, using the V slope method Pina et al; (1990) 
compared the detection of VT using four different protocols in CHF patients and 
concluded that the VT was more reproducible and effort independent than peak VO2 . The 
authors referred to a reproducibility to within ±  7% and did not mention any problems 
with the detection of VT. In CHF patients, Metra et al; (1990) found that peak VO2 , 
lactate threshold (LT) and VT were related to each other but significantly the VT could 
only be found in 77% of the patients tested. If there is an association between VT and LT 
it would be expected that lactate and ventilatory markers would correspond, this has not 
always been the case (Spurway, 1992). It has been shown that VT correlates more closely 
with K+ accummulation than lactate (Busse et al., 1991). The LT has been shown to be a 
sensitive marker of training status in athletes. Blood flow influences the removal of
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lactate and the uptake of lactate by the liver. Irregularities in blood flow in CHF may 
influence the LT so that blood lactate measurement may not reflect the production in 
exercising muscles. Thus, the use of AT (VT and LT) may have limitations in CHF.
2.3.3. SUBMAXIMAL EXERCISE TESTS.
In recognition of the inappropriateness of maximal tests to everyday life, researchers have 
attempted to use submaximal tests to evaluate CHF patients. For example, an attempt has 
been made to measure how long a patient can exercise at 70% of maximum (Poole- 
Wilson, 1989a). Personal experience of this method has shown that exercise times can 
exceed 30 minutes. Thus the excessive timescale makes this approach impractical. 
Cowley et al; (1991) compared a Bruce and a sub-maximal protocol in CHF patients. 
They found that with treatment that the constant work rate test showed a much greater 
percentage increase than the Bruce protocol. They concluded that a fixed sub-maximal 
workrate may be better to assess exercise tolerance in CHF as peak VO2  is difficult to 
attain. Van Baak et al; (1991) used a sub-maximal workrate on a cycle ergometer to 
evaluate the use of enalapril on hypertensives. However, the mean exercise time was over 
50 minutes making this timescale unaccetpable for clinical use. Koch and Broustet, 
(1993) used a constant workrate sub-maximal test (two stages under the maximal stage in 
a 10 watts per minute incremental maximal test) to assess training effects in CHF patients. 
The mean exercise times were 10 minutes (pre-training) and 19 minutes (post training). 
The standard deviations of around 14 minutes in both tests indicates a wide range of 
endurance times.
2.3.4. WALKING TESTS.
Some researchers have used a self paced walk test to evaluate CHF patients. Two types of 
test have been described. One where experimenters have measured how long a patient can 
walk in a certain length of time eg. 6  minute walk test. (Lipkin et al; (1986b) investigated 
the use of a six minute walking test in CHF patients. Patients were asked to walk as far as 
possible in 6  minutes in a 20 metre "shuttle” corridor test. All subjects preferred the 
corridor test to a maximal treadmill test. The authors concluded that the 6  minute test was
28
a simple objective guide to disability and of particular value in assessing patients with 
severe CHF. A marked limitation in this test is its inability to discriminate between 
patients with mild heart failure and normal subjects. A corridor walk test where the time 
taken to walk a fixed distance is measured is another form of walk test (Cowley et al; 
1986). The patient controls the pace during a timed corridor test but it is difficult to 
monitor physiological variables. There is the possibility of distraction and pace judgement 
may prove to be difficult. Furthermore, patients have been asked to adjust their speed to 
slow, normal and fast and assessment made on their responses to these descriptions. This 
methodology would appear to have limitations as the meaning of this approach is unclear.
Guyatt et al (1985) compared a variety of functional tests including incremental tests, a 6  
minute walk test and they administered functional status questionnaires. They concluded 
that the 6  minute walk was reproducible and reported that none of the functional status 
measures were as reproducible as the 6  minute walk. Cowley et al; (1991) are critical of 
standard 6  or 1 2  minute tests as they are symptom limited.
Parameshwar et al; (1989) measured the distance walked on a self powered treadmill and 
concluded that this method was simple, self paced and avoided the problems of congestion 
associated with corridor tests. The authors stated that this test has the sensitivity to detect 
change. However, the fact that the subject must hold on to the support rails would 
invalidate this test as it is not possible to standardise the workrate.
2.3.5. EXERCISE TESTS - THE FUTURE?
Cowley et al; (1991) considered the best marker of a patient’s symptomatic impairment 
was the amount of exercise carried out in daily activities, and indicated that step counting 
with body-borne pedometers may be a useful method of monitoring daily activities. This 
method does not detect pace fluctuations or changes in symptoms.
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Guyatt et al; (1985) have suggested that an ideal measure of function in CHF should be 
highly reproducible, reflect physiological function and be closely related to the patient's 
ability to cope with the demands of daily living. Undoubtedly the best indicator of 
exercise tolerance in CHF must be how it relates to every day activities.
Weber and Janicki, (1985) considered that any submaximal test which lacks objective and 
quantitative endpoints would appear to have limited use in CHF. Poole-Wilson, (1989a) 
concluded in his review of exercise testing in CHF that "there is a need for a simple 
exercise test which can be used to evaluate symptoms of patients with CHF and to test the 
efficacy of new drugs as they become available." He advocated that the test must be 
simple, cheap, reproducible and sensitive. In addition, he stressed the need for tests which 
relate to everyday life.
Treadmill exercise, no matter the protocol involves the patient in a learning process to 
become familiar with the apparatus and surroundings. Thus, it has been suggested that 
some form of free walking test may provide a better indicator of functional capacity. 
However, a treadmill test has several merits in the evaluation of CHF patients: Most 
patients can be quickly familiarised with the apparatus. Walking is a natural activity and 
part of daily activity. Exercise testing allows the experimenter to relate the patient's 
sensation of breathlessness and general fatigue to physiological markers. A treadmill in a 
laboratory enables the experimenter to establish a controlled and reproducible 
environment and allow for a direct comparison with previous tests, unlike a corridor test 
or a self powered treadmill which depend on the pace setting of the subject. It seems 
sensible to assess patients during walking and not cycling as walking is common to all.
A treadmill test which relates to daily activities can measure symptoms has a defined 
endpoint and is reproducible would be of great benefit in the evaluation and monitoring of 
CHF patients.
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Thus, the concept of two forms of exercise test for CHF patients seems plausible. A 
submaximal test which measures symptoms and a maximal test which predicts prognosis 
and measures functional capacity. Both types of test would be valuable in the assessment 
of drug intervention.
2.3.6. THE QUEST FOR THE "BEST" TEST.
It is important that the clinician is able to gain the patient's own perception of symptoms 
rather than the impression of an "external observer". Exercise testing can give the 
clinician the opportunity to assess symptoms in a stable environment. Furthermore, with 
monitoring of respiratory gases, it should be possible to study any relationship, if any, 
between the sensation of breathlessness and objective measures of respiration.
In recognition of a need for a new test an attempt was made to establish a protocol which 
was sub-maximal but had an end point within a reasonable period of time, included an 
assessment of symptoms, was reproducible and could be easily applied to a clinical 
setting.
Several CHF patients were given a sub-maximal test at 70% of peak VO2 . However, some 
subjects were able to continue at 70% peak VO2  for over 30 minutes. A second strategy 
involved the selection of the sub-maximal workrate by adopting the workrate at a 
ventilatory threshold. However, this method sometimes produced treadmill times in 
excess of 30 minutes.
Experimentation with workrates around 80% peak VO2  produced (in some instances) 
treadmill times between 8  and 17 minutes but not in all cases. Therefore, it was decided 
that it was not feasible to calculate an appropriate workrate which would result in an 
"acceptable" exercise duration time.
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A pilot study (see Appendix A for details) was conducted to determine which subjective 
scale (VAS and Borg CR10) was more reproducible during submaximal exercise in CHF 
patients. After two maximal tests the subjects performed a submaximal "trial’1 test which 
consisted of 6  minute stages. The subjects started at 60% peak VO2  and progressed in 
approximately 10% peak VO2  increments to a symptom limited endpoint. Based on the 
findings of the test the subjects were given 3 submaximal workrates during which they 
were asked to record their perceptions of breathlessness and general fatigue at various 
timepoints during the test. The subjects performed four tests at weeks 1,2 4 and 6  to 
examine the reproducibility of the scales.
The results of this pilot study demonstrated that both scales showed good reproducibility 
at the highest of the three submaximal workrates. Despite the attainment of a reproducible 
tests clinicians in the hospital considered that the methods employed had some limitations. 
A trial submaximal test was needed to establish the appropriate range of submaximal 
workrates. In addition, in most instances there was no symptom limited endpoint i.e. the 
subjects were stopped by the experimenter at the end of 18 minutes.
It was decided to once again attempt to find a method of selecting a submaximal workrate 
which would give a "subject limited" endpoint. Experimentation suggested that it was 
possible to determine an appropriate workrate by selecting 80% of the predicted maximum 
oxygen cost of the higher workrate attained by the subject during the two maximal 
incremental tests.
A study was undertaken to establish if this procedure would result in a test which would 
be simple, could be used to evaluate symptoms and be reproducible. The aim of this study 
was to evaluate the use of a submaximal test with a symptom limited end point and to 
measure symptoms in patients with chronic heart failure.
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CHAPTER 2 
SECTION FOUR
THE STEEP TEST.
2.4.1. THE STEEP TEST.
A variety of exercise protocols are used in cardiology but no single protocol is 
appropriate for a wide range of patients' exercise capacity. A new protocol (STEEP 
TEST - Standardised Exponential Exercise Protocol) was devised by Northridge et al;
(1990). This new exercise protocol consists of 15 one minute stages and is based on 
exponential rather than linear increments in workrate. The test begins with a low 
workrate and because it uses small, frequent increments in energy cost it is suitable 
for even severely limited patients. Nevertheless it is designed to induce cessation of 
exercise in cardiac patients within 15 minutes so that boredom and fatigue are not the 
limiting factors. As the STEEP protocol has very small energy cost increments every 
minute, it is hypothesised that the STEEP protocol may reflect a range of every day 
activities and energy costs. Thus, the STEEP protocol may be useful in evaluating 
symptoms encountered in every day life and may provide an easier method of 
assessing symptoms than the lengthy procedure of devising a relative intensity from a 
submaximal test and a maximum test. The STEEP protocol may have the advantage 
of providing meaningful submaximal information and maximal values in the one test. 
The STEEP protocol has been used in a number of hospitals and has been adopted to 
evaluate the effect of drug therapy in a number of drug trials. A limitation of the test 
is that normals with a relatively high VC^max score can exceed the highest workrate 
on the STEEP protocol.
2.4.2. STEXT PROTOCOL.
As the STEEP protocol has been readily accepted by patients and clinicians, it was 
decided to use the protocol in a study (MONICA) which involved screening of 2000 
men and women between the ages of 25-74 years in the West of Scotland. Exercise
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testing, blood pressure, lipid profile and echocardiography were included in the test 
battery. It was necessary to extend the protocol by three stages to accommodate the 
anticipated high scores from fit young people. The extension of the protocol to a 
maximum of 18 minutes would have a number of advantages:
It was anticipated that the STEEP extension protocol (STEXT) would be suitable for 
all subjects in the MONICA study. The West of Scotland population could be 
categorised into aerobic fitness levels according to the STEXT protocol. Comparison 
of aerobic fitness levels and coronary risk factors could be made.
While the STEXT protocol has been adopted by the MONICA project more 
information is required about this protocol. The reproducibility of the maximal 
values has not been established. The possible use of subjective scales with this 
protocol has not been investigated. Drug trials normally have a "run in" period to 
establish representative baseline levels. A possible sequence of tests (involving the 
STEXT protocol) for a drug trial in patients with stable angina has been proposed. 
Patients will undergo two tests within 48 hours of each other at weeks 0, 2, 6  and 10. 
No drug therapy will be administered in the first 4 tests. At weeks 6  and weeks 10, a 
comparison of drug therapy will be made.
Thus, it was decided to evaluate the STEXT protocol using normals and adhering to 
the proposed timescale for a patients' study to determine the reproducibility of the 
physiological variables and subjective scales (Borg CR10 and VAS). No intervention 
would be made in the first four tests but "therapy" with beta blockers and placebo at 
weeks 6  and 1 0  would provide information on the sensitivity to change of the 
subjective scales.
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CHAPTER 2 
SECTION FIVE.
SUBJECTIVE SCALES.
2.5. SUBJECTIVE SCALES.
Many studies rely on subjective measures to evaluate outcomes including quality of life, 
dyspnoea and fatigue. Major debate has centred around the selection of the optimal 
response options. Guyatt et al; (1987) referred to several studies and concluded that 
different methods of presenting response options have produced consistently high 
correlations with each other. However, selection of an outcome measure must be related 
to its ability to detect clinically important change even if the change is small (Kirshner and 
Guyatt, 1985). Responsiveness of different scales can be examined by comparing 
outcome measures in the same trial. A number of subjective scales have been used to 
measure response options. The choice of subjective scale includes the Visual Analogue 
Scale (VAS), Likert scale, the Borg 6-20 scale and the Borg Category Ratio Scale (Borg 
CR10).
2.5.1. VISUAL ANALOGUE SCALE.
The VAS scale consists of a straight line labelled at either end. The subject is asked to 
respond by registering on the line to indicate his perception of a symptom (eg 
breathlessness). One end is labelled "none" and the other "very severe" and a title heading 
depending on the variable being measured (for example, with a breathlessness heading for 
breathlessness). The scale is scored from 0-100 but this subdivision into numbers is not 
visible to the subject.
2.5.2. LIKERT SCALE.
A Likert scale is a multi-item scale with verbal descriptors of feelings. For example, a 
four point Likert scale relating to pain - no pain, a little pain, moderate pain, a great deal 
of pain.
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2.5.4. BORG SCALES.
In 1962 Borg produced a 21 point category rating scale for perceived exertion. This scale 
was established by taking the fairly close relationship between heart rate and perceived 
exertion into account. In 1970, Borg devised a 15 point category scale (Borg 6-20 scale). 
The change to the 15 point scale included changing some of the verbal anchors and the 
mid-point was lowered. The Borg 6-20 scale has been used to assess subjective rating of 
perceived exertion. Astrand and Rodahl, (1986) state that this scale can be modified to 
give a rating of general fatigue, leg fatigue and dyspnoea. In 1982 Borg developed a 
category ratio scale. This scale consists of a vertical scale labelled 0-10 with verbal 
anchors of progressively increasing perceived sensation. The scale range is from 0-10. 
Using the Borg CR10 scale, perceived exertion was shown to increase exponentially when 
related to exercise. Borg stated in 1982 that the new scale may be appropriate for 
determining other subjective symptoms eg breathing difficulties.
2.5.3. COMPARISONS OF SCALES.
Comparison of some subjective scales has included the magnitude of between-subject 
variability, test-retest reliability and the strength of relationship with other measures. The 
visual analogue scale (VAS) has been considered to be able to detect small clinically 
important change and therefore be highly responsive (Scott and Huskisson, 1977). 
However, (Guyatt et al; 1987) concluded that there is little evidence to support this 
contention. For example, a four point Likert scale and the VAS were compared in a trial 
to measure pain ratings. The results of this study were inconclusive (Guyatt et al; 1987). 
It has been shown that subjects found a 7 point Likert scale easier to use than a VAS in a 
quality of life assessment in patients with respiratory disease. The subjects needed more 
training time to understand the VAS. Guyatt et al; (1987) stressed that time may not be 
available in a clinical setting to educate patients in the use of the VAS. Guyatt et al; 
(1987) considered that the Likert 7 point scale has an added advantage over the VAS in 
that a change in a 7 point scale seems easier to grasp than a change of 10 or 20 mm in a
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VAS scale. They concluded that there was no difference in the responsiveness between 
the Likert 7 point scale and the VAS. Guyatt et al; (1987) have stated that the Likert 7 
point scale is easier to administer than the VAS. They concluded that clinicians intuitively 
grasp the Likert scale results. Thus, Guyatt and his colleagues recommended the use of 
the Likert scale. They conceded that results from a quality of life study may not be 
generalizable to other areas including symptoms. They recommended that other studies 
are undertaken with other outcome measures in different patient groups.
2.5.5. THE NEED FOR MORE RESEARCH.
The paucity of information on the comparison of response outcomes involving 
breathlessness and general fatigue makes investigation in this area desirable. Clearly a 
weakness of subjective scales is the unavoidable subjectivity. However, it is important to 
establish which scale if any, is reproducible and sensitive to change when the symptoms of 
breathlessness and general fatigue are assessed.
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CHAPTER 2 
SECTION SIX.
BREATHLESSNESS (DYSPNOEA).
2.6.1. BREATHLESSNESS (DYSPNOEA).
Dyspnoea has been difficult to evaluate because it is a subjective sensation which may or 
may not correlate with physiological measurements. There is no generally accepted 
definition of dyspnoea.
Dyspnoea according to Comroe, (1966) is "difficult, laboured breathing, uncomfortable 
breathing". Other workers have defined dyspnoea as "an uncomfortable awareness of 
breathing" (Mahler et al; (1984). Wasserman and Casaburi, (1988) described dyspnoea as 
"feeling breathless, air hunger" and they state that this symptom is experienced by normal 
people and patients. "The common experience of an uncomfortable need to breathe" 
(Adams et al; 1985a), "discomfort in the act of breathing" (Killian, 1988) and "an 
uncomfortable need to breathe" (Wilson and Jones, 1989) are examples of the various 
definitions used to define breathlessness.
Normal healthy individuals experience breathlessness which is usually experienced in 
association with an increase in ventilation but other potential links with breathlessness 
have not been clearly established.
2.6.2. VENTILATORY CONTROL MECHANISMS DURING EXERCISE.
Exercise results in an increase in cellular oxygen requirement and an increase in CO2  
production. In an incremental exercise test VE, VO2  and VCO2  increase linearly to 
around 60% of a normal persons VO2  max. Above this value VE shows a disproportionate 
increase compared with VO2 . VE and VCO2  both rise more steeply above the 
"breakpoint" in VE. This increased ventilatory drive has been attributed to metabolic 
acidosis. During exercise, VCO2  increases as the intensity becomes greater and VE must
increase to keep the arterial PCO2  (PaCC^) constant. The increased levels of VE at the 
higher intensities is considered to be related to the buffering of lactic acid by bicarbonate 
and the increase in hydrogen ion concentration resulting in a lower arterial bicarbonate 
following the buffering reaction. During moderate work PaCC>2 stays fairly constant due 
to the increase in VE but, as the VE increases more quickly the PaCC>2 falls (Wasserman, 
1978). The control of breathing during exercise is considered to be an amalgam of several 
factors. It has been suggested that neurogenic stimuli from the cerebral cortex or the 
active limbs result in the initial abrupt increase in VE at the start of exercise. Artificially 
induced increases in blood flow through canine hearts have resulted in an immediate 
increases in VE similar to the VE response at the onset of exercise (Wasserman et al; 
1974). It has been speculated that chemoreceptors play the most important role in the 
overall regulation of VE. The precision with which arterial blood gases and acid-base 
balance are regulated makes this suggestion plausible (Wasserman and Carraburi, 1988).
2.6.3. DYSPNOEA PRODUCING STIMULI.
There are a variety of possible stimuli to breathing and hence dyspnoea. Several studies 
have reported that during exercise in normals that there is a linear relationship between 
VE and dyspnoea. Dyspnoea producing stimuli are integrated through the central nervous 
system. However, the location of the dyspnoea producing stimuli are unknown.
2.6.4. CHEMICAL VENTILATORY STIMULI AND DYSPNOEA -
HYPERCAPNIA.
In a study using normals Lane et al; (1987) monitored the perception of dyspnoea while 
the subjects breathed inspired air in which the CO2  content was varied in an oscillatory 
pattern. Subjects were asked to copy the CO2  breathing pattern without allowing the 
PC02 to change. The subjects did not experience dyspnoea. The authors concluded that 
the perception of dyspnoea did not arise from the mechanical act of breathing alone but 
must involve input from the chemoreceptors as well. In their review, Adams and Guz
(1991) concluded that experiments do not support the role of hypercapnia per se as a cause
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of breathlessness but they suggest that the degree of reflex activation of VE whether by 
exercise or CO2  is a major factor in determining the intensity of breathlessness.
2.6.5. HYPOXIA.
Progressive hypoxia is associated with increasing levels of breathlessness compared with 
exercise at equivalent levels of VE (Ward and Whipp, (1989), Chronos et al; (1988). 
Adams and Guz (1991) suggested that afferent activity from the peripheral 
chemoreceptors may have direct access to the sensory cortex and that the effect of hypoxia 
may be particularly noticeable in the time lag between the degree of reflex ventilatory 
activation of the respiratory centres and the resulting ventilatory response.
2.6.6. PULMONARY RECEPTORS AND DYSPNOEA.
Two lung reflexes which stimulate ventilation are thought to contribute to the sensation of 
dyspnoea and lie in the pulmonary vagus nerves. The inhibitory Hering-Breuer reflex 
takes place when the pulmonary stretch receptors fire during inspiration. This reflex 
operates in man only at increased tidal volumes. It has been suggested that J recptors are 
stimulated by distortion of the interstitial space of the lung. It is believed that disease 
states (eg. pneumonia) cause tachpnoea by stimulating the J receptors (Adams and Guz, 
1991).
2.6.7. LENGTH TENSION.
Campbell and Howell (1963) postulated that dyspnoea arises because there is a mismatch
between the demand for breathing and the effort required to achieve it. Campbell and 
Howell, (1963) hypothesised that tension to breath is appropriate to the tidal volume. 
When a resistance is imposed, there is a transient decrease in tidal volume which causes 
stimulation of muscle spindles within the respiratory muscles resulting in an increase in 
respiratory motor neurone output so that greater tension is produced. Thus tidal volume is 
maintained but with a greater muscle tension. Campbell and Howell, (1963) postulated 
that the alteration in the length/tension ratio is responsible for the sensation of
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breathlessness being detected. The fact that reflexly stimulated increases in VE result in a 
perception of breathlessness but increases in volitional VE do not, appears to invalidate 
the length/tension theory.
2.6.8. CENTRAL RESPIRATORY COMMAND AND BREATHLESSNESS.
It has been suggested that the perception of breathlessness shares the same 
neurophysiological lanes as the sensation of muscular effort Furthermore, the sensation 
of breathlessness comes mainly from the sensing of central nervous system activity and 
not from specific peripheral receptors (Adams and Guz, (1991)
2.6.9. METHODS OF ASSESSING BREATHLESSNESS.
Clinical interviews are a common method of assessing breathlessness. Interpretation of 
the responses is difficult as the answer may depend on several factors including the 
current level of physical activity, the subject’s tolerance level, the intensity (energy cost of 
the task), the prevalence or otherwise of other symptoms, the accuracy of reporting 
distance and recall. In recognition of the problems associated with the assessment of 
breathlessness, questionnaires have been developed to categorize patients according to 
their symptoms reported during a variety of activities. For example, a five point scale has 
been used to assess breathlessness in daily activities (Medical Research Council, 1966). 
This five point scale has limitations as it is too insensitive to detect meaningful differences 
and gives little information on the intensity of the sensation. The scoring system of 
Mahler et al; (1984) has three different categories "functional impairment", "magnitude of 
task" and "magnitude of effort". This approach has many theoretical advantages including 
the offer of many responses by the patient. However, Adams and Guz, (1991) concluded 
that there is no evidence that the Mahler scale and its finer categorisation has any clear 
advantage over the five point grading system of the Medical Research Council, (1966).
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2.6.10. EXERCISE TESTS.
The use of predetermined workrates (eg cycle ergometer) and the measurement of 
respiratory variables with concomitant assessment of the patient's symptoms provides the 
opportunity to compare physiological data with symptoms and both of these responses 
over time in a standardised environment. Criticisms of exercise tests include the 
unsettling feeling that many patients report As a result, corridor walk tests have been 
used to provide a simple reproducible test which gives an objective index of functional 
impairment, but does not offer comparison between physiological and symptomatic data.
It is clearly important to be able to assess symptoms and be able to relate them to 
physiological data.
2.6.11. TERMINOLOGY TO DESCRIBE THE SENSATION OF
BREATHLESSNESS.
The fact that there is no universally accepted definition of breathlessness has resulted in 
the use of a variety of terminology by researchers to describe the sensation of 
breathlessness. The description of breathlessness has varied greatly and may explain the 
different results in some studies. Some researchers have asked subjects to measure 
breathlessness without attempting to define the sensation (O'Neil et al; 1986). Other 
studies have employed a variety of terminology including "difficult" (Mahler et al; 1987) 
or "effort" in breathing (Killian et al; 1984). Several groups have referred to the 
"uncomfortable" nature of the sensation of breathlessness (Wilson and Jones, 1989). 
Wilson and Jones, (1991b) asked normals to differentiate between intensity and distress of 
breathlessness. They found that the mean intensity scores were greater than distress scores 
and that there was no common pattern between intensity and distress. They concluded 
that different elements of breathlessness could be identified and selectively measured 
depending on the wording used. These findings support Comroe's suggestion that 
breathlessness is not a unitary measure and stress that subjects are able to differentiate
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between some aspects of breathlessness. The findings of Simon et al; (1989) support the 
contention that breathlessness is multidimensional in nature. Simon et al; (1989) studied 
30 normals and induced breathlessness using 8  different stimuli. The subjects were asked 
to choose descriptions of their sensation(s) from a questionnaire listing 19 descriptors. 
Using cluster analysis the investigators were able to look for relationships among the 
descriptors and identify natural groupings. They found that subjects could distinguish 
different sensations of breathlessness and they reported an association between certain 
descriptor groups and stimuli. They concluded that the term breathlessness may 
encompass a variety of sensations and may not be a single physiological mechanism.
The literature indicates that breathlessness is a multi-dimensional sensation. Thus, it 
seems reasonable to speculate that the wording of instructions to subjects will influence 
how they respond to questions on their perception of breathlessness.
2.6.12. MEASUREMENT OF BREATHLESSNESS - VISUAL ANALOGUE 
SCALES.
Visual analogue scales (VAS) were first used to assess the sensation of pain and sedation 
but for more than a decade they have been used to assess the perception of breathlessness 
in normals and patients. Using the VAS in a group of six healthy males, Stark et al; 
(1981) quantified breathlessness during treadmill walking. They showed that VE and 
breathlessness scores increased and both values returned to resting levels during recovery. 
A paired t-test showed they there was no significant difference between VE or VAS scores 
between test 1 and test 2 which were one week apart. In 4 subjects sensitivity of the VAS 
was tested by using inspiratory resistances which resulted in an increased level of 
breathlessness for a given level of VE.
Later, Stark and his colleagues (1982) examined the reproducibility of the VAS in chronic 
bronchitis and emphysema patients. The patients visited the laboratory three times to 
allow for a familiarisation period and two identical treadmill tests 5 days apart. They
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concluded (despite no statistical back-up) that the relationship between breathlessness 
scores and VE generally showed adequate within subject reproducibility. Using five 
asthmatic patients to test sensitivity, Stark et al; (1982) gave the patients a bronchodilator 
to promote a reduction in breathlessness. They found that in 3 subjects improvement 
could be clearly detected by the VAS scale, but cautioned that reproducibility could not be 
invariably attained. Stark et al; (1982) concluded that the assessment of breathlessness in 
patients was generally reliable and that responses are modified by drug intervention. The 
authors stressed that the patients in their study were selected for their cooperation and 
understanding. They cautioned that unselected subjects may use the VAS in an unreliable 
way. The authors advised that patients should undergo checks to ensure that the VAS is 
being used in a meaningful way.
Stark et al; (1983) examined the relationship of breathlessness and VE in 6  normals during 
a sub-maximal treadmill test of three two minute stages. On two different occasions two 
tests 90 and 130 minutes apart were given, one in the presence of and the other in the 
absence of inspiratory resistance. Using analysis of variance in accordance with the 
factorial design the authors reported high reproducibility. In the presence of a respiratory 
resistance, VE was slightly depressed but a significantly greater sensation of 
breathlessness was reported in relation to VE with the respiratory resistance.
Adams et al; (1985a) examined the reproducibility of the VAS over a time interval 
ranging from a day to one year. The subjects (34 males and females) were divided into 
groups and given a variety of ’’treatments" including hypercapnia and hypoxia and steady 
state exercise on a cycle ergometer. Statistics were conducted using a t-test and the 
relationship was clarified by linear regression analysis. The authors concluded that the 
reproducibility of the VAS when related to VE was independent of the nature of the 
ventilatory stimulus. Reproducibility was as good after one week (r= 0.95), as one day (r= 
0.95) but was less good after one year (r= 0.64).
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Despite the fact that it has been shown that VE is not directly related to breathlessness 
many studies have compared the relationship between VE and subjective scales. The 
relationship between VE and breathlessness is not fixed but is related to how 
breathlessness is induced. Adams et al; (1985b) have shown that breathing 15% O2  
caused an increase in breathlessness (using VAS) before an increase in VE was noted.
VAS scores have been shown to increase independently of VE during the fourth to sixth 
minute of steady state exercise (O'Neil et al; 1986). O'Neil et al; (1986) examined the 
response of 6  subjects to two steady state cycle exercise bouts and a progressive cycle test. 
Both sets of tests were repeated over a period of two days. A paired t-test showed that 
there was no significant difference in VAS and VE in the progressive test. Despite no 
change in heart rate, VE VCO2  or VO2  in the steady state protocol, the VAS was 
significantly increased at 6  minutes compared with 4 minutes. The authors concluded that 
breathlessness is not simply a sensing of VE achieved. This conclusion may be somewhat 
simplistic as it is unclear as to what is happening to individuals in these analyses. In 
addition, Wilson and Jones, (1989) have shown that subjects perceived a higher level of 
breathlessness relative to VE throughout the second half of an identical protocol over a 
two part test using VAS and Borg CR10 scales.
Muza et al; (1990) examined the "sense of effort" in breathing in chronic obstructive 
pulmonary disease (COPD) patients 3-5 times. The 6  subjects performed a progressive 
maximal test on a cycle with 1 hour between tests 1 and 2  and 1 - 1 0  days between tests 2  
and 3. Tests 4 and 5 were carried out two weeks after the third test The VAS correlated 
linearly with VE in all trials (r= 0.98) and when converted to common units correlated 
closely with the Borg Category scale (R= 0.99). Using z scores Muza et al; (1990) found 
that the VAS had almost twice the resolution of the Borg category scale. This finding 
suggests that the VAS may be almost twice as sensitive an indicator of a change in 
breathlessness than the Borg category scale. Muza et al; (1990) speculated that the
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difference in the resolution may be due to the stated boundary present in Borg category 
scale. They considered that the subjects were constrained by the apparent maximum in the 
Borg category scale.
Research has shown that subjects use the VAS scale in an individual way and that only 
meaningful comparisons are those conducted on within subject basis (Stark and Guz). 
Debate has centred on whether the VAS should be anchored. One group of researchers 
has established a maximum point by using a short bout of strenuous exercise (Stark et al; 
1981). Others have produced reproducible results without anchoring (Guz et al; 1981). A 
major repeatable difference between how individuals rate breathlessness has been reported 
using the VAS scale. One possible reason may be that individuals may interpret the 
meaning of the upper limit of VAS differently. Adams and Guz, (1991) recommended 
that the use of a reference point based on general experience is probably the best strategy 
for long term studies. In his review of breathlessness and VAS scales Stark, (1988) 
concluded that a proportion of patients appear to be unable to use VAS scales in a 
meaningful way. He recommended that clinical studies should incorporate tests to 
determine how well the VAS is used in a specific group.
2.6.13. MEASUREMENT OF BREATHLESSNESS - BORG CR10 SCALE.
Wilson and Jones (1991a) investigated the reproducibility of breathlessness scores on 7 
occasions over 40 weeks in 7 healthy subjects during cycle exercise. The authors used an 
incremental cycle protocol and showed that the mean VE measured at each work rate did 
not differ significantly in any of the 7 tests. There was no significant difference between 
the mean Borg scores (compared with a given level of VE) for 5 out of the 7 tests. They 
found that the mean Borg scores at week 3 and week 6  were significantly lower than some 
other time points but they concluded that despite the downward trend at week 3 and week 
6  there was no pattern in the change over time. They considered that the duration without 
testing between consecutive tests had no effect on reproducibility. The slope of the
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analysis included analysis of variance and co-variance. It was concluded that the Borg 
CR10 scale provided a reliable technique for studying the sensation of breathlessness over 
extended time periods.
2.6.14. MEASUREMENT OF BREATHLESSNESS - COMPARISON OF 
VAS AND BORG CR10 SCALES.
It has been shown that VAS and Borg CR 10 scales correlate closely with VE during
exercise in patients and normals. Wilson and Jones, (1989) compared the reproduciblity
of VAS and Borg CR10 scales in 10 normals during cycle exercise using a test re-test
design . Tests were 2-6 weeks apart and consisted of a progressive increase to 105 watts
and a gradual return to zero load.
Wilson and Jones used the slope of the relationship of VE/breathlessness to compare tests 
and reported that the relationship was slightly higher in the second half of the test. They 
performed repeatability comparisons on the slope of the relationship as it was felt that VE 
would relate more closely to breathlessness than to workrate. Scores on both scales were 
lower in the second test compared with the first with the mean Borg CR10 score 16% 
lower and the VAS 27% lower. The authors reported a large inter-subject variation in the 
relationship between minute ventilation and breathlessness scores and a good correlation 
between the VAS and Borg CR10 scales. They suggested that the Borg CR10 scale 
appeared to have greater stability than the VAS and correlated slightly better with VE than 
the VAS. They reported that the Borg CR10 scale was used over a narrower range than 
the VAS and speculated that this result may be due to the effect of the verbal descriptors 
on the Borg CR10 scale which may have imposed a certain threshold of sensation 
intensity which had to be exceeded before proceeding to the next digit or it may be that 
"fit" subjects did not use the upper part of the scale. Descriptors may also increase 
preferential use of certain digits. The Borg CR10 scale has an in-built ratio bias with a 
tendency to restrict scores to the lower half of the scale. The midway point is labelled 
severe. The VAS has no constrictors. Wilson and Jones, (1989) favoured the Borg CR10
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scale as they found it to be slightly more reproducible than the VAS and it correlated more 
with VE. However, they speculated that the VAS might be better because it has 
potentially a larger number of scoring levels whereas the Borg CR10 scale has only 12 
levels and the subjects in their study used only 6 . The limited range on the Borg scale 
may have contributed to the higher reproducibility compared with the VAS. However, the 
Borg CR10 scaling system forces subjects into preordained limits. The VAS offers greater 
potential for identifying small changes but this may depend on the study design and 
analysis.
Wilson and Jones; (1991a) mentioned one study (Jones et al; 1984) where the 
reproducibility of the VAS was so low that analysis of the results could not be undertaken 
and they recommended that the long term reproducibility should be confirmed before 
studies of long duration are attempted.
2.6.15. SUMMARY.
In principle, the VAS offers greater potential for identifying very small changes but this 
may depend on study design. Referring to the VAS and the Borg CR10 scales Adams and 
Guz, (1991) concluded that any differences between the scales was more theoretical than 
real.
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CHAPTER 2 
SECTION SEVEN.
GENERAL FATIGUE.
2.7.1. GENERAL FATIGUE.
General fatigue is a general term which may be applied to a variety of situations and may 
range from a slight feeling of tiredness to outright exhaustion. General fatigue need not 
arise directly from the subject's immediate exercise history: alternatively it can be a 
symptom of a disease or be psychological in nature, being associated with a lack of 
motivation or lack of interest. Christensen, (1960) has defined physical fatigue as a state 
of disturbed homeostasis which may result in subjective and objective symptoms. 
Linkage of symptoms with physiological variables may be possible in some instances. For 
example, high intensity exercise which results in high lactate levels correlates highly with 
subjective symptoms of fatigue. However, this relationship will not be present in 
prolonged work at low or moderate intensities. The area of fatigue and contributory 
factors to fatigue will vary depending on the type of and length of the exercise bout. In 
low intensity exercise (less than 50% VC>2 max) fatigue is often determined principally 
by factors which influence the CNS including pain, discomfort, dehydration, and changes 
in transmitter precursors. At intensities between 60-90% VO2  max fatigue is associated 
with depleted stores of muscle glycogen. Endurance performance is closely related to the 
pre-exercise muscle level of glycogen (Costill and Hargreaves, 1992). At even higher 
intensities, the metabolic end products (i.e. lactate, H+, Pi and ADP) accumulate and are 
associated with fatigue (Sahlin, 1992).
There is agreement that the possible causes of fatigue are multifactorial in nature. 
Sustained physical activity can result in fatigue which may be explained by central 
(impairment is located in the CNS) and peripheral (impairment is found in the peripheral 
nerve or contacting muscle) mechanisms (Sahlin, 1992).
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2.7.2. CENTRAL FACTORS.
Amongst the mechanisms contributing to central fatigue is hypoglycaemia which has long 
been known to impair the function of the CNS (Costill and Hargreaves, 1992). NH3  
increases with exercise and might also impair CNS function (Mutch and Bannister, 1983). 
Endurance exercise raises the free plasma concentration of tryptophan which can increase 
the entry of tryptophan into the brain raising the brain level of 5-hydroxytryptamine which 
is linked to central fatigue (Newsholme et al, 1992). The more apparently psychological 
factors of motivation, discomfort and pain are also, of course, recognised as being 
considered to be extremely important in central fatigue (Sahlin, 1992).
2.7.3. PERIPHERAL FACTORS.
Fatigue has been described as a fall in power output during a period of activity (Lannergen 
et al, 1992). Muscle contraction varies in a number of ways including the mode of 
stimulation, the type of contraction, the frequency, intensity duration, and type of muscle. 
Thus, it is not surprising that the site and causes of peripheral fatigue may vary. Fatigue 
does not appear to be as a consequence of low ATP levels as studies have shown that there 
is only a small decrease in ATP in fatigued muscle and that force generation is virtually 
independent of ATP in the range of concentrations found in normal and fatigued muscles 
(Jones and Round, 1990). A decrease in intracellular pH resulting from glycolysis and H+ 
accumulation has been shown to produce a decrease in force production. Possible 
mechanisms for this decrease in force production include interference with the interaction 
of myosin and actin and a fall in the affinity of troponin for Ca^+ (Jones and Round, 
1990). A fall in pH cannot be the only cause of fatigue as McArdle's patients demonstrate 
an increase in pH during exercise but fatigue easily. Accumulation of Pi which also 
inhibits cross bridge activity (Cook and Pate, 1985) is one of the mechanisms which could 
operate in these patients. Slowing of relaxation is a further feature of acutely fatigued 
muscles. This implies decreased cross bridge detachment speed which is another 
phenomenon which could be brought about by a decrease in ATP or increased ADP but 
the concentrations of these in the normal fatigued muscle are unlikely to produce the
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observed slowing. Instead, increased H+ is thought to slow the cross bridge cycle. 
Changes in phosphorus metabolites lead also to a decreased uptake of Ca^+ in the 
sarcoplasmic reticulum (Cady et al, 1989) which could further contribute to the slowing of 
relaxation. A slower relaxation has been attributed to a reduced rate of cross bridge 
cycling and not slowed Ca^+ handling (Westerblad and Allen, 1993).
Decreased Ca^+ release has been shown to contribute to fatigue. The importance of the 
fall in Ca^+ release for the decrease in tension has been confirmed by Westerblad and 
Allen, (1991) who showed a concomitant recovery of both force and Ca^+ when caffeine 
was applied. Yet another mechanism operative at least during high frequency stimulation, 
is a loss of membrane excitability leading to a reduced force. The two factors implicated 
in the reduced membrane potential are the large K+ fluxes from the working muscle 
resulting in high extracellular concentrations and the possibility of a metabolic change 
affecting the membrane characteristics, the result of which could have an influence on the 
rate at which the membrane Na+ K+ transport mechanism acts to redress the ionic 
balance. K+ concentrations have been shown to be very high in the T-tubules so that they 
are unable to convey the action potential, the consequence is a decreased Ca^+ release, 
hence reduced force (Jones and Round, 1990). The above relates to short term fatigue 
mechanisms. A causal relationship between the depletion of intramuscular glycogen 
stores and fatigue in endurance exercise has been shown (Bergstrom and Hultman, 1967).
It used to be believed that transmission failure at the neuromuscular junction was another 
operative factor in physical fatigue (Stephens and Taylor, 1972). However, Bigland - 
Ritchie et al, (1982) have been unable to find any evidence for neuromuscular junction 
failure even in the most likely case of sustained maximal isometric contraction. There is 
also no indication of neuromuscular transmission failure in "total body" dynamic exercise 
(Spurway et al, 1987).
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2.7.4. MEASUREMENT OF SUBJECTIVE RESPONSES TO EXERCISE -
PERCEIVED EFFORT/PERCEIVED FATIGUE.
In measuring subjective responses to exercise, Rejeski, (1981) considered that there may 
be a need to distinguish between perceived effort (short term work) and perceived fatigue 
(long term work). He stated that it is necessary to take into account the duration of the 
task. Borg, (1962) stated that "short term" work on the cycle ergometer, during which 
time muscular force appears to be important, and that it may be convenient for healthy 
persons to speak of perceived or apparent force, effort, exertion or pedal resistance". 
However, for exercise involving a fairly long duration, Borg (1962) advised that it may be 
more appropriate to "speak of perceived exertion, laboriousness or fatigue....". Borg 
attempted to differentiate between short and longer term work by considering that the 
latter relates more to the length of exercise time and stress that is placed on the circulation. 
Pollock et al; (1984) referred to the studies of Borg (1978) and Skinner et al; (1973a) 
when they stated that "the RPE scale has been shown to be a valid indicator of the level of 
physical exertion ("relative fatigue)". When Pollock et al; (1984) quoted instructions to 
subjects (page 191), they stated, "By perceived exertion we mean the total amount of 
exertion and physical fatigue". They explained that participants should not focus on any 
one problem but, "on a general fatigue". Thus, these authors perceived a strong linkage 
between general fatigue and RPE. While there may be a relationship, it is possible to 
argue that these two concepts are not necessarily the same. It is possible to be "fatigued" 
and not make an effort or make a considerable effort and not be fatigued. Maresh and 
Noble, (1984) defined perceived exertion as a method to determine the sensations 
(feelings) experienced during exercise. They debated whether the sensation should be 
described as the effort expended eg. the perception of increased resistance or as the 
physiological response resulting from the effort The authors prefer the latter.
Enoka, (1988) considered the task of carrying a suitcase for a long period when he 
described fatigue. He stated that at some point it will become more and more difficult to
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hold the suitcase and the individual will have to try harder to do so. Finally, the individual 
will be unable to hold the suitcase. Enoka emphasised two conditions:
1 ) the increasing difficulty.
2 ) the impossibility that is ascribed to the concept of fatigue.
Fatigue is considered to be a series of adaptations which occur during a sustained effort 
and not one single happening. Fatigue has subjective (ie. difficulty) and objective (ie. 
impossibility) components. Enoka described fatigue "as a progressive increase in the 
effort required to exert a desired force and the progressive inability to maintain this force 
in sustained or repeated contractions”. He stated that assessment of the difficulty of a task 
can be made by the psychophysical phenomenon known as sense of effort- "a relative 
subjective measure of the effort”. Borg, (1962) conceded that the subjective perception of 
effort, exertion and fatigue is very difficult to define in a general way.
2.7.5. MEASUREMENT OF FATIGUE Le. PERCEPTION OF FATIGUE.
"Fatigue" and "perceived exertion" have been used interchangeably by some researchers 
(Tesch, 1985, Gullestad et al; 1989). Many studies have used subjective scales to compare 
drugs, particularly beta blockers. It appears that "heavy" submaximal exercise i.e. at and 
above 70% V0 2  max is associated with increased effort and fatigue (Tesch, 1985).
Some studies have used subjective scales to measure fatigue even although the timescale 
of the test has been fairly short The word, "fatigue" has been used to monitor fatigue in 
patient groups and in normals. Dargie et al; (1991) compared two beta blockers (atenolol 
and celiprolol) using a VAS scale during submaximal exercise. They found that the 
normal male subjects recorded a significantly higher level of fatigue with atenolol and 
celiprolol compared with placebo. Gullestad et al; (1989) used a Borg 6-20 scale to assess 
subjective perception of fatigue. The aim of the study was to compare the effects of the 
opiod receptor antagonist naxolone and the non-selective beta blocker timolol on exercise 
performance and the subjective perception of fatigue. The 8  males (24-35 years) cycled 
for 30 minutes at a steady state. Thereafter, the workrate was increased every 2 minutes to
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exhaustion. Timolol lowered physical work capacity and increased the perception of 
fatigue whereas naloxone had no effect on physical work capacity or fatigue. Lees et al; 
(1987) compared two beta blockers in 10 male hypertensives. During an incremental 
bicycle exercise to exhaustion the investigators used a Borg 6-20 scale to measure fatigue. 
Despite variable effects on heart rate, the subjective perception of fatigue during exercise 
was the same for all treatments including placebo.
The author has been unable to find any studies which examined the reproducibility of 
subjective scales assessing general fatigue. However with regard to rate of perceived 
exertion Carton and Rhodes, (1985) have shown that RPE scales are reliable and 
independent of exercise intensity involving various protocols. The authors have reviewed 
the relationship between physiological stimuli and RPE. For example, they stressed that 
while heart rate and RPE may be correlated, this relationship does not imply a causal 
relationship. A variety of stimuli have been proposed as making contributions to 
perception of effort. Morgan et al; (1976) used hypnosis to investigate the peripheral and 
metabolic contribution to effort perception. Hypnotic suggestion of uphill work resulted in 
an increase in effort ratings despite the fact that heart rate and VO2  remained stable. In 
the exercise treatment, increases in RPE were in tandem with VE. Several studies have 
examined the role of VE and frequency of breathing on RPE. Noble et al; (1973) reported 
that VE and frequency of breathing were the best predictors of RPE. Other studies have 
reported correlations between VE and frequency of breathing and RPE between 0.52 and
0.94.
2.7.6. SUMMARY.
It may be important to distinguish between subjective exertion and subjective fatigue. The 
assessment of fatigue in a patient population can be of great value. It is important to 
establish if general fatigue can be measured reproducibly and if a change a patient status 
can be monitored using scales which assess the subjective perception of general fatigue.
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CHAPTER 2 
SECTION EIGHT.
OVERVIEW OF RATIONALE AND AIMS.
2.8. OVERVIEW OF RATIONALE AND AIMS.
Three studies are described in this thesis. All the studies have investigated the perception 
of symptoms (breathlessness and general fatigue) during exercise. While there are some 
common aims, other aims are specific to each study.
2.8.1. STUDY ONE: THE REPRODUCIBILITY AND SENSITIVITY TO 
CHANGE OF VISUAL ANALOGUE, BORG CR10 AND LIKERT 
SCALES
This study was carried out to determine which, if any, of three subjective scales was most 
reproducible and most sensitive to change during submaximal exercise. Normal healthy 
volunteers were used as it was felt that the findings of this study could be applied to a 
patient population. Submaximal exercise was selected as it was proposed that submaximal 
tests would be applied to a patient population.
2.8.2. STUDY TWO: SYMPTOMATIC AND PHYSIOLOGICAL
RESPONSES TO SUBMAXIMAL EXERCISE IN CHRONIC HEART 
FAILURE.
The two best scales from Study One were used to assess the symptomatic responses during 
submaximal exercise of CHF patients. The main aims of this study were:
1) to examine the reproducibility of subjective scales in CHF.
2) to establish appropriate relative intensities which CHF subjects
could sustain for a reasonable length of time and elicit symptoms.
3) to examine the feasibility of establishing a method of determining 
the length of a submaximal test with an endpoint within a clinically 
acceptable time (i.e. 8-17 minutes).
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4 ) to determine the reproducibility of the endurance time of the 
submaximal tests.
2.8.3. STUDY TH REE: AN EVALUATION OF THE STEXT PROTOCOL.
The STEXT protocol has been developed to cater for subjects with a wide range of aerobic 
fitness. It was deemed appropriate to assess the reproducibility and sensitivity to change 
of subjective scales using this protocol. In addition, it was important to measure the 
reproducibility of the maximum physiological responses.
2.8.4. COMMON AREAS.
As beta blockade was given to the subjects (in Studies One and Three) to promote a 
feeling of breathlessness and general fatigue, it was deemed appropriate to quantify the 
effect of beta blockade on the physiological variables. As exercise testing is carried out 
on an on going basis in cardiology, it was considered appropriate to quantify the 
visit/leaming/familiarisation effects for the subjective scales and physiological variables in 
all three studies. Comparison of the visit and therapy effects would give an indication of 
the possible value of monitoring patients over a period of time and evaluating the therapy 
effect.
Linkage of the perception of symptoms to physiological variables could be of value in the 
treatment of patients. Thus, an aim in all three studies was to compare the relationship 
between the responses to the subjective scales and the physiological variables.
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CHAPTER 3 
SECTION ONE.
METHOD
REPRODUCIBILITY AND SENSITIVITY TO CHANGE OF VISUAL 
ANALOGUE, BORG CR10 AND LIKERT SCALES.
3.1.1. SUBJECTS, RESEARCH DESIGN, EQUIPMENT AND 
SUBJECTIVE SCALES.
3.1.2. SUBJECTS.
Twenty three healthy male volunteers aged 30.3+4 years (mean S.D.) participated in this 
study. All took regular exercise, were familiar with treadmill testing and gave informed 
consent to this study which had been approved by the West Ethical Committee.
3.1.3. RESEARCH DESIGN.
3.1.3.(a) PRELIMINARY TESTS.
Subjects reported to the laboratory at the same time of day. A submaximal economy 
profile was established for each subject using at least three four-minute periods of 
treadmill exercise. After 30 minutes rest, each subject then undertook a symptom limited 
maximal treadmill test to measure VC>2 max. Depending on submaximal performance, 
either a "Lamb Normal Subject Treadmill Protocol" or "Lamb Athlete Treadmill Protocol" 
was used for this test so that treadmill time was around 10 minutes (Lamb, 1984). This 
time period has been shown to be optimal for eliciting maximal oxygen uptake values 
(Buchfuhrer et al; 1983).
3.1.3.(b) SUBMAXIMAL TESTS.
The results of the symptom limited maximal test and the submaximal economy profile 
were used to devise a standardised submaximal exercise protocol for each individual. 
This consisted of an initial workrate of 60% VO2  max, increasing after 2 minutes to 70% 
VO2  max which was maintained for a further six minutes.
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3.1.4. EXPERIMENTAL PROTOCOL
3.1.4. (a) VISITS/TREATMENTS.
Each subject attended the exercise laboratory on four occasions at intervals of one week. 
The order of visits was randomised according to a Latin rectangle design. The visits were 
termed "Reproducibility One" (Rl), "Reproducibility Two" (R2), "Placebo" (P) and 
Active" (A), i.e. propranolol. On visits R l and R2 no medication was administered. On 
the other two occasions propranolol 80 mg or matching placebo was taken 1 2  hours and 2  
hours before the exercise test. To test sensitivity, subjects were randomised to receive 
either propranolol or matching placebo prior to two tests (see below). Propranolol was 
given as an intervention known to increase the perception of breathlessness and general 
fatigue.
3.1.5. SYMPTOM SCALES.
During each test, symptom scales (see below) were administered at 1 minute 30 seconds, 5 
minutes 30 seconds and 7 minutes 15 seconds. Two different scales were used at each 
timepoint. Each scale was used twice at each timepoint, i.e. once to measure 
breathlessness and once to measure general fatigue. In other words, a total of 12 symptom 
scores were recorded during each exercise test. The presentation of scales was alternated
i.e. VAS/other and other/VAS. Twelve subjects were randomised to the Likert scale/VAS 
group and 11 to the Borg CR10 scale/VAS group. The symptom of breathlessness was 
always measured before general fatigue.
3.1.6.(a) EQUIPMENT - TREADMILL, ECG AND GAS ANALYSIS.
Marquette MAC2 treadmill and ECG console were used. Heart rate was monitored 
throughout all tests and recorded during the last 1 0  seconds of each minute in all tests. 
Expired air was collected using a Hans Rudolph 2700 valve with a mouthpiece which was 
attached by tubing to the metabolic cart All subjects wore a noseclip. Expired gases 
were analysed using a Beckman Metabolic Cart (Classic Exercise Model System 2).
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Before each test the oxygen and carbon dioxide sensors were calibrated with standard gas 
mixtures. Volume was calibrated using the procedures outlined by the Beckman 
instruction manual. Gas collection and analysis were continuous and respiratory values 
for every 30 seconds were given on a print-out.
3.1.6.(b) EQUIPMENT - SUBJECTIVE SCALES.
Each scale was administered by a computer (BBC Master) and displayed on a colour 
television screen placed at eye level in front of the subject while he exercised on the 
treadmill. The subject recorded his response by means of finger controls (see below) and 
the information was stored in the computer. An audible prompt was given each time a 
new scale appeared on the screen. On each occasion the subjects had to move the lever 
before the cursor appeared on the screen, i.e. before any score was displayed (thus the 
previous score was not displayed when the new scale was presented). Equipment details 
are given in Appendix B.
3.1.7. SUBJECTIVE SCALES
3.1.7.(a) VISUAL ANALOGUE SCALE.
The VAS scale (see Appendix F) consisted of a horizontal line. The word "none" was 
placed at one end (left) of the scale and the word "very severe" at the other (right). A 
sliding lever allowed the subject to move the light cursor horizontally in either direction 
along the scale. Once the subject had chosen the desired score, he pressed a button to 
record this in the computer. At this point another scale was displayed.
3.1.7.(b) BORG CR10 SCALE.
This consisted of a vertical line labelled 0-10 with verbal descriptors at fixed points on the 
scale (see Appendix F). Using the lever and button described above, the subject selected 
and recorded his chosen score.
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3.1.7.(c) LIKERT SCALE.
This consisted of five boxes placed vertically with verbal descriptors adjacent to each (see 
Appendix F). The score was selected and recorded as described above.
3.1.7.(d) USE OF SCALES.
A demonstration of the use of the scales was given before the maximal test and each 
subject was given an opportunity to practise using the finger controls. To enable subjects 
to appreciate the range of scales, they were asked to record scores for breathlessness and 
general fatigue at the end of their symptom limited maximal test. Two symptoms were 
measured with the scales. Subjects were given the following instructions before each of 
the submaximal tests.
3.1.7.(e) BREATHLESSNESS.
Breathlessness was described as, "breathless”, out of breath, air hunger, unable to breathe 
enough". Subjects were told, "Based on these descriptions, quantify your sensation of 
breathlessness by referring to your common experience of "an uncomfortable awareness of 
breathing. Avoid simply observing an increase in breathing - think of "an uncomfortable 
need to breathe". Disregard other sensations like leg fatigue or general fatigue."
3.1.7.(f) GENERAL FATIGUE.
General fatigue was described as "overall tiredness and overall fatigue". "Based on these 
descriptions and by referring to your common experience of general fatigue you are asked 
to quantify your sensation of general fatigue. Disregard other sensations like leg fatigue 
and breathlessness."
60
CHAPTER 3 
SECTION TWO.
METHOD
SYMPTOMATIC AND PHYSIOLOGICAL RESPONSES TO SUBMAXIMAL 
EXERCISE IN CHRONIC HEART FAILURE.
3.2.1. SUBJECTS, RESEARCH DESIGN, EQUIPMENT, SUBJECTIVE
SCALES.
3.2.2. SUBJECTS.
Ten male subjects aged 59.9 ±  7.9 years (mean S.D.) gave informed consent to participate 
in the study. All subjects had chronic heart failure (NYHA 1 and 2) and all were taking 
some form of diuretic. All subjects gave informed consent to this study which had been 
approved by the West Ethical Committee.
3.2.3. RESEARCH DESIGN.
The subjects performed two maximal exercise tests (see Appendix C). From the longer of 
the two tests a submaximal workrate was calculated using a diagrammatic aid (see 
Appendix D). The subjects performed four submaximal tests at weeks 1,2,4 and 6  after 
the second maximal test.
3.2.3.(a) PRELIMINARY EXERCISE PROTOCOLS.
Subjects reported to the laboratory at the same time of day and with the same timing of 
medication on each occasion. Subjects underwent two maximal incremental treadmill 
tests at least four days apart. Before the maximal test the subjects were familiarised with 
the treadmill and the use of the subjective scales (see below). The subjects performed an 
incremental test (see Appendix C). At the end of the test the subjects were asked to 
quantify their perception of breathlessness and general fatigue.
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3.2.3(b) CONSTANT WORKRATE TEST.
The predetermined speed and gradient were set on the treadmill using a diagrammatic aid 
(see Appendix D). Calculation of the work rate was carried out using 80% of the 
predicted oxygen cost of the stage attained in the longer of the two incremental tests. 
Calculation was based on the ACSM, (1986) equations. This procedure results in a 
workrate approximately two stages below that attained in the incremental protocol and 
allows for subjects who only manage a few seconds into a stage or almost complete a 
stage.
3.2.4. CONSTANT WORKRATE METHOD.
Subjects reported to the laboratory at the same time of day and with the same timing of 
medication on each occasion. The subjects' feet were placed on the side of the treadmill. 
At a given signal the subject walked on the treadmill and held on to the support bars for a 
few seconds until he had gained balance. Thereafter the subject walked without support. 
The subjects were asked to continue for as long as possible. At the end of the test the 
subjects were asked to state the reason(s) why they had stopped exercising.
3.2.5. SYMPTOM SCALES.
During each test, symptom scales (see below) were administered every two and half 
minutes. Each scale was used twice at each time point i.e. to measure breathlessness and 
general fatigue. The symptom of breathlessness was always measured before general 
fatigue.
3.2.6.(a) EQUIPMENT - TREADMILL, ECG AND GAS ANALYSIS.
During all tests expired air was collected using a Hans Rudolph 2700 valve with a 
mouthpiece which was attached by tubing to the metabolic cart. All subjects wore a 
noseclip. Respiratory variables were determined during exercise by an automated gas 
analysis system (Beckman metabolic measurement cart; classic exercise model system 2). 
Before each test the oxygen and carbon dioxide sensors were calibrated with a standard
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gas mixture containing 16% oxygen 4% carbon dioxide and 80% nitrogen. Volume was 
checked using standard procedures. Gas collection and analysis were continuous and 
respiratory values for every 30 seconds were given on a print-out. A marquette MAC2 
treadmill and ECG console were used. Heart rate was taken from the electrocardiogram 
during the last 1 0  seconds of each minute.
3.2.6.(b) EQUIPMENT - SUBJECTIVE SCALES.
Each scale was administered by a computer (BBC Master) and displayed on a colour 
television screen in front of the subject while he exercised on the treadmill. The subject 
recorded his response by means of finger controls and the information was stored in the 
computer. An audible prompt was given each time a new scale appeared on the screen. 
On each occasion the subjects had to move the lever before the cursor appeared on the 
screen i.e. before any score was visible (thus the previous score was not displayed when 
the new scale was presented).
3.2.7. SUBJECTIVE SCALES.
The scales had a heading of either breathlessness or general fatigue. The following scales 
were used:
3.2.7(a) VISUAL ANALOGUE SCALE.
The visual analogue scale (see Appendix F) consisted of a horizontal line. At the left hand 
side of the scale the word "none" was labelled and at the far right the word "very severe" 
was placed. Subjects indicated their level of breathlessness or general fatigue by moving 
the lever on the treadmill which adjusted the line on the TV monitor. Once the subject 
had chosen the desired score, he pressed the button to record this in the computer. At this 
point another scale appeared.
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3.2.7.(b) BORG CR10 SCALE.
The Borg CR10 scale (see Appendix F) consisted of a vertical scale labelled 0-10 with 
verbal descriptors at various numbers on the scale. Operation of the lever on the treadmill 
allowed the subjects to select the appropriate number.
3.2.7.(c) USE OF SCALES.
Subjects were randomly assigned to a VAS/Borg CR10 or a Borg CR10/VAS sequence of 
presentation. The subjects were introduced to the subjective scales between the treadmill 
familiarisation and the first maximal test. Firstly, the subjects were shown how to operate 
the scales and they were given the opportunity to practise using the finger controls. The 
subjects were allowed to practise until they could carry out the procedures with no 
difficulty. To enable the subjects to appreciate the range of the scales, they were asked to 
record scores for breathlessness and general fatigue at the end of the incremental tests. 
Subjects were given the following instructions before each of the constant workrate tests.
3.2.7.(d) BREATHLESSNESS.
Breathlessness was described as:
"breathless, out of breath, air hunger, unable to breathe enough".
Subjects were told:
"Based on these descriptions, quantify your sensation of breathlessness by referring to 
your common experience of "an uncomfortable awareness of breathing." Avoid simply 
observing an increase in breathing - think of "an uncomfortable need to breathe". 
Disregard other sensations like leg fatigue or general fatigue".
3.2.7.<e) GENERAL FATIGUE.
General fatigue was described as "overall tiredness", overall fatigue". "Based on these 
descriptions and by referring to your com mon experience of general fatigue you are asked 
to quantify your sensation of general fatigue. Disregard other sensations like leg fatigue 
and breathlessness.
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The subjects again practised with the scales and were asked to think about the range of the 
scales and their past experience in relation to breathlessness and general fatigue.
The subjects were asked if they understood the instructions. It was suggested to the 
subjects that zero on the scales may relate to their feelings at rest and at the upper end of 
the scales, subjects were asked to think of previous experiences which may relate to the 
upper ranges of the scales. It was also suggested to them that their perception of 
sensations at the end of the maximum tests may help them with their judgement of the 
range of the scales. Any questions from the subjects were answered.
During the constant workrate test the subjects were asked to respond to the scales when 
they appeared on the TV monitor.
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CHAPTER 3 
SECTION THREE.
METHOD.
AN EVALUATION OF THE STEXT PROTOCOL.
3.3.1. SUBJECTS, RESEARCH DESIGN, EQUIPMENT AND
SUBJECTIVE SCALES
3.3.2. SUBJECTS.
Twelve healthy male volunteers (aged 32.8+8.9) (mean S.D.) who were regular exercisers 
gave informed consent to participate in the study which had been approved by the West 
Ethical Comittee.
3.3.3. RESEARCH DESIGN.
Subjects underwent two tests within 48 hours of each other at week 0 (Timepont 1), week 
2 (Timepoint 2), week 6  (Timepoint 3) and week 10 (Timepoint 4). Tests were conducted 
at the same time of day. Subjects reported to the laboratory three hours fasted. Subjects 
were asked to exercise as long as possible and to indicate when they could no longer 
continue. At weeks 0 and 2 there was no intervention. At weeks 6  and 10 subjects were 
given a placebo or 80 mg of propranolol which were taken 1 2  hours and 2  hours before 
testing. Propranolol was given to promote sensations of breathlessness and general 
fatigue. At week 6 , six subjects were given placebo first, and 48 hours later propranolol. 
At week 10, the same six subjects were given propranolol first and placebo 48 hours later. 
The other six subjects were given the opposite order of drug administration. Six subjects 
were given a VAS/Borg CR10 order of presentation and six subjects a Borg CR10/VAS 
order.
3.3.4. TEST PROTOCOL.
Subjects reported to the laboratory at the same time of day. The subjects performed the 
STEXT protocol (see Apendix E). The subjects were asked to continue on the treadmill as
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long as possible and to signal when they wanted to stop. When the signal was given, the 
treadmill was slowed to an appropriate walking pace and the subjects recorded their 
responses to the scales at maximum exercise.
3.3.5. SYMPTOM SCALES.
Symptom scales (see below) appeared on the TV monitor every 2 minutes (ie. the scales 
appeared on the TV monitor 10 seconds into the third stage and every two minutes 
thereafter) and at maxmium. Each scale was used twice at each timepoint, i.e. to measure 
breathlessness and general fatigue. Six subjects were given a VAS/Borg CR10 
combination and six subjects were given a Borg CR10/VAS order of presentation. The 
symptom of breathlessness was always measured before general fatigue.
3.3.6.(a) EQIUPMENT - TREADMILL AND GAS ANALYSIS.
A Marquette MAC2 and ECG console were used for the treadmill test. Heart rate was 
monitored by ECG continuously and recorded during the last 10 seconds of each one 
minute stage. Expired air was collected using a Hans Rudolph 2700 valve with a 
mousepiece which was attached by tubing to the metabolic cart. All subjects wore a 
noseclip. Respiratory variables were determined during exercise by an automated gas 
analysis system (Beckman metabolic measurement cart; classic exercise model system 2). 
Before each test the oxygen and carbon dioxide analysers were calibrated with a standard 
gas mixture containing 16% oxygen and 4% carbon dioxide and 80% nitrogen. Volume 
was checked using standard procedures and analysed using a Beckman Metabolic Cart. 
Gas collection and analysis were continuous and a print-out of respiratory variables was 
given every 30 seconds.
3.3.6.(b). EQUIPMENT - SUBJECTIVE SCALES.
The VAS and Borg CR10 scales are shown in Appendix F. A description of the scales is 
given in Section 3.1.7. Each scale was administered by a computer (BBC Master) and 
displayed on a colour television screen in front of the subject while he exercised on the
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treadmill. The subject recorded his response by means of finger controls and the 
information was stored in the computer. An audible prompt was given each time a new 
scale appeared on the screen. On each occasion the subjects had to move the lever before 
the cursor appeared on the screen, i.e. before any score was dislayed (thus the previous
score was not displayed when the new scale was presented). Equipment details are given
in Appendix B.
3.3.7. SUBJECTIVE SCALES.
3.3.7.(a) USE OF SCALES.
Before Test 1 a demonstration of the use of the scales was given. Subjects were 
introduced to the scales and shown how to operate the lever system which adjusted the 
scale on the TV monitor and the button which recorded the score. After the subjects were 
familiar with the operation of the scales, the subjects were read the instructions outlined 
below. Thereafter the subjects again practised with the scales and were asked to think of 
the range of the scales and how the scales applied to their common experience of 
breathlessness and general fatigue. The subjects were asked if they understood the 
instructions. Any questions from the subjects were answered. The subjects were asked to 
respond to the scales when they appeared on the TV monitor throughout the exercise 
period and as soon as possible after the end of the test Two symptoms were measured 
with the scales. Subjects were given the following instructions before each of the tests.
3.3.7.(b) BREATHLESSNESS.
Breathlessness was described as "breathless, out of breath, short of breath, air hunger, 
unable to breathe enough". Subjects were told "Based on these descriptions, quantify your 
sensation of breathlessness by referring to your common experience of an uncomfortable 
awareness of breathing. Avoid simply observing an increase in breathing - think of "an 
uncomfortable need to breathe, disregard other sensations like general fatigue and tired 
legs."
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3.3.7.<c) GENERAL FATIGUE.
General fatigue was described as "overall tiredness, overall fatigue." "Based on these 
descriptions and by referring to your common experience of general fatigue you are asked 
to quantify your sensation of general fatigue. Disregard other sensations like 
breathlessness and leg fatigue."
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CHAPTER 4.
STATISTICAL TREATMENT OF DATA.
4.1.1. OVERVIEW OF THE STATISTICAL ANALYSIS PLAN.
Three separate studies are reported in this thesis. An attempt has been made to standardise 
the statistical treatment of the data to allow for consistency of approach and a meaningful 
comparison of the data to take place. However, as the designs of the three studies differ, a 
consistent approach throughout was not possible and statistical treatment and presentation 
of data varies slightly among the studies. With such a wide ranging data set many 
different forms of analysis could be conducted but statistical analysis was limited to 
answer the most pertinent questions. The key questions arising through all three studies 
were:
1 ) what is the more (most) reproducible subjective scale?
2 ) which is the more (most) sensitive subjective scale to change?
3 ) what is the magnitude of the visit and therapy effects in the studies
involving a therapy effect?
4) what is the relative magnitude of the visit effect?
5) how strong is any relationship between the subjective scales and the
physiological variables?
The statistical approach to answering these questions is described in the remainder of this 
chapter.
4.1.2. GENERALISED LINEAR MODEL.
The basis for most of the analysis is in the form of Generalised Linear Models (GLMS) 
where an additive model attempts to describe the composition of each measurement of 
each variable. For example, taking data from the "The comparison of VAS, Borg CR10 
and Likert scales", minute ventilation is measured on subject i (i=l to 23 in this case) at 
timepoint j (j=l, 2 or 3 here corresponds to 2, 6  and 8  minutes respectively), for visit k
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(k=l, 2, 3 or 4 here), with intervention 1 (1=1 for no beta blocker and 1=2 if the subject is 
on the beta blocker). The GLM assumes that the minute ventilation on this subject 
averages to the grand mean
plus an effect for subject i* 
plus an effect of timepoint j* 
plus an effect for visit k* 
plus a beta blocker effect 1* 
plus random/natural/error variation 
♦all effects are relative to the grand mean and simply measure differences from the grand 
mean (i.e. sum to zero).
NOTES.
1) The grand mean is effectively the average minute ventilation, in this case, over all 
subjects, timepoints, visit and the presence /abscence of the beta blocker.
2) Formally the subject effect is treated as a RANDOM effect in the sense that 
interest lies not in the specific subjects involved in the study but in the overall 
variability BETWEEN subjects. The between subject variability estimated through 
the GLM is used as the basis of the measure of reproducibility of the variable 
under consideration.
3) The last term in the model is assumed to have zero mean and a constant standard 
deviation across all subjects, timepoints etc and behave as if from a normal 
distribution. For each variable, all the data for all subjects, timepoints etc. is used 
in a least squares procedure to estimate all the above effects (i.e. subject, 
timepoint, visit and beta blocker). As far as was possible all possible two-way 
interactions among these effects were checked and found to be non significant.
The output from the least squares procedure contains point estimates of all possible 
effects together with estimated standard errors of these effects which give some 
indication of the significance of the effects themselves.
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The first stage in the analysis is a series of hypothesis tests in the form of an 
analysis of variance (ANOVA) table to investigate separately any subject, 
timepoint, visit and therapy effects.
Formally, a significance test is carried out of each null hypothesis that there are no 
differences at all among the levels of the effect under consideration (eg. of the null 
hypothesis that there are no significant differences across four visits). These are 
reported in the form of an ANOVA table and significance is based on a 5% level. 
Any of these effects which subsequently prove to be significant at the 5% level are 
then followed up using a Bonferrroni multiple comparisons procedure. For 
example, if some variable produced a significant visit effect, then the Bonferroni 
multiple comparisons procedure would attempt to identify exactly where any such 
differences lay. Bonferrroni multiple comparisons procedures involve the 
PAIRWISE comparison of all possible levels of the effect under consideration (eg. 
in a study with four visits and a significant visit effect all 6  possible pairwise 
comparisons of the visits would be made). This procedure retains the probability 
of any spurious significant results at the same 5% significance level as the 
ANOVA.
4.1.3. THE CONCEPT OF THE REPRODUCIBILITY COEFFICIENT.
The reproducibility of each variable in turn was quantified as the proportion of the total 
variance (i.e. between subject plus within subject variance) explained by the between 
subject variance. Appropriate estimates of these were obtained using a generalised linear 
model incorporating visit, intervention, timepoint and subject effects. In effect, this means 
that the subject differences are pooled to produce an estimate of the between subject 
variance while the residual sum of squares is the basis for the estimate of the within 
subject variance. For example, if the between subject variance was 278 and the within 
subject variance was 63, the reproducibility coefficient would be 82% i.e. 278/(278+63) as 
a percentage. A score of 100% would signify perfect reproducibility (i.e. no within 
subject variability at all).
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Conservative (i.e. at least ninety five percent) confidence intervals were calculated for the 
reproducibility coefficients of VAS, Borg CR10 and Likert scales for breathlessness and 
general fatigue to investigate differences between any two scales.
To illustrate the interpretation of a reproducibility coefficient, an example using a 
population with a VO2  max ranging between 50 -70 ml.kg-  ^ min"* is given. A 
reproducibility coefficient of 80% would imply that the observed measurement of VO2  
max for any individual whose "true" VO2 " max was 55 ml.kg"^ .m in'l . could be 
measured between 50 and 60 ml.kg"* .min-* . This is in effect because a reproducibility 
coefficient of 80% corresponds to the between subject standard deviation being twice that 
of the within subject standard deviation. Further, a reproducibility coefficient of 90% 
corresponds to the corresponding ratio of between to within standard deviations being 
three.
4.1.4. THE CONCEPT OF THE SENSITIVITY COEFFICIENT.
Sensitivity was defined as the ratio of the estimated effect of the active drug over the 
placebo divided by the estimated within subject standard deviation. Ninety five percent 
confidence intervals for the sensitivity were used to determine if there was a significant 
"intervention" effect. For example, taking the data from "The comparison of VAS, Borg 
CR10 and Likert scales", ninety five percent confidence intervals were used to determine 
if there was a significant beta blocker effect i.e. the active treatment was significantly 
different from the other "interventions" (Rl, R2 and placebo).
The reason why this measure of sensitivity was chosen was to allow assessment of the 
effect of the intervention on an INDIVIDUAL not on a group basis. For example, a 
sensitivity ratio of 1.5 for a particular intervention means that the effect of the intervention 
is to change the average level of the variable by one and half times the variability in the 
measurement seen across (within) any individual. Thus, sensitivity ratios under one would
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be considered to be of limited value as the change in the variable is not very different from 
the variability in the measurement seen across (within) any individual.
4.1.5. STATISTICAL METHODS FOR THE LINK BETWEEN THE
SYMPTOMATIC SCALES AND PHYSIOLOGICAL VARIABLES.
The relationship between each symptomatic scale and physiological variable is 
complicated as it may be influenced not only by differences among subjects but also by 
the effects of any therapy, intervention or indeed the cumulative effect of exercise through 
the effect of time into a test itself.
Accordingly, to provide as simple a summary as possible of such relationships it was 
decided that the best way to indicate which perception of symptom was best related to 
each physiological variable was to evaluate correlations based on all observations for each 
subject. The correlation summarised the following:
a) INDIVIDUAL VISIT CORRELATIONS correlations between the pairs of 
all measurements (subjective scales and physiological variables) for each 
individual were calculated for each of the visits in each study.
b) POOLED INDIVIDUAL VISIT CORRELATION the correlations for all 
visits were combined to give a pooled correlation for each individual.
c) ESTIMATED POOLED CORRELATION (OVERALL GROUP 
CORRELATION) a pooled overall correlation for each pair of 
relationships was calculated i.e. the pooled correlations for each subject 
were combined to give an overall pooled correlation.
It is assumed that any effect of therapy or time into the test within an individual merely 
pulls out both the scale and physiological variable in the same direction for any visit.
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4.1.6. PRESENTATION OF RESULTS.
As some tables have a great deal of information in them, it was decided to miss out the 
units of measurement in some instances. If units are not included, the units used are those 
outlined in Appendix G.
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CHAPTER 5 
SECTION ONE.
REPRODUCIBILITY AND SENSITIVITY TO CHANGE OF VISUAL 
ANALOGUE, BORG CR10 SCALES AND LIKERT SCALES.
RESULTS SECTION OF THE SUBJECTIVE SCALES.
5.1.1. THE DESIGN AND AIMS OF THE STUDY.
SUMMARY OF THE DESIGN OF THE STUDY.
Twenty three subjects took part in the study. Each subject had a maximal test and a 
submaximal economy test to enable relative intensities to be calculated for four 
subsequent submaximal tests (of 8  minutes duration) at 70% V02max. Two tests (R1 and 
R2) were given to assess reproducibility of scores obtained with each subjective scale and 
two other tests were undertaken to assess the sensitivity of each scale to a drug 
intervention. Here a double blind treatment with a beta blocker (to increase the sensation 
of breathlessness and general fatigue during exercise) or a matching placebo was given.
Three subjective scales were used to assess breathlessness and general fatigue - (1) visual 
analogue (VAS) (continuous scale) (2) Borg CR10 scale (12 fixed points) and (3) Likert 
scale (5 fixed points). Each subject had symptomatic assessment at 2, 6  and 8  minutes. 
Subjects were given either a VAS/Borg CR10 or a VAS/Ukert combination. A range of 
physiological variables were monitored continuously and recorded every minute.
THE MAIN AIMS OF THE STUDY.
These were to:
1 ) compare the reproducibility and sensitivity to change of visual analogue, 
Borg CR10 and Likert scales.
2 ) determine the magnitude of the visit and therapy effects of the subjective 
scales and physiological variables.
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3 ) investigate the relationship between the subjective scales and the 
physiological variables for the FOUR submaximal tests of 8  minutes 
duration at 70% V0 2 max.
5.1.2. RESULTS OF SUBJECTIVE SCALES.
5.1.3. STATISTICAL METHODS FOR THE SUBMAXIMAL TESTS - THE 
SYMPTOMATIC SCALES.
For each separate scale at each timepoint (i.e. 2, 6 , and 8  minutes), a generalised linear 
model was used to investigate possible systematic differences among the four 
"interventions" (i.e. the test, re-test, the placebo treatment and the active treatment), as 
well as any systematic learning or visit/familiarisation effects across the four visits. The 
model also included components of variability due to between subject variation and due to 
within subject variation.
5.1.4. AN ILLUSTRATION OF THE RAW DATA FOR THE 
SUBMAXIMAL TESTS.
An impression of how the scales were used by the subjects is given in Figures 5.1-5.6. 
which show the ranges for the three scales for breathlessness and general fatigue for all 
four "interventions". The VAS and Likert scales are used over a much wider range than 
the Borg CR10 scale. The highest score on the Borg CR10 scale was five (general 
fatigue) and therefore only half of the scale was actually used whereas the corresponding 
proportion of the scales used for the other two scales was 80%. Examination of Figures 
5.1-5.6. shows that the scores on the active visit tend to be higher than the other three 
"interventions" which show little difference from each other. The plots suggest that the 
scales in the three "non intervention" tests are reproducible. Subjects scored in an 
individualistic way i.e. despite exercising at the same 70% of V(> 2  max, there was a wide 
range of values among the subjects for the subjective scales.
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5.1.5. MEASUREMENT OF BREATHLESSNESS.
REPRODUCIBILITY.
The estimated reproducibility coefficients for the three scales at the three different 
timepoints are shown in Table 5.1. At all three timepoints there is a clear tendency for the 
VAS to be better than the other two scales i.e. to have higher reproducibility. At minute 
six the VAS was significantly higher than the Borg CR10 scale.
SENSITIVITY.
The VAS and Likert scale tend to be more sensitive to change than the Borg CR10 scale 
(see Table 5.2). At minutes six and eight the VAS is significantly higher in sensitivity 
than the Borg CR10 scale.
5.1.6. MEASUREMENT OF GENERAL FATIGUE.
REPRODUCIBILITY
Reproducibility tended to be better for the VAS than the other two scales but there were 
no statistically significant differences (see Table 5.1).
SENSITIVITY.
The Borg CR10 scale was significantly better than the Likert scale at 6  and 8  minutes and, 
perhaps surprisingly, better than the VAS at 6  minutes (see Table 5.2).
5.1.7. VISIT AND THERAPY EFFECTS FOR MINUTE 8 .
As it was considered to be unwieldy to compare visit and therapy effects for all three 
timepoints, minute 8  was selected to provide a detailed and representative example of visit 
and therapy effects. An important issue here is to establish if the visit effect was as 
substantial as any therapy effect as this would raise major questions over the effective use 
of such a test protocol in clinical practice.
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Using a GLM, point estimates were produced for the visit and therapy effects of each 
subjective scale separately. Table 5.3 shows the estimated visit and therapy effects for 
both breathlessness and general fatigue respectively. It is important to remember that 
these estimated effects are all relative to the grand mean (i.e. in the sense that all four visit 
effects sum to zero). If the ANOVA test of a visit effect proved significant for the 
particular variable under question, a Bonferroni based multiple comparisons procedure 
was used to assess where significant differences, if any, lay.
BREATHLESSNESS.
The VAS showed significant visit effects decreasing through the four visits. Formally, 
visit 3 was significantly lower than visit 1 and visit 4 was significantly lower than any 
other visit (in simple terms, visit 1 was 3.9 units on average ABOVE the grand mean 
while visit 4 was 5.6 units BELOW the grand mean producing a significant fall of 3.9+5.6 
= 9.5 units in he VAS on average across allindividuals for visit 1 to 4). For the Likert 
scale the visit 4 value was significantly lower than the other three visits. There was no 
visit effect for the Borg CR10 scale.
ALL scales showed a SIGNIFICANT therapy effect. The therapy effect was MUCH 
HIGHER than any visit effects for all the scales.
GENERAL FATIGUE.
The VAS showed significant visit effects, again decreasing through visits. Formally, visit 
2 and 3 were significantly lower than visit 1 and visit 4 was significantly lower than the 
other 3 visits. Visit 1 for the Borg CR10 scale was significantly higher than the other 
three visits which were not significantly different from each other. The Likert scale 
showed no significant visit effect.
ALL scales showed a SIGNIFICANT therapy effect. Again the therapy effects were much 
HIGHER than any of the visit effects.
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5.1.8. SUMMARY.
REPRODUCIBILITY.
These results showed that the VAS tended to be consistently more reproducible than the 
Borg CR10 and Likert scales at all timepoints for breathlessness and general fatigue. At 
minute six the VAS was significantly so compared to the Borg CR10 scale for 
breathlessness. No clear pattern emerged when a comparison was made between the Borg 
CR10 and Likert scales.
SENSITIVITY.
For breathlessness, the VAS was the best scale at pulling out the intervention effect 
relative to the within subject variability whereas the Borg CR10 scale was best for general 
fatigue.
VISIT AND THERAPY EFFECTS.
Some scales did demonstrate a visit effect but the magnitude of the visit effect was small 
compared with the therapy effect which was always substantial.
8 0
CHAPTERS 
SECTION TWO.
RESULTS OF THE PHYSIOLOGICAL VARIABLES.
REPRODUCIBILITY AND SENSITIVITY TO CHANGE OF VISUAL 
ANALOGUE, BORG CR10 SCALES AND LICKERT SCALES.
5.2.1. STATISTICAL METHODS FOR THE FOUR SUBMAXIMAL 
TESTS - THE PHYSIOLOGICAL VARIABLES.
A generalised linear model (GLM) was applied to the data to include the possible effects
of visit, therapy, subject and natural (or error) variability. A Bonferroni multiple
comparisons procedure was used to assess where the significant differences, if any, lay for
any visit and/or therapy effect respectively. The variables investigated were VE, V0 2 »
VCO2 , frequency of breathing, heart rate, VE/VCO2 , VE/V0 2 » tidal volume and
respiratory exchange ratio (RER).
5.2.2. SOME COMMENTS ON THE RAW DATA FOR THE
PHYSIOLOGICAL VARIABLES.
5.2.2.(a) AEROBIC POWER AND RELATIVE INTENSITY.
The mean VO2  max of the subjects was 56.9 ml.kg'^.min:^ + 4.7. During the placebo 
test, the mean percentage VO2  max was 70.8% Thus, the targeted value of 70% VO2  
max was achieved.
5.2.2.(b) AN ILLUSTRATION OF THE SUBMAXIMAL RAW DATA.
It was considered to be unnecessary and unwieldy to illustrate all of the physiological raw 
data. Figure 5.7 provides a flavour of the physiological data and shows VE for all subjects 
for each of their four visits for the four submaximal tests. Scores on the active therapy 
appear to be higher than the other three "interventions’1. In the three "non active" 
treatments there is a suggestion that a steady state has been achieved between 6  and 8  
minutes. For some subjects on the active therapy VE continues to rise from 6  to 8  
minutes.
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5.2.3. AN ANALYSIS OF THE EFFECT OF "INTERVENTION"
THROUGH THE TEST.
In this section the main area of interest is the magnitude of change at each minute into the
test of each of the physiologial variables due to the intervention of the beta blocker (i.e.
the magnitude of the therapy effect through the test). Figures 5.8-5.16 display the point
estimates of those variables where a significant therapy effect was found (i.e. VE, VO2 ,
VC02, frequency of breathing, heart rate, VE/V02, VE/VCO2 , tidal volume and RER).
It must be remembered that the therapy effects are all relative to the grand mean and these
sum to zero. There were no significant differences among the three "interventions," R l,
R2 and placebo for any physiological variable but in general there were substantive and
significant effects on the active therapy. The "bars" attached to each highest letter in the
figures denote one pooled standard error of the therapy effects for each timepoint.
VENTILATION.
The active treatment was significantly HIGHER than the other three treatments after 3 
minutes (Figure 5.8).
vo2
The active treatment was significantly LOWER than the other three treatments until the 
last 2 minutes (Figure 5.9).
vco2
There was a complex pattern to the active therapy effect. The only significant differences 
were at 1, 2 and 8  minutes. At minutes 1 and 2 the active therapy was significantly 
LOWER than all the non-intervention treatments which at 8  minutes was significantly 
HIGHER (Figure 5.10).
FREQUENCY OF BREATHING.
After 2 minutes the frequency of breathing was significantly HIGHER for the active 
treatment compared with the other three "interventions" (Figure 5.11).
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HEART RATE.
The major effect was a significantly LOWER heart rate at all timepoints for the active 
treatment compared with the other "interventions" (Figure 5.12).
v e /v o 2
The active treatment was always significantly HIGHER than the other three 
"interventions" (Figure 5.13).
v e /v c o 2
The pattern for the active treatment was exactly the same as for VE/VO 2  with the active 
drug always HIGHER than the other three "interventions" (Figure 5.14).
TIDAL VOLUME.
The therapy effect showed no consistent pattern except that the active treatment tended to 
produce the lowest values for tidal volume. The only significant results were achieved at 
2 and 6  minutes with the active treatment LOWER than replicate 2 (Figure 5.15).
RER.
For all eight timepoints the active therapy was HIGHER than the other three 
"interventions" (Figure 5.16).
5.2.4. THE RELATIVE MAGNITUDE OF ANY VISIT EFFECT.
The aim of this section was to determine how any visit effect compared in magnitude to 
the therapy effect. Again it was considered unnecessary to examine this relationship over 
all three timepoints. Minute 8  was selected to give an in depth examination of the visit 
and therapy effects. Table 5.4 shows the visit and therapy effects for the physiological 
variables at minute 8 . The values given are in relation to the grand mean. A Bonferroni 
based multiple comparisons procedure was used to assess where significant visit 
differences, if any, lay.
Only VE, frequency of breathing and VE/VC02 produced significant VISIT effects 
among the physiological variables, although V 02 was close to the significance borderline.
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However, the pattern across almost all the physiological variables was the same in the 
sense that the variable was highest at visit 1 and decreased through the remaining three 
visits. For example, for VE, the average fell from visit 1 to visit 4 by 2.99+2.08 =5.07 
which in this case proved significant.
As discussed in the previous section there were significant THERAPY effects for all 
variables apart from VC>2 and tidal volume.
For the variables with significant visit effects (i.e. VE, frequency of breathing and 
VE/VCO2 ), the therapy effect was much greater than the visit effect. Indeed for all the 
physiological variables the visit effects were of much lesser magnitude than the therapy 
effect. Thus it is reasonable to conclude that the therapy effect can be easily identified and 
is much more substantial than any learning/familiarisation effect
5.2.5. SUMMARY.
The active treatment had a lowering effect on heart rate and increased several respiratory 
variables including VE, frequency of breathing, RER, VCO2 , VE/V0 2 , and VIVVCO2  at 
some or all timepoints. At some timepoints VO2  and VCO2  were reduced. It is 
concluded that the therapy effect is much more substantial than any 
learning/familiarisation effect.
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CHAPTER 5 
SECTION THREE.
REPRODUCIBILITY AND SENSITIVITY TO CHANGE OF VISUAL 
ANALOGUE, BORG CR10 SCALES AND LICKERT SCALES.
RESULTS OF THE RELATIONSHIP BETWEEN PHYSIOLOGICAL 
VARIABLES AND THE SUBJECTIVE SCALES.
5.3.1. WHY? HOW?
If a relationship exists between a physiological variable and a symptomatic scale a strong 
correlation would be evident Any strong relationship may be of value in the assessment 
and treatment of symptoms during exercise. It was decided that the best way to indicate 
which perception of symptom was the best related to each physiological variable was to 
evaluate individual subject correlations based on all observations for each subject across 
all timepoints.
An explanation of how the correlations were calculated is given in Section 4.5.
5.3.2. A VISUAL IMPRESSION OF THE RELATIONSHIP BETWEEN
THE SUBJECTIVE SCALES AND VE.
A flavour of the relationship between the subjective scales and the physiological variables 
is given by taking the VAS (breathlessness) and VE and displaying these variables in the 
following examples. For minutes 2, 6  and 8 , Figure 5.17 shows the VE/VAS 
(breathlessness) relationship for subject 4 for all four tests. Figure 5.18 shows the 
VE/VAS (breathlessness) relationship for all subjects for all tests. Both figures suggest 
that there is a marked increase in VE and VAS (breathlessness) from timepoint 1 to 
timepoint 2. Figure 5.18 suggests that VE is fairly stable for many subjects between 6  and 
8  minutes but for some subjects, the VAS (breathlessness) score increases from 6  to 8  
minutes.
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5.3.3. CORRELATIONS.
A visual impression of "correlations" of one subjective scale and physiological variable is 
given in Figure 5.19. Figure 5.19 gives the correlations for VE and VAS (breathlessness) 
for:
1) individual visit correlations for each subject.
2) pooled individual correlations.
3) estimated pooled correlation (overall group correlation).
For some subjects, eg 1, 12, 22 and 23, the individual visit correlations are very close 
together whereas other subjects showed a wide range of individual visit correlations eg 9, 
13,14 and 21.
The overall group correlations, the pooled individual correlations and the minimum and 
maximum individual visit correlations for VAS, Borg CR10 and Likert scales 
(breathlessness and general fatigue) and VE, VO2 , VCO2 , frequency of breathing, heart 
rate, VE/VO2  VE/VCO, 2  tidal volume and RER are shown in Table 5.5.
There were high overall group correlations for all the subjective scales and VE, VO2 , 
VCO2 , frequency of breathing, heart rate, VE/VO2 , tidal volume and RER. For VE, VO2 , 
VCO2  and heart rate and all the subjective scales overall pooled correlations were above 
0.90. For the other physiological variables (apart from VE/VCC^) and the subjective 
scales, the overall group correlations were above 0.75. The overall group correlation for 
all scales and VE/VCO2  were very low. A wide range in the minimum and maximum 
(individual and pooled) visit correlations was found for all the subjective scales and the 
physiological variables.
5.3.4. TIME EFFECT- COMPARISON OF THE CHANGES IN 
SUBJECTIVE SCALES AND PHYSIOLOGICAL VARIABLES FOR 
MINUTES 2,6 and 8.
A comparison of the responses to the subjective scales and physiological variables was
made to investigate any relationship between the changes in scores. If it could be
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demonstrated that there was no increase in some physioloical variables (i.e. a steady state 
had been attained) but the scores for the subjective scales increased, it could be concluded 
that the perception of symptoms changed despite no difference in some physiological 
markers. The variables investigated were all the subjective scales and the following 
physiological variables, VE, VO2 , VCO2 , frequency of breathing, heart rate, VE/VO2 , 
VE/VCO2  and tidal volume.
Using the output from the GLM, point estimates for time effects were obtained. A 
Bonferroni multiple comparisons procedure were used to determine if there were 
differences among the timepoints (see Table 5.6).
For all three timepoints, all three subjective scales were significantly different at each 
timepoint except for Likert (breathlessness) which showed no change between timepoint 2 
and timepoint 3. The differences between 6 and 8 minutes were 3.8 for the VAS 
(breathlessness). For VAS (general fatigue) the difference between 6 and 8 minutes was
3.2. The Borg CR10 (breathlessness) scale was significantly higher (0.25) at 8 minutes 
compared with 6 minutes. On the Borg CR10 (general fatigue) scale the 8 minute score 
was 0.22 higher than the 6 minute score. On the Likert (general fatigue) scale the 8 
minute value was 0.24 higher than the 6 minute value.
There were significant differences for all the physiological variables between timepoint 1 
and 2. For VE, VO2 , VCO2 , frequency of breathing, VE/VO2 , VE/VCO2  and tidal 
volume there were no differences between timepoints 2 and 3. Between timepoints 2 and 
3 there was a significant increase in heart rate of 3.1 beats.min'^ .
Table 5.7 gives an example of the respiratory values and heart rate at 6 and 8 minutes for 
the placebo test. There were no significant differences among the variables. Thus it can 
be said that a steady state had been attained in the placebo test A one way analysis of 
variance and 95% confidence intervals showed that in the "active" treatment, there was a
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significant increase in VE of 4.1 litres.min'l 0.1 litres.min'^ in VO2 , 0.06 litres.min"^ in 
VCO2  and 1.5 beats.min"-  ^ in heart rate between 6 and 8 minutes.
5.3.5. SUMMARY.
These findings indicate that there is a very good correlation between the subjective scales 
and VE, VO2 , VCO2 , frequency of breathing, heart rate, VE/VO2 , tidal volume and RER. 
Examination of the data from timepoint 2 to 3, showed that on almost all occasions, the 
perception of breathlessness and general fatigue increased despite the fact that there was 
no change in a range of physiological variables.
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Table 5.1
Reproducibility coefficients and 95% Confidence Intervals for Breathlessness and General 
Fatigue for Visual Analogue, Borg CR10 Scales and Likert Scales.
REPRODUCIBILITY.
Breathlessness
Time
Scale 2 Min 6 Min 8 Min
VAS 59% 74%* 78%
(45-76) (59-86) (66-89)
Borg CR10 55% 42% 50%
(39-78) (33-66) (36-76)
Likert 50% 55% 76%
(36-76) (39-80) (55-90)
General Fatigue
Time
Scale 2 Min 6 Min 8 Min
VAS 63% 69% 78%
(50-78) (55-82) (66-89)
BorgCRIO 45% 63% 66%
(33-72) (42-83) (45-85)
Likert 45% 50% 55%
(36-72) (36-76) (39-80)
VAS significantly higher than Borg CR10.
Confidence intervals are in brackets beneath each estimate of reproducibility.
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Table 5.2
Sensitivity co-efficients and 95% Confidence Intervals for Visual Analogue, Borg CR10 and Likert 
Scales.
SENSITIVITY.
Breathlessness
Time
Scale 2 Min. 6 Min. 8 Min.
VAS 1.3 2.6* 2.7*
(1.0,1.6) (2.3,2.9) (2.4,3.0)
Borg CR10 1.3 2.0 2.0
(0.9,1.7) (1.7,2.4) (1.6,2.4)
Likert 1.4 2.2 2.6
(1.0,1.8) (1.8,2.6) (2.2,3.0)
VAS significantly higher than Borg CR10
General Fatigue
Time
Scale 2 Min. 6 Min. 8 Min.
VAS 1.7 2.1 2.4
(1.4,2.0) (1.8,2.4) (2.1,2.7)
BorgCRIO 1.6 2.9*+ 3.0*
(1.2,2.0) (2.5,3.3) (2.6,3.3)
Likert 1.6 2.0 2.0
(1.2,1.9) (1.6,2.4) (1.7,2.4)
* Borg CR10 significantly higher than Likert
+ Borg CR10 significantly higher than VAS.
Confidence intervals are in brackets beneath each estimate of reproducibility.
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Table 5.7
Respiratory Variables and Heart Rate at Minutes 6 and 8 for the Placebo Test.
MI NUTE
6 8
v o 2 1 < 
(ml.Kg’ Lmin"')
40.43+5.4 40.25+5.5
vco2
(litres.min”1)
2.62+0.48 2.60+0.44
VE 1 (litres.min'1)
66.96+12.9 66.98+13.1
RER 0.895+0.06 0.897+0.06
Tidal Volume 
(litres)
2.27+0.41 2.28+0.42
Frequency of
Breathing
(breaths.min*1)
30.52+6.8 30.4+7.5
Heart Rate 
(beats.min'1) 154.6+13.8 156.8+13.8
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Fig 5.1
VAS breathlessness for the four submaximal tests (Rl, R2, placebo and
active) labelled by subject numbers 1-23.
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Fig 5.2
VAS general fatigue for the four submaximal tests (Rl, R2, Placebo and
active) labelled by subject numbers 1-23.
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Fig 5.3
Borg CR10 breathlessness for the four submaximal tests (Rl, R2,
placebo and active) labelled by subject numbers 1-23.
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Fig 5.4
Borg CR10 general fatigue for the four submaximal tests (Rl, R2,
placebo and active) labelled by subject numbers 1-23.
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Fig 5.5
Likert breathlessness for the four submaximal tests (Rl, R2, placebo
and active) labelled by subject numbers 1-23.
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Fig 5.6
Likert general fatigue for the four submaximal tests (Rl, R2, placebo
and active) labelled by subject numbers 1-23.
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Fig 5.7
Minute ventilation for the four submaximal tests (Rl, R2, placebo and
active) labelled by subject numbers 1-23
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FIG 5.8
Therapy effects for minute ventilation
A: Rl B: R2 C: PLACEBO D: ACTIVE
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FIG 5.9
Therapy effects for volume of oxygen consumed 
A :  R l  B: R2 C: PLACEBO D: ACTIVE
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FIG 5.10
Therapy effects for volume of carbon dioxide produced
A: Rl B: R2 C: PLACEBO D: ACTIVE
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FIG 5.11
Therapy effects for frequency of breathing,
A: R l B: R2 C: PLACEBO D: ACTIVE
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FIG 5.12
Therapy effect for heart rate
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Therapy effect for VE/VO 2
A: Rl B:R2 C: PLACEBO D: ACTIVE
.0  2 .0  4 .0  6 .0  8 .0
TIME (MINUTES)
* Denotes Significant Therapy Effect
FIG 5.14
Therapy effects for VE/VCO 2
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Therapy for tidal volume
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The VE/VAS breathlessness relationship for subject 4 for all tests
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CHAPTER 6 
SECTION ONE.
SYMPTOMATIC AND PHYSIOLOGICAL RESPONSES TO SUBMAXIMAL 
EXERCISE IN CHRONIC HEART FAILURE.
RESULTS OF THE SUBJECTIVE SCALES.
6.1.1. DESIGN AND AIMS OF THE CHF STUDY.
SUMMARY OF THE DESIGN OF THE CHF STUDY.
Ten patients with chronic heart failure underwent two maximal incremental tests followed 
by four submaximal (constant workrate) symptom limited tests at weeks 1, 2, 4 and 6. 
Two subjective scales were used - (1) visual analogue (VAS) (continuous scale) (2) Borg 
CR10 scale (12 fixed points) to measure breathlessness and general fatigue. During the 
submaximal tests, scales were used to measure the symptoms of breathlessness every 2.5 
minutes. A variety of physiological variables were measured at each minute throughout 
the tests.
THE MAIN AIMS OF THE CHF STUDY WERE TO:
1) Compare the reproducibility of the visual analogue and Borg CR10 scales.
2) Determine the reproducibility of the submaximal tests.
3) Assess the relative intensity at which the subjects work during the
submaximal test.
4) Investigate the relationship between the subjective scales and physiological 
variables.
6.1.2. RESULTS FOR THE SUBJECTIVE SCALES.
6.1.3. STATISTICAL METHODS FOR THE SUBMAXIMAL TESTS.
Statistical analysis was limited to the first four timepoints i.e. 2.5, 5.0, 7.5 and 10 minutes 
as there were insufficient data after 10 minutes to allow for meaningful analysis. A 
generalised linear model (GLM) was applied to the data to include the possible effects of 
visit, subject, time and natural (or error) variability.
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6.1.4. AN IMPRESSION OF THE RAW DATA FOR THE SUBMAXIMAL 
TESTS.
An impression of how the scales were used is given in Figures 6.1. to 6.4. which show the 
ranges for both scales for breathlessness and general fatigue.
These figures highlight that the scales are used in a highly individualistic way. For 
example, subject 1 tends to score very low for all scales for all tests, whereas subject 7 
scores high throughout all scales for all tests. The figures show that the scales were used 
over a wide range throughout the four timepoints.
6.1.5. THE REPRODUCIBILITY OF THE SUBJECTIVE SCALES.
The estimated reproducibility coefficients for VAS and Borg CR10 for the first four 
timepoints are given in Table 6.1. For both breathlessness and general fatigue the 
reproducibility of the VAS was clearly higher than the Borg CR10. Ninety-five percent 
confidence intervals, however, showed that there were no significant differences between 
the scales. For the VAS (breathlessness), the reproducibility appeared to decrease through 
time into the test (i.e. the coefficients were lowest at 7.5 and 10 minutes).
In general, reproducibility was better for the VAS on general fatigue than on 
breathlessness.
6.1.6. THE IMPORTANCE OF ANY VISIT EFFECTS.
Using a GLM, the visit effect was investigated only for timepoint three (i.e. 7.5 minutes) 
as it was deemed unnecessary and impractical to examine the visit effects for all 
timepoints. Table 6.2 shows that there was no visit effect for any subjective scale at this 
timepoint.
6.1.7. THE CONSISTENCY OF THE SYMPTOMATIC SCALES IN THE 
MAXIMAL INCREMENTAL TESTS.
As part of the protocol leading up to the above four submaximal tests, two maximal
incremental tests were carried out at least four days apart. The symptomatic scores for
breathlessness and general fatigue measured at the end of each of these two tests were
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compared to determine if the subjects had reassessed their perception of symptoms after 
the experience gained in the first test. Table 6.3 shows the peak values for breathlessness 
and general fatigue for the VAS and Borg CR10 for these two incremental maximal tests. 
All scales were used over a very wide range. For example, in test 2 for general fatigue, 
the ranges were 15-80 and 1-7 for the VAS and Borg CR10 scales respectively. Table 6.4 
shows the mean differences and 95% confidence intervals for the differences between 
tests. There were no significant differences for any scale.
6.1.8. SUMMARY OF THE SUBJECTIVE SCALES DATA.
For breathlessness and general fatigue, the VAS consistently had higher reproducibility 
coefficients than the Borg CR10 scale which, however, did not reach statistical 
significance. The scales were used over a wide range at maximum in the incremental tests 
and during the constant workrate tests. There were no significant visit/familiarisation 
effects in the incremental and constant workrate tests.
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CHAPTER 6 
SECTION TWO.
RESULTS FOR THE PHYSIOLOGICAL VARIABLES.
6.2.1. STATISTICAL TREATMENT FOR THE SUBMAXIMAL TESTS.
A generalised linear model was applied to the data to include the possible effects of visit, 
subject and natural (or error) variability. A Bonferroni multiple comparisons procedure 
was used to assess where the significant differences, if any, lay. The variables investigated 
were VE, V02« VCO2 , frequency of breathing, heart rate, VE/VO2 , VE/VCO2  and tidal 
volume.
6.2.2. RAW DATA.
6.2.2.(a) THE MAXIMAL VALUES OF THE PHYSIOLOGICAL
VARIABLES FROM THE MAXIMAL INCREMENTAL TESTS.
The maximal values for the two incremental tests were investigated for two major
purposes:
1) To allow comparison with other studies.
2) To determine if there was any learning/familiarisation effect across the two 
tests.
Table 6.5 gives the peak values for VO2 , VCO2 , VE, RER, frequency of breathing, tidal 
volume and heart rate and endurance time for the two maximal tests. Table 6.6. shows the 
mean differences and 95% confidence intervals for the differences between the two test 
results for each of the physiological variables. Only for VE was the test 1 score 
significantly higher than the test 2 score. There was a tendency for VO2  and VCO2  to be 
lower on test 2. Only two of the test 2 Peak V02SCores were higher than test 1.
6.2.2.(b) AN ILLUSTRATION OF THE RAW DATA FOR THE
PHYSIOLOGICAL VARIABLES ON THE SUBMAXIMAL TESTS.
It was considered unnecessary to illustrate all the physiological data from the constant
workrate tests. Figure 6.5 provides a flavour of the physiological data and shows VE for
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all subjects for each of the four visits and each of the submaximal tests. The VE scores 
look to be consistent for all subjects for the four tests.
6.2.3. VISIT EFFECT FOR THE PHYSIOLOGICAL VARIABLES.
Timepoint 3 (i.e. 7.5 minutes) was selected to give examples of possible visit effects since 
the data were somewhat sparse at 10 minutes. Table 6.7 shows that there were no visit 
effects for any physiological variable at 7.5 minutes.
6.2.4. ENDURANCE TIME.
6.2.4.(a) RAW DATA FOR ENDURANCE TIME.
The endurance times for all four submaximal constant workrate tests for all subjects are 
illustrated in Figure 6.6, while the mean and standard deviation for the four tests are given 
in Table 6.8. Figure 6.6 suggests that the endurance times were relatively stable. 
However, subject 6 showed a large increase in endurance time from Test 1 to Test 2.
6.2.4 (b) VISIT EFFECT FOR ENDURANCE TIME.
A reproducibility coefficient of 51% was estimated over all tests. This figure increased to 
76% when the first test of subject 6 was excluded. Subject 6 increased his endurance time 
from 7 minutes on Test 1 to 18 minutes on Test 2. There were no significant visit effects 
for endurance time.
6.2.5. RELATIVE PERCENTAGES FOR THE CONSTANT WORKRATE
TESTS.
The relative percentages for VE, VO2 , and heart rate during the final minute of the 
constant workrate test are given in Table 6.9. Values are the overall mean for all tests and 
relative to the higher score for each individual in the two maximal incremental tests. The 
mean relative intensities for VO2 , VE and heart rate were 89.3%, 92.5% and 98.5% 
respectively. For VE and heart rate, the ranges show that the values attained in the 
constant workrate tests were sometimes higher than the values reached in the maximal 
incremental tests.
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6.2.6. SUMMARY.
A decrease in VE in Test 2 was the only significant difference in any physiological 
variable in the incremental tests. There were no significant visit/familiarisation effects in 
any physiological variable or endurance time in the submaximal constant workrate tests. 
During the constant workrate tests the subjects worked close to the maximum they 
attained in the incremental tests.
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CHAPTER 6 
SECTION THREE.
RESULTS OF THE RELATIONSHIP BETWEEN THE PHYSIOLOGICAL 
VARIABLES AND THE SUBJECTIVE SCALES FOR 
BREATHLESSNESS AND GENERAL FATIGUE.
6.3.1. WHY? HOW?
If a relationship exists between a physiological variable and a symptomatic scale, a strong 
correlation would be evident Any strong relationship may be of value in the assessment 
and treatment of symptoms during exercise.
It was decided that the best way to indicate which perception of symptom was best related 
to each physiological variable was to evaluate correlations based on all observations for 
each subject, where possible, over the first four timepoints.
An explanation of how the correlations were calculated is given in Section 4.1.5.
6.3.2. A VISUAL IMPRESSION OF THE RELATIONSHIP BETWEEN
THE SUBJECTIVE SCALES AND VE.
A flavour of the relationship between the subjective scales and the physiological variables
is given by graphically showing the relationship between VE and the VAS
(breathlessness). Figure 6.7 gives an example of the relationship between VE and VAS
(breathlessness) for subject 9 for all four tests. Figure 6.8 shows the VE/VAS
(breathlessness) relationship for all subjects for all tests. There is an inconsistent pattern
among the subjects. The VE for some subjects, eg 3, 9, and 10, looks fairly stable but the
VAS (breathlessness) score rises throughout the 10 minute period. For subject 8, VE rises
between 5 and 7.5 minutes with little change in VAS (breathlesness) during this time.
6.3.3. CORRELATIONS.
A visual impression of "correlations" for one subjective scale and physiological variable is 
given in Figure 6.9. Figure 6.9 gives the correlations for VE and VAS (breathlesness) for:
1) individual visit correlations for each subject.
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2) pooled individual correlations.
3) estimated pooled correlations (overall group correlations)
The individual visit correlations for subject 5 are very similar whereas the individual visit 
correlations for subjects 1 and 7 show a wide range. The pooled individual correlation for 
subject 1 is very poor.
The overall group correlations, the pooled individual correlations and the minimum and 
maximum individual correlations for the VAS and Borg CR10 scales (breathlessness and 
general fatigue) and each of VE, VO2 , VCO2 , frequency of breathing, heart rate, VE/VO 2  
VE/VCO2  and tidal volume are given in Table 6.10. The highest overall group correlation 
for each subjective scale is with heart rate. Correlations for all four scales were around 
0.80. For VC>2 , there was a good overall group correlation (0.78) with VAS 
(breathlessness and general fatigue) whereas for the Borg CR10 scales the correlations 
were around 0.67 with VO2 . Perhaps surprisingly, VE and frequency of breathing had 
overall group correlations of around 0.6 with the subjective scales. The overall group 
correlations for VE/VO2 , VE/VCO2  and tidal volume and the subjective scales were low 
and for RER the correlations for all scales were very low.
There were no meaningful differences among the subjective scales i.e. similar correlations 
were found for each subjective scale with each physiological variable. The only slight 
difference between the scales was for VO2  where correlations with the VAS were 0.78 
and Borg CR10 scale were around 0.67. A wide range in minimum and maximum pooled 
pooled individual correlations and individual visit correlations across individuals was 
found for all the subjective scales and the physiological variables.
6.3.4. TIME EFFECT- COMPARISON OF THE CHANGES IN
SUBJECTIVE SCALES AND PHYSIOLOGICAL VARIABLES FOR 
TIMEPOINTS 1,2 AND 3.
An examination of the differences of the subjective scales and physiological variables was
made to determine the association between the subjective scales and the physiological
variables over time (see Table 6.11.). Time effects were calculated for the subjective
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scales and the physiological variables to examine the change in values over time. Using 
the output from the GLM, point estimates for time effects were obtained. A Bonfeironi 
multiple comparisons procedure was used to assess where significant differences if any, 
lay. The variables investigated were the VAS and Borg CR10 scales and the following 
physiological variables, VE, VO2 , VC02, frequency of breathing, heart rate, VE/VO 2, 
VE/VCO2  and tidal volume.
6.3.4.<a) SUBJECTIVE SCALES - TIME EFFECT.
Apart from VAS (breathlessness) between timepoint 2 and timepoint 3, there was a 
significant difference at all timepoints i.e. scores increased for all scales over time.
6.3.4.(b) PHYSIOLOGICAL VARIABLES - TIME EFFECT.
VE.
For VE, there was a significant INCREASE in scores to timepoint 3. VE decreased from 
timepoint 3 to 4. There was no difference between timepoints 2 and 4.
vo2
There was a significant INCREASE in VO2  between timepoints 1, 2 and 3. Timepoint 4 
was significantly LOWER than the other three timepoints.
vco2
VC02 INCREASED significantly from timepoint 1 to 2 and decreased between timepoint 
2 and 3 with timepoint 4 LOWER than timepoint 3.
FREQUENCY OF BREATHING.
Frequency of breathing INCREASED significantly over the first three timepoints but 
DECREASED from timepoint 3 to 4.
HEART RATE.
Heart rate INCREASED significantly over ALL four timepoints. There was no difference 
between timepoints 3 and 4.
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v e /v o 2
The VE/VO2  ratio INCREASED significantly from timepoint 1 to 2 and remained stable 
thereafter.
v e /v c o 2 .
The VE/VC02 ratio remained the SAME throughout.
TIDAL VOLUME.
Tidal volume was significantly LOWER at timepoint 1 compared to timepoint 3.
The decreases in some variables between timepoints 3 and 4 can be explained by the 
smaller number of subjects at timepoint 4 compared to timepoint 3.
6.3.5 SUMMARY.
These findings indicate that at all timepoints the perception of breathlessness and general 
fatigue increased apart from the VAS (breathlessness) between timepoints 2 and 3. In 
several instances, there was a concomitant change in physiological variables (eg VE, 
frequency of breathing and heart rate). The highest correlations were between heart rate 
and the subjective scales (around 0.80). Correlations for all the subjective scales and the 
respiratory physiological data (except V 02) were not particularly good and indicate a 
fairly poor relationship between these variables.
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Table 6.1.
Reproducibility Coefficients and 95% Confidence Intervals for Visual Analogue and Borg Scales for 
Breathlessness and General Fatigue.
REPRODUCIBILITY.
Breathlessness
Time
Scale 2.5 Min 5.0 Min 7.5 Min 10.0 Min
VAS 82% 83% 68% 66%
(58,91) (61,92) (36,83) (22,78)
Borg CR10 51% 48% 46% 38%
(16,73) (13,70) (11,69) (•0.57)
General Fatigue
Time
Scale 2.5 Min 5.0 Min 7.5 Min 10.0 Min
VAS 77% 86% 83% 81%
(51,89) (66,93) (60,92) (48,82)
Borg CR10 51% 77% 64% 46%
(17,73) (50,89) (32,81) (6,64)
Confidence intervals are in brackets beneath each estimate of reproducibility.
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Table 6.3
Peak Values for Breathlessness and General Fatigue using Visual Analogue and Borg 
CR10 Scales (Mean, S.D. and Range) for the Incremental Tests.
VAS Borg CR10
Breathlessness General
Fatigue
Breathlessness General
Fatigue
Test 1 60.7+19.0 54.5+12.7 4.4+1.7 3.5+1.1
(32-87) (28-74) (2-7) (2-5)
Test 2 65.4+23.9 51.3+22.5 5.0+2.0 3.9+1.6
(22-99) (15-80) (2-9) (1-7)
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Table 6.4
Mean Differences and Ninety-Five Percent Confidence Intervals for the Differences 
Between the Test 1 and Test 2 Incremental Tests for Visual Analogue and Borg CR10 
Scales for B reathlessness and General Fatigue.
Variable Mean S.D. 95%
Confidence
Interval
VAS
(Breathlessness)
4.7 18.3 -18,8
VAS
(General Fatigue)
-3.2 22.1 -13,19
Borg (CR10 
(Breathlessness)
0.6 1.78 -1.9,0.7
Borg CR10 
(General Fatigue)
0.4 1.90 -1.8, 1.0
Mean values are the Test 1 values minus the Test 2 values.
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Table 6.6.
Mean Differences and Ninety Five Percent Confidence Intervals for the Differences 
Between Incremental Test 1 and Test 2 for the Physiological Variables.
Variable Mean S.D. 95% Confidence Interval.
v o 2
(litres.min"1) -0.14 0.28 -0.01,0.4
VC02 1 
(litres.min'1) -0.25 0.38 -0.01,0.5
VE 1 (litres.min- ') ■ CD b> CD 10.38 1.3,16.1*
Frequency of Breathing 
(breaths.min'1) -2.73 4.08 -0.2,5.7
Heart Rate. 
(beats.min'1) -2.50 1.09 -5.3,10.3
RER -0.066 0.13 -0.1,0.2
Tidal Volume 
(litres) -0.127 0.26 -0.1,0.3
Endurance Time 
(Seconds)
-40.6 215 -194,113
Significantly different.
Mean values are the Test 1 values minus the Test 2 values.
130
Vi
sit
 E
ffe
cts
 a
t t
he 
Th
ird
 T
im
ep
oin
t 
for
 th
e 
Ph
ys
iol
og
ica
l V
ar
iab
les
.
i"-
( Da>
<o
St
an
da
rd
 
Er
ror
 o
f 
Vi
sit 
Ef
fe
ct.
1.
11
0.
02
7
0.
02
7
0.
64
2.
4
0.
83
0.
87
0.
03
1
0.
02
P 
va
lue
 
for
 V
isit
 E
ffe
ct
0.
61 0.
54
0.
53
0.
58
0.
40
0.8
1
0.
89
0.
09
0.
35
-0.
65
 
a
-0.
01
 a
-0.
02
0 
a
0.4
8 
a
0.4
5 
a
-0.
45
 
a
-0.
01
 a
-0.
05
6 
a
-0
.01
16
 
a
CO 1.4
6 
a
0.0
4 
a
0.0
39
 
a
0.1
7 
a
3.7
4 
a
0.1
2 
a OB
OO
o
o 0.0
32
 
a
0.0
02
0 
a
OJ -0.
08
 
a
-0.
02
 
a
-0.
01
2 
a
0.8
0 
a
-1.
75
 
a
0.6
9 
a
0.5
5 
a
0.0
53
 
a
0.0
04
8 
a
-
COr—
G> -0.
01
 
a
-0.
00
7 
a
0.1
5 
a
-2.
44
 
a <a
COCO
o1 -0.
62
 
a
-0.
02
9 
a
0.0
04
8 
a
Vi
sit
Va
ria
bl
e
•C
E
CO©
LU>
•
c
'E
CO<D
CM
o>
1C
'E
COo■H
CM
oo> Fr
eq
ue
nc
y 
of 
Br
ea
th
in
g 
(b
re
ath
s-m
in
"1
)
He
art
 R
at
e 
(b
ea
ts.
m
in
-1
)
CM
O
LU>
CM
oo
LU> Ti
da
l V
ol
um
e 
(li
tre
s)
RE
R
co
A 
co
mm
on
 
sy
m
bo
l 
(e.
g. 
a) 
de
no
tes
 v
isi
ts 
are
 
in 
co
mm
on
 
(i.e
. 
no 
sta
tis
tic
all
y 
sig
nif
ica
nt 
di
ffe
re
nc
e)
.
Table 6.8
Endurance tim es (Mean, S.D. minimum and maximum for the four constant workrate 
tests  in seconds.
TEST MEAN S.D. MINIMUM MAXIMUM
1. 609 159 395 942
2. 715 218 492 1009
3. 706 295 407 1272
4. 754 214 542 1295
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Table 6.9
Relative percentages for VO? , VE and heart rate during the final minute of the 
constant work rate test. (Values are the overall mean for all tests and relative to the  
higher score for each individual in the two maximal incremental tests.
Variable Mean Median S.D. Range
V 02 89.3 91.4 7.3 80.1-99.1
VE 92.5 88.4 13.9 73.7-123.0
Heart Rate 98.5 99.7 3.7 91.4-102.3
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CHAPTER 7 
SECTION ONE.
AN EVALUATION OF THE STEXT PROTOCOL.
RESULTS OF THE SUBJECTIVE SCALES.
7.1.1. DESIGN AND AIMS OF THE STUDY.
SUMMARY OF THE DESIGN OF THE STUDY.
Twelve male subjects took part in the study. Each subject underwent eight exercise tests 
using the STEXT protocol. The subjects were asked to exercise for as long as possible 
and to indicate when they could no longer continue. Subjects underwent two tests within 
48 hours of each other at weeks 0, 2, 6 and 10. At weeks 0 and 2 there was no 
intervention. At weeks 6 and 10 subjects were given a beta blocker (propranolol) or 
placebo. Propranolol was given to promote a perception of breathlessness and general 
fatigue. At week 6, six subjects were given placebo first and 48 hours later propranolol. 
At week 10 the same six subjects were given propranolol first and placebo second. The 
other six subjects were given the opposite order of drug administration. Six subjects were 
given a VAS/Borg CR10 scale order of presentation and six subjects a Borg CR10/VAS 
order. Scales appeared on the TV monitor every 2 minutes (starting at 2 minutes 10 
seconds) for breathlessness and general fatigue using VAS and Borg CR10 scales.
The main aims of the STEXT protocol study were to:
1) Compare the reproducibility and sensitivity to change of VAS and Borg 
CR10 scales.
2) Determine the magnitude of the visit and therapy effects on the subjective 
scales and physiological variables.
3) investigate the relationship between the subjective scales and physiological 
variables.
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7.1.2. RESULTS FOR THE SUBJECTIVE SCALES.
7.1.3. STATISTICAL METHODS.
It is important to note that the STEXT protocol includes submaximal and maximal data 
incorporated into one test. For each scale at each timepoint a generalised linear model 
was used to investigate possible systematic learning effects, differences among the tests 
and treatment differences. The model also included components of variability due to 
between subject variation and within subject variation. Minute 15 was selected to 
examine in detail any systematic visit/learning effect.
7.1.4. AN IMPRESSION OF THE RAW DATA FOR STEXT TESTS.
An impression of how the subjective scales were used is given in Figures 7.1-7.4 which 
show data from 7 minutes onwards because there was little movement in the scales in the 
early stages of the tests. Figures 7.1-7.4 show that all scales were used over a wide range 
for most subjects. For all four scales, subject 11 consistently scored low. Subject 5 did 
not rate general fatigue "high" on any test. Subjects 9 and 12 did not use the upper ranges 
in any of the scales in any of the tests. The scores from subject 8 showed the greatest 
variability and he rated breathlessness and general fatigue much more highly than the 
other subjects throughout the tests.
7.1.5. MEASUREMENT OF BREATHLESSNESS.
REPRODUCIBILITY.
The reproducibility of VAS was low at 3 minutes (48%) but increased to 83% at 9 minutes 
and was stable at around 82% to maximum (see Table 7.1). The Borg CR10 was very low 
at 3 minutes (23%), increased to 77% at 7 minutes and was relatively stable thereafter. 
There were no significant differences between the scales.
SENSITIVITY.
The sensitivity ratios and confidence intervals for VAS and Borg CR10 scales are shown 
in Table 7.2. For the VAS the 95% confidence intervals showed that at minutes 5 and 7 
the sensitivity ratio was not significantly different from zero whereas it was at 3 minutes
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and from 9 to 15 minutes. For the Borg CR10 scale there was only a significant therapy 
effect from 11-15 minutes. Examination of the 95% confidence intervals showed that 
there was an overlap at all timepoints between the scales and suggests no real difference 
between the scales. Analysis of the sensitivity for the maximum values is not given as it 
was considered that the values would be misleading. There was no sensitivity effect at 
maximum and in fact a reversal of the sign. This finding may be explained by the fact that 
the subjects perceived that they were exercising at maximum (during the active therapy) 
despite the fact that their endurance time was reduced.
7.1.6. MEASUREMENT OF GENERAL FATIGUE.
REPRODUCIBILITY.
At minute 3 the reproducibility ratio for the VAS was 35% and by minute 9 increased to 
84% with little change to maximum (see Table 7.3). For the Borg CR10 scale the 
reproducibility ratio was 26% at minute 3 and increased to 83% at minute 11 and 
remained relatively stable thereafter. There were no significant differences between the 
scales.
SENSITIVITY.
The sensitivity ratios and confidence intervals for the VAS and Borg CR10 scales are 
given in Table 7.4. For the VAS and Borg CR10 scales, the sensitivity ratio was 
significantly increased from minutes 9-15. There were no significant differences between 
the scales. Analysis of the sensitivity for the maximum values is not given for the reasons 
outlined above.
7.1.7. INVESTIGATION OF THE RELATIVE EFFECTS OF VISIT AND
THERAPY.
An examination of the differences in the subjective scales attributed to the visit and 
therapy effects was made for minute 15. It was considered to be unrealistic to compare 
the visit and therapy effects over all timepoints. Using the output from the GLM, point 
estimates were obtained for visit and therapy effects. A Bonferroni based multiple
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comparisons procedure was used to assess where significant differences, if any, lay. All 
scales showed a marked therapy effect which was generally much higher than the visit 
effect. The visit effect was most marked in the first two or three tests.
BREATHLESSNESS.
There were no significant differences among Tests 2-8 for the VAS. Test 1 was 
significantly lower than tests 3-8. Tests 5 and 6 were 17 and 14 units respectively, higher 
than Test 1 and the therapy effect for VAS was 12 units. Thus, the therapy effect for VAS 
was less than the visit effect (see Table 7.5) between Test 1 and Tests 5 and 6.
There were no significant differences for the Borg CR10 scale among tests 2-8. Test 1 
was significantly lower than tests 3-8. On average Tests 5-7 were 1.5 units higher than 
Test 1 and the therapy effect was 1.24. As for the VAS, the therapy effect was less than 
the visit effect between Test 1 and Tests 5-7.
These findings suggest that the subjects reassessed their perception of breathlessness on 
both scales after Test 1 i.e. the subjects rated breathlessness higher after Test 1. Thus, it is 
advisable to include a "run in" period of at least two visits to allow for stabilisation of 
scores before any intervention is attempted.
GENERAL FATIGUE.
For the VAS there were no significant differences among tests 2-8. Test 1 was lower than 
tests 3-8. The therapy effect was much higher than any visit effect.
For the Borg CR10 scale there were no significant differences among tests 2-8. Test 1 
was significantly lower than tests 5-8 (see Table 7.5). The therapy effect was much higher 
than any visit effect.
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7.1.8. SUMMARY.
There was no clear or consistent difference between the VAS and Borg CR10 scales in 
terms of reproducibility and sensitivity. All scales showed a visit effect in the sense that
generally the scores for Test 1 were much lower than the other tests. From Test 3 to Test/
8 scores tended to be quite stable. Care has to be taken in the use of this protocol when 
breathlessness is assessed as it has been shown that the visit effect between Test 1 and the 
latter tests is greater than the therapy effect. Thus, it is advisable to incorporate a "run-in" 
period when breathlessness is assessed using this protocol.
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CHAPTER 7 
SECTION TWO.
AN EVALUATION OF THE STEXT PROTOCOL.
RESULTS OF THE PHYSIOLOGICAL VARIABLES.
7.2.1. STATISTICAL METHODS.
A generalised linear model (GLM) was used to investigate possible visit, therapy, subject 
and natural (or error) variability. A Bonferroni multiple comparisons procedure was used 
to assess where the significant differences, if any, lay.
7.2.2.(a) AN IMPRESSION OF THE MAXIMAL RAW DATA.
It was considered unnecessary and unwieldy to illustrate all the physiological raw data. 
An example of the maximal data is given in Figure 7.5 which shows the VO2  max scores 
for all subjects for all 8 tests. For technical reasons it was not possible to obtain 
representative maximum respiratory variables for subject 8 on Test 3. The impact of beta 
blockade can be clearly seen. There is a marked decrease in scores on two occasions for 
all subjects between tests 5-8.
7.2.2.(b) AN IMPRESSION OF THE SUBMAXIMAL DATA.
Figure 7.6 provides a flavour of the physiological data and shows VE for all subjects for 
all 8 tests. VE looks very reproducible apart from early in the tests for subjects 7 and 9. 
The increases in VE with beta blockade in the latter stages of the test is not particularly 
noticeable as the scale is very small.
7.2.3.(a) MAXIMAL VALUES - THE EFFECT OF BETA BLOCKADE.
Table 7.6 shows the maximum mean values for VE, VO2 , VCO2 , VE, frequency of 
breathing, heart rate, tidal volume, RER and endurance time for all eight tests. For clarity 
of presentation, the data were arranged as follows - at the third timepoint (i.e. tests 5 and 
6) the placebo and active treatment scores have been combined so that test 5 refers to the 
placebo and test 6 refers to the active treatment. Similarly, at timepoint 4, test 7 is the 
placebo, and test 8 the active treatment. The output from the GLM showed that under beta
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blockade there were significant differences between the beta blockade and non beta 
blockade tests for VE, VO2 , VC02, frequency of breathing, heart rate, tidal volume and 
endurance time. All these variables showed a significant decrease under beta blockade. 
There were no significant visit effects.
Reproducibility was calculated for the maximal physiological values (see Table 7.7). 
Reproducibility coefficients were high for all variables EXCEPT RER and heart rate.
7.2.3.<b) SUBMAXIMAL VALUES - THE EFFECT OF BETA
BLOCKADE.
A GLM was used to investigate the therapy effects for the submaximal variables. No 
statistical analysis was carried out for minutes 16 and 17 as there was insufficient data to 
draw meaningful conclusions. The values displayed on the graphs (see Figures 7.7-7.15) 
illustrate these therapy effects for all relevant physiological variables.
VE.
At minute 8 VE was significantly LOWER on the active treatment compared with the non 
beta blocker tests. At minute 14 and 15 VE was significantly INCREASED compared 
with the non beta blocker tests (see Figure 7.7).
vo2
At ALL timepoints VO2  was significantly LOWER on non beta blocker tests (see Figure 
7.8).
vco2
At minutes 8, 11 and 15 VC02 was significantly HIGHER on the non beta blocker tests 
(see Figure 7.9).
FREQUENCY OF BREATHING.
The frequency of breathing at minutes 14 and 15 with beta blockade was significantly 
HIGHER than on the non beta blockade tests (see Figure 7.10).
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HEART RATE.
Heart rate was significantly LOWER at ALL timepoints with beta blockade compared 
with the non beta blocker tests (see Figure 7.11).
v e /v o 2
The VE/VO 2  ratio was significantly INCREASED from minute 10 to minute 15 compared 
with the non beta blocker tests (see Figure 7.12).
v e /v c o 2
The VE/VC02 ratio was significantly INCREASED from minute 10 to minute 15 
compared with the non beta blocker tests (see Figure 7.13).
TIDAL VOLUME.
Tidal volume was significantly INCREASED at minutes 14 and 15 compared with the non 
beta blocker tests (see Figure 7.14).
RER.
RER was significantly INCREASED from minute 10 to minute 15 compared with the non 
beta blocker tests (see Figure 7.15).
7.2.4. THE RELATIVE MAGNITUDE OF ANY VISIT EFFECTS.
The visit and therapy effects for the physiological variables for minute 15 are given in 
Table 7.8. Minute 15 was chosen to give an in-depth examination of the visit and therapy 
effects as it is unrealistic to examine all timepoints in detail. There were no significant 
visit effects for any variable.
The therapy effect was significant for all variables i.e. there were significant INCREASES 
for VE, frequency of breathing, VE/V02, VE/VC02, tidal volume and RER and 
significant DECREASES for V 02, VC02 and heart rate due to the intervention of a beta 
blocker.
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7.2.5. SUMMARY.
MAXIMAL VALUES.
The maximal values for VE, VO2 , VCO2 , frequency of breathing, tidal volume and 
endurance time were very reproducible. There were no significant visit effects. There 
were significant differences between the beta blockade and non beta blockade tests for 
VE, VC>2 , VCC>2 , frequency of breathing, heart rate, tidal volume and endurance time. 
All these variables showed a significant decrease under beta blockade.
SUBMAXIMAL VALUES.
In the latter stages of the test, there were significant differences for all submaximal 
variables. VE, VCO2 , frequency of breathing, VE/VO2 , VE/VCO2 , tidal volume and 
RER were increased. Heart rate and VO2  were significantly reduced throughout the test. 
There were no significant visit effects.
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CHAPTER 7 
SECTION THREE.
AN EVALUATION OF THE STEXT PROTOCOL
RESULTS OF THE RELATIONSHIP BETWEEN PHYSIOLOGICAL 
VARIABLES AND THE SUBJECTIVE MEASURES OF BREATHLESSNESS AND 
GENERAL FATIGUE.
7.3.1. WHY? HOW?
It was decided that the best way to indicate which perception of symptom was best related 
to each physiological variable was to evaluate individual subject correlations based on all 
observations for each subject across all timepoints.
An explanation of how the correlations were calculated is given in Section 4.5.
7.3.2. A VISUAL IMPRESSION OF THE RELATIONSHIP BETWEEN 
THE VAS AND VE.
A flavour of the relationship between the subjective scales and physiological variables is 
given by taking the VAS (breathlessness) and VE and displaying these variables 
graphically in the following examples. For minutes 3 to 17, Figure 7.16 shows the 
VE/VAS (breathlessness) relationship for subject 4. The limited movement in the scales 
in the early stages of the test is evident. Figure 7.17 shows the VE7VAS (breathlessness) 
relationship for all subjects for all tests for minutes 3-17. For almost all subjects, there is 
little movement in the scales for the first few timepoints.
7.3.3. CORRELATIONS.
A visual impression of the various correlations for one subjective scale and one 
physiological variable is given in Figure 7.18. Figure 7.18 gives the correlations for VE 
and VAS (breathlessness) for:
1) individual visit correlations for each subject.
2) pooled individual correlations.
3) estimated pooled correlation (overall group correlation).
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The individual visit correlations for subject 7 are wide ranging and the pooled individual 
correlation is lowest for subject 10 and highest for subjects 4,11 and 12.
The overall group correlations, the pooled individual correlations and the minimum and 
maximum individual visit correlations for VAS and Borg CR10 scales (breathlessness and 
general fatigue) and VE, VC>2 , VCO2 , frequency of breathing, heart rate, VE/VO2  
VE/VCO2  and tidal volume are shown in Table 7.9. For both scales, for breathlessness 
and general fatigue, there were high correlations for all physiological variables apart from 
VE/VCO2  and VE/VCO2 . For VE and VCO2  the correlation was greater than 0.8 for all 
four scales. Apart from VE/VO2  and VE/VCO2  all the other correlations were above 0.7. 
The minimum and maximum individual visit correlations for the physiological variables 
and the subjective scales showed a wide range. Several maximum individual visit 
correlations were 0.99 but some minimum individual visit correlations were under 0.1. 
The range was not so great with the pooled individual visit correlations.
There were no meaningful differences among the subjective scales i.e. a similar 
correlation was found for each subjective scale for effectively every physiological 
variable. All the subjective scales showed a negative correlation with VE/VCO2
7.3.4. SUMMARY.
There appeared to be a close relationship between all the physiological variables (apart 
from VE/VCO2  and VE/VCO2 ) with all four subjective scales.
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Table 7.7
Reproducibility of Maximum Values for the Physiological Variables.
Variable Reproducibility 
(Percentage and 95% C.I.)
VE (litres.min'1) 77 (51,88)
VO2 (ml.kg.'1min'1) 76 (49,87)
VCO2 (litres.min"1) 96 (90,98)
Frequency of Breathing (breaths.min"1) 73 (46,86)
Heart Rate(beats.min'1) 43 (15,64)
Tidal Volume (litres) 80 (56,90)
RER 54 (23,73)
Endurance Time (seconds) 79 (54,89)
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Effect of beta blocker on VE/V0£
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Effect of beta blocker on VE/VCO2
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Effect of beta blocker on tidal, volume.
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Effect of beta blocker on respiratory exchange ratio.
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CHAPTER 8 
SECTION ONE.
DISCUSSION.
A COMPARISON OF THE REPRODUCIBILITY AND THE SENSITIVITY TO 
CHANGE OF VAS, BORG CR10 AND LIKERT SCALES.
8.1. SUBJECTIVE SCALES.
8.1.1. MEASUREMENT OF BREATHLESSNESS - REPRODUCIBILITY.
In this study, the VAS was more reproducible for the measurement of breathlessness than 
the Borg CR10 scale. The Likert scale tended to perform better than the Borg CR10 scale 
but there were no significant differences between the scales. The Likert scores tended to 
be lower than the VAS.
Several groups have shown that the VAS allows reproducible measurement of 
breathlessness, in the short term, in both normal subjects and patients (O'Neil et al; 1986, 
Stark et al; (1982), Stark et al; (1981). Wilson and Jones have shown that the Borg CR10 
scale measurements of breathlessness are also reproducible in both the short and long term 
(Wilson and Jones, 1989, 1991a). Due to different exercise protocols and statistical 
methods of evaluation, it is impossible to say from these studies whether one scale is more 
reproducible than the other. There have, however been no descriptions of the 
reproducibility of Likert scale measurements of breathlessness during exercise. In the only 
other direct comparison of the repeatability of the VAS and the Borg CR10 scale, Wilson 
and Jones, (1989) reported that the Borg CR10 scale was more reproducible over the short 
term (a 2 to 6 week period) than the VAS. Wilson and Jones, (1989) favoured the use of 
the Borg CR10 because it correlated with VE more closely than the VAS and provided a 
more reproducible measure. These authors, however, made repeatability measurements of 
the slope of the relationship between the breathlessness score and VE and not on scores at 
fixed time points, as was carried out in this study.
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8.1.2. MEASUREMENT OF BREATHLESSNESS - SENSITIVITY.
The VAS demonstrated significantly better sensitivity at 6 and 8 minutes than the Borg 
CR10 scale. The Likert scale tended to be higher than the Borg CR10 scale but there was 
no significant difference. There was a non significant trend for the VAS to be higher than 
the Likert scale. There is limited published information on the sensitivity of scales to 
protocol, drug or disease induced changes in breathlessness. Stark et al; (1983) found the 
VAS to be sensitive to change in three of five patients with chronic obstructive airways 
disease before and after non-randomised bronchodilator or placebo treatment, given in a 
single session. O'Neil et al; (1986) increased the respiratory resistance to assess the 
sensitivity of the VAS scale before evaluating beta blockers and concluded that the VAS 
was sensitive to change. Muza et al; (1990) suggested that the VAS may be better at 
identifying changes in breathlessness than the Borg 6-20 scale as there were less 
restrictions with the VAS. In the present study the VAS was the most sensitive for 
detecting change in breathlessness following pharmacological intervention, though it 
should be noted that this change was in a different direction (i.e. increased symptom 
intensity) than in the Stark et al; (1983) study.
Some studies have induced a greater degree of breathlessness using resistive loading and 
found that the VAS and Borg CR10 scales to be responsive to this type of intervention. 
An increase in the inspiratory resistance was used to increase the perception of 
breathlessness at a given VE in normals (Stark et al; 1981). They found that 
breathlessness was more severe with the inspiratory resistance and they suggested that the 
plot of breathlessness (using the VAS) and VE was sensitive to change. El-Manshawi et 
al; (1986) used the Borg CR10 scale to quantify the intensity of breathlessness associated 
with exercise and respiratory resistive loading. They found that the perception of 
breathlessness increased at any given workload with resistive loading.
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8.1.3. MEASUREMENT OF GENERAL FATIGUE - REPRODUCIBILITY.
In this study the VAS tended to be the most reproducible scale. The Borg CR10 scale 
tended to perform better than the Likert scale but not as well as the VAS. No other 
reproducibility study has been carried out on general fatigue.
8.1.4. MEASUREMENT OF GENERAL FATIGUE - SENSITIVITY.
The Borg CR10 was clearly much more sensitive to change than the other two scales for 
general fatigue. It is unknown why the Borg CR10 scale was the most sensitive of the 
three scales. Furthermore, it is unclear why the Borg CR10 scale for general fatigue is 
much more sensitive than the Borg CR10 scale for breathlessness.
The fact that there is such a great difference in the performance of the Borg CR10 scale 
between breathlessness and general fatigue indicates that the subjects were able to 
differentiate between breathlessness and general fatigue. Lees et al; (1987) failed to alter 
the perception of fatigue (Borg Category Scale) after epanolol or metoprolol during an 
incremental cycle test compared with placebo.
While this study asked subjects to quantify general fatigue, it may be of value to examine 
how other studies have used subjective scales to assess RPE as some authors have 
suggested that RPE scores could have implications for fatigue. Using the Borg category 
scale Pearson et al; (1979) reported that RPE scores were higher on propranolol than 
placebo and concluded that this finding may have relevance to the symptom of fatigue 
reported by patients on these drugs. Van Herwaarden et al; (1979) found that propranolol 
had no effect on RPE but their subjects worked at only moderate intensities.
Other studies have distinguished between "central” and "leg" effort. During 25 minutes at 
65% VO2  max Kaiser et al; (1985) found that "central" RPE was increased in 3 out 5 
timepoints but "leg" effort was higher at all 5 timepoints with 80 mg of propranolol 
compared with placebo. Tesch and Kaiser, (1983) found that "leg" RPE (Borg Category) 
was higher than central RPE during steady state exercise at 73% V0 2  Max with 80 mg of
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propranolol compared with placebo. The authors speculated that changes within the 
skeletal muscles were probably causing an increased sensation of fatigue. Tesch et al; 
(1984) asked subjects to rate "local and central" fatigue during incremental steady state 
exercise using the Borg category scale. Both were significantly increased at the higher 
workrates after beta blockade compared with placebo but they found no difference at the 
low workrates. The authors concluded that the subjects reported an increased sensation of 
fatigue with propranolol compared to placebo during heavy steady state exercise.
The findings of Tesch that the perception of leg effort was increased more than "central" 
with beta blockade may indicate that "overall fatigue" may not have been affected. 
However, subjects in this study were asked to clearly distinguish between general fatigue 
and leg fatigue. Somewhat surprisingly Violante et al; (1984) reported that untrained 
subjects scored RPE lower at 25 and 150 watts after 40 mg of propranolol compared with 
placebo.
8.1.5. BREATHLESSNESS/GENERAL FATIGUE DIFFERENCES.
Reproducibility coefficients for breathlessness and general fatigue were highest for the 
VAS throughout the three timepoints but only statistically significant at minute 6 for 
breathlessness. Indeed, the reproducibility coefficients for breathlessness and general 
fatigue follow a similar pattern. It could be hypothesised that the subjects were unable to 
distinguish between the two symptoms. However, all subjects reported that they could 
discriminate between breathlessness and general fatigue. Furthermore, there is a marked 
difference in the sensitivity scores between the two symptoms. It may be expected that 
the VAS would be the most sensitive scale as it offers finer adjustment. In breathlessness, 
this is the case but perhaps somewhat surprisingly for general fatigue the Borg CR10 scale 
is the most sensitive of the three scales.
8.1.6. RANGE OF SCALES.
The VAS and Likert scales were used over a wider range than the Borg CR10 scale for 
breathlessness and for general fatigue. As in the study of Wilson and Jones, (1989) the
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Borg CR10 scale was used over a narrower range for breathlessness than the VAS. The 
terminology used in the upper part of the Borg CR10 scale is likely to restrict the use of 
the upper part of the scale particularly during submaximal exercise. For example, five on 
the Borg CR10 is "severe". The verbal descriptors in the Borg CR10 scale may have 
imposed a certain threshold of sensation intensity at each level before proceeding to the 
next digit. The Borg CR10 has an in-built ratio bias and a resultant tendency to restrict 
scores to the lower half of the scale. Wilson and Jones (1989) concluded that the limited 
range of the Borg CR10 scale may have contributed to the higher repeatability of 
breathlessness using this scale in their study. However, the repeatability comparisons 
were compared on the slope of the relationship.
Conversely, it could be expected that the VAS was more reproducible than the Borg CR10 
scale because it allows greater precision in measurement than the Borg CR10 scale. The 
Borg CR10 scale has constrictors. Differences between VAS and category scales have 
been detected in other studies. For example, the level of discomfort during a helicopter 
trip was assessed using a category scale and a scale without descriptors. The former scale 
was scored within the central region while the latter was used in a more progressive 
manner (Osborne and Clarke, 1976). A similar finding was reported by Scott and 
Huskinson, (1976) who used different scales to estimate pain. It could be hypothesised 
that the Borg CR10 and the Likert scales would be more reproducible as the verbal 
descriptors may have enabled subjects to target a particular number by increasing 
preferential use of certain digits whereas the VAS offers more opportunity for a wider 
selection.
Furthermore, it could be hypothesised that it is necessary for large changes in status before 
subjects are likely to move to another point on the Likert scale. If this were true, it would 
be anticipated that the Likert scale would be very reproducible in similar conditions. 
However, any movement in subjects' scores is likely to heavily "penalise" the Likert scale 
as a change of one is equivalent to 20% of the range of possible scores. Word descriptors
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did not restrict the use of the Likert scale as a score of 4 was given for Likert 
(breathlessness and general fatigue) on the active treatment and R1 and placebo.
8.1.7. ANCHOR POINTS.
Subjects were asked to refer to their common experience of the symptoms, breathlessness 
and general fatigue. In addition, they were asked to score their perception of these 
symptoms at the end of the maximal test. It is unknown if these procedures had any 
influence on the results obtained. Stark et al; (1982) fixed the 100% mark on a 
breathlessness VAS scale by reference to a familiar everyday activity. Others have found 
acceptable reproducibility without any attempt to anchor (Guz et al; (1981). It was felt 
that reference to "common experience" and feelings at the end of the maximal test were of 
value. Subjects reported that reference to theses "markers" helped them establish 
reference points. Restricting the anchor points to familiar everyday activities or maximal 
test endpoints could have limitations. For example, one subject scored relatively low on 
general fatigue at the end of the maximal test as he reported that he had experienced much 
greater general fatigue after he had run up Ben Lomond. Subjects who have not exerted 
themselves for a long period of time may not have a meaningful reference point to which 
they can refer.
8.1.8. COMPARISON OF THE VISIT AND THERAPY EFFECTS.
The VAS (breathlessness and general fatigue) and Likert (breathlessness) showed a 
significant visit effect. These visit effects were small compared with the therapy effects 
but fairly large in comparison with the absolute scores. Care has to be taken in the use of 
this protocol as it has been shown that there is a visit effect for some scales. Despite the 
fact that the therapy effect was much greater than the visit effect, it is advisable to 
incorporate a "run-in" period when this protocol is used. Wilson and Jones, (1989) found 
that the mean score for the Borg CR10 scale (breathlessness) was reduced by 16% 
compared with day 1 and the VAS (breathlessness) score was 27% lower on day 2.
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8.1.9. SUMMARY.
BREATHLESSNESS AND GENERAL FATIGUE.
Overall the VAS was the best scale with the Borg CR10 scale second and the Likert third. 
Therefore, it was decided to evaluate the VAS and Borg CR10 scale in CHF patients using 
a submaximum protocol.
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CHAPTER 8 
SECTION TWO.
A COMPARISON OF THE REPRODUCIBILITY AND SENSITIVITY TO 
CHANGE OF VISUAL ANALOGUE, BORG CR10 AND LIKERT SCALES
8.2. PHYSIOLOGICAL DISCUSSION.
8.2.1. AEROBIC POWER AND SUBMAXIMAL RELATIVE INTENSITY.
The mean VO2  max of 56.5 ± 5.8 ml.kg'-^.min"^reflects the high aerobic fitness level of 
this group of recreationally active males. The projected steady state relative intensity was 
70% VO2  max and the measured mean %V02 max of 70.8% is very close to this targeted 
value of 70% VO2  max. The fact that there was no significant difference between the 
minute 6 and minute 8 values on R l, R2 and placebo for VO2 , VCO2  and VE indicates 
that a steady state was achieved in these treatments.
8.2.2. EFFECT OF PROPRANOLOL.
No blood analysis was undertaken to verify that the subjects had taken the propranolol 
tablets. However, on the active treatment day all subjects showed a marked decrease in 
exercise heart rates. The magnitude of decrease during the eighth minute of exercise was 
42 beats.min'l on propranolol compared with placebo (155 to 113 beats.min‘1 i.e. 27%). 
This decrease is similar to other studies which have used the same dosage of propranolol. 
For example, the normal subjects of Wilmore et al; (1985) showed a decrease in heart rate 
from 158 to 116 beats.min"^ and those of Anderson et al; (1985) from 154 to 116 
beats.min'l during submaximal steady state exercise. Tesch (1985) in his review
indicated that heart rates at 50-70% VO2  max are normally reduced by 18-28% after short 
term administration of propranolol. There was a significant decrease in heart rate at each 
minute during the 8 minutes of exercise. The increase in heart rate associated with the 
onset of exercise is blunted after beta blockade as is the normal augmentation of 
myocardial contractility (Epstein et al; (1965). Most studies have shown that cardiac 
output is decreased by about 10% during submaximal exercise, with an increased stroke 
volume. Joyner et al; (1986) reported that an increase in stroke volume maintained
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cardiac output at >94% of unblocked values at 60% VO2  max. The decrease in cardiac 
output of around 5-15% during beta blockade is counteracted by an increase in oxygen 
extraction from the blood (Van Baack, 1988).
Propranolol will influence peripheral circulation as it potentiates the normal rise in 
catecholamines during exercise (Galbo et al; (1976) and blocks beta receptors which are 
involved in vasodilation in forearm blood vessels (Brick et al; (1966). At the start of 
exercise muscle perfusion will probably be decreased as cardiac output is lower. 
Consequently O2  delivery will be decreased and the contribution of anaerobic metabolism 
will be increased and the rate of CO2  and lactate removal from exercising muscle will be 
decreased. As anaerobic metabolism metabolites increase, it is probable that they will 
over-ride any local beta blockade resulting in vasodilation and an increase in the removal 
of metabolites will result, leading to an increase in CO2  flux to the lungs.
It is concluded that all subjects took propranolol and this resulted in a variety of 
physiological changes compared with placebo.
8.2.3. V 02 V C02and VE.
The lower V 02 values for timepoints 1-7 minutes, the lower VC02 values early in 
exercise, the higher values later in exercise and an increase in VE between 3-8 minutes are 
consistent with the findings of Twentyman et al; (1981) whose normal subjects worked at 
70% Vo2max one hour after taking 80 mg of propranolol.
8.2.4. V 02 and RER.
The decrease in V 02 in this study for most of the exercise period is consistent with some 
but not all of the literature. In heavy submaximal exercise (over 60% V 02 max) V 02 is 
reduced or the same (Van Baack, 1988). Other researchers have shown that oxygen 
kinetics are delayed in steady state exercise as a consequence of beta blockade (Hughson 
et al; 1978, Twentyman et al; 1981). Wilcox et al; (1984) concluded that the 
administration of propranolol lengthens the time constant relating to the increase in V 02
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but has no effect on the eventual steady state value. Van Herwaarden et al; (1979) found 
no fall in VO2 . This finding was probably due to the low relative intensity selected.
In some instances as in this study a decreased VO2  has been accompanied by an increased 
RER suggesting a shift towards a greater fractional use of carbohydrate. Joyner et al; 
(1987) found an increase in RER at 75% VO2  max with trained subjects but not with 
untrained. McLeod et al; (1985) found no difference in RER at 20% VO2  max after 40 
mg of propranolol but reported a significant increase at the 10th minute of steady state at 
60% VC^max.
The increased RER in this study is suggestive of an increase in glycolysis and decreased 
lipolysis. Assuming a greater reliance and usage of glycolytic precursors as fuel, a small 
decrease in VO2  could be expected as carbohydrate utilisation gives approximately 10% 
higher energy yield per litter of C>2 Compared with fat.
8.2.5. V C02
There has been a varied response in VCO2  after beta blockade and some "beta blocker” 
studies have failed to report VCO2  values. Van Herwaarden et al; (1979) and Petersen et 
al; (1983) found that VCO2  was unaffected with propranolol administration. In both these 
studies the subjects worked at fairly low relative intensities. Butland et al; (1982) found a 
decrease in VCO2  after infusion of propranolol which they attributed either to a decrease 
in metabolic rate or directly by an effect on chemoreceptors. The differences for VCC>2 
following beta blockade can be explained by changes in cardiac output and muscle blood 
flow. The decreased VCO2  in the early stages can be explained by a lower cardiac output 
(Winsborough et al; 1980) and a resultant increase in mixed venous PCO2  and CO2  
stores. Until a new equilibrium was reached this would lower VCO2  after propranolol. 
At a later stage in exercise, VCO2  would reflect CO 2 production in the tissues.
192
8.2.6. VE.
VE was increased from 3-8 minutes compared with placebo. The increase in VE during 
high intensity steady state exercise during the later stages of the exercise bout agrees with 
Twentyman et al; (1981) and Pearson et al; (1987). Wilcox et al; (1984) found no change 
in VE with propranolol but at low relative intensities while Tesch and Kaiser, (1983) 
reported a non significant increase in VE at 64-69% of VO2  max. Pearson et al; (1987) 
showed that VE was increased compared to placebo with atenolol at "higher" intensity 
steady state exercise. Propranolol showed the same trend but did not reach statistical 
significance. Some studies have shown a decrease in VE with propranolol. Pearson et al; 
(1987) found that VE was depressed at "lower" steady state intensities on atenolol 
compared with placebo. The lack of consensus may be explained by the varying intensities 
and dosage of the different studies.
An increase in plasma potassium during exercise after beta blockade due to reduced 
reuptake in inactive tissues has been found (Van Baak, 1988). This could result in an 
increased ventilatory drive via the peripheral chemoreceptors (Busse et al; 1990). 
Changes compared with placebo might be due to an effect on respiratory control 
mechanisms, cardiovascular function or metabolism. Twentyman et al; (1981) concluded 
that the above effects on VO2  and VCO2  and the increase in VE at the end of the 70% 
steady state cannot be explained by depression of central or peripheral ventilatory control 
by propranolol or changes in lung mechanics. Twentyman et al; (1981) suggested that the 
increase in VE in the latter stages of the 70% VO2  max steady state was the VE 
responding to increased levels of lactic acid. Airway resistance and lung mechanics are 
not usually influenced to any great extent by propranolol at rest or during exercise in 
normals and cannot explain the increase in VE (Warren et al; 1984).
8.2.7. FREQUENCY OF BREATHING/TIDAL VOLUME.
On the "active" treatment, the frequency of breathing was significantly increased from 
minute 2 onwards but there were only 2 timepoints when tidal volume was lowered by 
beta blockade. Joyner et al; (1987) reported a small decrease in tidal volume after non
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selective blockade which was compensated by an increased frequency of breathing. 
Pearson et al; (1987) reported that tidal volume was increased with atenolol but not with 
propranolol.
8.2.8. VE/V02 AND VE/VC02
The increase in these ratios are a reflection of an increase in VE and/or a decrease in 
VO2 /VCO2  at various timepoints.
8.2.9 VISIT EFFECT.
At minute 8, VE, frequency of breathing and VE/VCO2  showed a visit effect. These visit 
effects were very small. There were no other significant visit effects for any of the other 
physiological variables. Armstrong and Costill, (1985) found significant day to day 
differences for VO2  and VE on a treadmill in some but not all of a wide range of 
submaximal intensities. They found a systematic decrease in VE at low intensities and a 
decrease in VO2  over range of intensities. These authors stressed that little work has been 
done in this area.
8.2.10. SUMMARY.
There were small but significant visit effects for only VE, frequency of breathing and 
VE/VCO2 . Therefore, it is suggested that subjects had very similar physiological 
responses to the exercise tests throughout the "non beta blocker" tests. The active 
treatment had a lowering effect on heart rate and increased several respiratory variables 
including VE, frequency of breathing, RER, VCO2 , VE/VO2 , VE/VCO2  at some or all 
timepoints. At some timepoints, VO2  and VCO2  were reduced. These findings suggest 
that these differences could result in a change in perception of breathlessness and general 
fatigue.
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CHAPTER 8 
SECTION THREE.
8.3. THE RELATIONSHIP BETWEEN THE PERCEPTION OF
SYMPTOMS AND PHYSIOLOGICAL VARIABLES.
8.3.1. BREATHLESSNESS.
All the scales showed high overall group correlations with VE, VO2 . VCO2 , frequency of 
breathing, heart rate, VWVO2 , tidal volume and RER. However, it must be stressed that a 
high correlation does not necessarily imply a causal relationship.
Other studies have shown a very strong relationship between VE and the perception of 
breathlessness assessed by VAS and Borg CR10 scales (Muza et al; 1990) Wilson and 
Jones, 1989). However, it has been suggested that breathlessness is not merely a sensing 
of VE. O'Neil et al; (1986) have shown that the perception of breathlessness increased 
despite no change in the level of VE. In this study VE remained stable between 6 and 8 
minutes in the R l, R2 and placebo "treatments” but rose by 4 litres.min'^ in the active 
treatment. Despite the stability of all respiratory variables on R l, R2 and placebo, the 
perception of breathlessness increased as measured by the VAS and Borg CR10 scales.
Chronos et al; (1988) investigated the subjective changes accompanying alterations in 
inspired oxygen concentration in normal subjects. During and after inspiration of 15% 
oxygen, changes in the VAS score occurred relatively more quickly than VE. The authors 
suggested that hypoxia per se could be a contributory factor to the genesis of 
breathlessness. The authors speculated that there was a neural basis for the dissociation 
between breathlessness and VE observed in studies in which hypoxia was induced. They 
hypothesised that increases in neural traffic from the stimulated carotid body may be 
directly perceived as breathlessness whereas the ventilatory responses take longer to 
develop because of the time constant of the integrating mechanisms within the medullary 
respiratory centres. Using normal subjects Lane et al; (1987) concluded that it was not the
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level of VE per se which related to the level of breathlessness but it was the reflexly 
driven VE which was responsible for the perception of breathlessness. Thus, the 
relationship of breathlessness to VE is not fixed but depends on the methods used to 
induce the sensation.
Despite a good correlation between VE and the subjective scales, there was a large inter 
subject variation in the range of the scales used in relation to VE. The wide ranging use of 
the scales has also been found by previous workers (Wilson and Jones, 1989, Stark et al; 
1981). Therefore, comparison between subjects is hazardous because of the individual use 
of scales. There are a number of possible reasons for the inter-subject variation. The 
subjects may use the scales in a different way. Interpretation of the instructions and 
varying sensitivities of the sensory inputs provoking a sensation of breathlesness are two 
possible explanations. The subjects may be influenced by the experimenter and could 
perhaps score lower than what is perceived.
The correlations between breathlessness (VAS) and frequency of breathing was 0.85 and 
0.89 for the correlation between tidal volume and the Likert scale (the highest correlations 
for frequency of breathing and tidal volume). Chronos et al; (1988) compared ventilatory 
responses with the sensation of breathlessness using a VAS. They concluded that changes 
in the perception of breathlessness did not correspond with changes in frequency of 
breathing or tidal volume. Using a least squares correlation analysis and rank correlation 
analysis the authors were unable to demonstrate any statistically significant relationship 
between the individual's VAS scores and the level of any of the physiological variables 
measured.
8.3.2. GENERAL FATIGUE.
All 3 scales showed very high correlations between VE, VO2 , VCO2 , heart rate, and RER 
and general fatigue. In their review of RPE scales, Carton and Rhodes, (1985) stated that 
it is VE and frequency of breathing which have the greatest impact on the perception of
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effort. In this study the correlations for VE and the frequency of breathing and the 3 
scales was around 0.92 and 0.80 respectively. The fact that there was no significant 
difference in VE and frequency of breathing between 6 and 8 minutes in R l, R2 and 
placebo and the perception of general fatigue was higher at 8 minutes compared with 6 
minutes, suggests that the perception of general fatigue is not merely a sensing of VE and 
frequency of breathing. Noble et al; (1973) reported that VE and frequency of breathing 
were the best predictors of RPE in a hot or "normal" environment. Edwards et al; (1972) 
indicated that VE has afferent nervous system input which can be consciously monitored 
unlike VO2 . In their review, Watt and Grover, (1993) concluded that RPE "involved a 
weighted average of dominant local signals and perceptibly less intense central signals." 
They suggested that central factors serve as amplifiers to local factors relative to aerobic 
demand. This implies that central factors dominate at high intensities.
All the subjective scales were highly correlated with heart rate. Several studies have 
reported that heart rate and RPE are highly correlated (Borg, 1962; Edwards et al; 1972) 
but Carton and Rhodes, (1985) stressed that at no point has it been implied that these 
variables are causally related. Furthermore, it has been shown that the relationship 
between heart rate and RPE can be disturbed. For example, it has been demonstrated that 
heart rate can be lowered using beta blockade without affecting RPE at a given relative 
percentage of VC^max (Davies and Sargeant, 1979)
8.3.3. SUMMARY.
The Borg CR10 scale was used over a narrower range than the VAS. Thus it may have 
been expected that the VAS would have shown a better correlation with physiological 
variables such as VE.
All the scales had high correlations with VE, VO2 , VCO2 , frequency of breathing, heart 
rate, VE/VO2 , tidal volume and RER for breathlessness and general fatigue. Several 
physiological variables, VE, VO2 , VCO2 , frecluency of breathing, and heart rate) were 
stable between 6 and 8 minutes. Despite this stability the scores for the subjective scales
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increased. These findings suggest that there is not a direct association between the 
perception of symptoms and physiological variables.
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CHAPTER 8 
SECTION FOUR.
SYMPTOMATIC AND PHYSIOLOGICAL RESPONSES TO SUBMAXIMAL 
EXERCISE IN CHRONIC HEART FAILURE.
8.4.1. SUBJECTIVE SCALES.
In this study the VAS tended to be more reproducible than the Borg CR10 for 
breathlessness and general fatigue. However, 95% confidence intervals showed no 
significant difference between the scales. Reproducibility coefficients were highest with 
the VAS scale measuring general fatigue. There have been no other studies on the 
reproducibility of subjective scales in CHF.
8.4.2. MEASUREMENT OF BREATHLESSNESS.
In the CHF pilot study, it was found that the higher the relative intensity, the higher the 
reproducibility coefficient. In the CHF main study the mean % of peak VO2  was 89% 
and the mean % peak VO2  on the third stage in the CHF pilot study was 83%. While the 
VAS tended to be more reproducible than the Borg CR10 in the CHF main study, there 
was hardly any difference between the scales in the CHF pilot study. In the comparison of 
the VAS, Borg CR10 and Likert scales the VAS was clearly more reproducible than the 
Borg CR10 scale. In the above study using normal subjects, the reproducibility coefficient 
for the VAS was 78% for breathlessness at the third timepoint. For this CHF study, 
reproducibility was highest (83%) at 5 minutes for breathlessness and fell to 66% at 10 
minutes. Compared with 5 minutes, reproducibility was also much lower at 7.5 minutes 
(68%). Thus the reduced number of subjects at 10 minutes cannot be the only explanation 
for the change over time.
8.4.3. MEASUREMENT OF GENERAL FATIGUE.
In the CHF pilot study and main study, the VAS tended to be was more reproducible than 
the Borg CR10 scale. Similarly the VAS scale tended to be higher than the Borg CR10 in 
the VAS Borg CR10 and Likert comparison. In this CHF study, the reproducibility
199
coefficients for VAS were very constant throughout the first 10 minutes whereas the 
reproducibility coefficients for the Borg CR10 scale showed a large fluctuation in values.
8.4.4. BREATHLESSNESS/GENERAL FATIGUE.
In the CHF main study it is unknown why the reproducibility coefficients for general 
fatigue were higher than breathlessness. Reproducibility coefficients for breathlessness 
and general fatigue for the VAS were favourable and compare well with the results from 
the VAS, Borg CR10 and Likert scales comparison using normal subjects.
8.4.5. VISIT EFFECT.
Analysis showed that there was no visit effect over the four tests for the VAS and the Borg 
CR10 scales. In this CHF study the subjects were given 2 maximal incremental tests but 
only one maximal test was given in the comparison of the VAS, Borg CR10 and Likert 
scales. With only one maximal test, this "normals" study showed a significant visit effect 
in both VAS scales and for Likert (breathlessness) in the subsequent submaximal tests. 
There were no significant differences between the incremental test 1 and test 2 values for 
any subjective scale in the CHF study. Thus, experience gained in Test 1 does not appear 
to influence the perception of breathlessness and general fatigue in Test 2. Some subjects 
reported that they felt the start of the test to be somewhat daunting as they had to "jump 
on" the treadmill at the selected speed and gradient. At all times a relaxed friendly 
atmosphere was promoted and this factor may have contributed to a lessening of 
apprehension and a "non visit" effect. In addition, there was no visit effect on any 
physiological variable. The fact that there was no learning effect suggests that the use of 
the VAS offers a stable baseline from which assessment of changes in patient status may 
be assessed.
8.4.6. ANCHOR POINTS.
It is unknown if the use of the scales at the end of the two progressive maximal tests 
helped the subjects to relate the intensity of their symptoms to other situations. This 
procedure did not exclude the possibility of the subjects referring to their previous
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experience of these symptoms as they were asked to, "refer to their common experience 
of", for the appropriate symptom. The subjects considered that the use of the scales at the 
end of the two progressive maximal tests was a useful reference point for the subsequent 
submaximal tests.
8.4.7. UNDERSTANDING OF TERMINOLOGY.
Before each constant workrate test subjects confirmed that they understood the
instructions and they indicated that they could differentiate between breathlessness and 
general fatigue. Two subjects were excluded from the study as they could not grasp the 
use of the scales. For some subjects, considerable time was taken to give advice on the 
use of the lever and button on the treadmill and to clarify the problems relating to the use 
of the scales. These problems were also highlighted by Stark, (1988) when he referred to a 
patient group.
8.4.8. RANGE OF SCALES.
At the end of the maximal incremental tests, there was a wide range of values for the
perception of breathlessness and general fatigue using both scales. Somewhat surprisingly 
a score of two was given for breathlessness and general fatigue on the Borg CR10 scale. 
Similarly, on the VAS scale it was not anticipated that subjects would rate breathlessness 
and general fatigue under 30 at the end of a maximal test. Sylven et al; (1991) concluded 
that CHD patients interrupt exercise tests at lower ratings of leg exertion and 
breathlessness than healthy volunteers in an incremental protocol. The authors speculated 
that patient apprehensiveness and/or quality of symptom could be the explanation.
During the constant workrate tests the mean scores increased throughout the test but there 
was a very wide range of values at each timepoint for both scales for breathlessness and 
general fatigue. These wide ranges illustrate the individual use of the scales. For 
example, taking into account the 4 tests, at 2.5 minutes, the range for the VAS 
(breathlessness) was 5-79 and 4-81 for the VAS (general fatigue). At 2.5 minutes the 
range for the Borg CR10 scale was between 0.5 and 4 for breathlessness and 0 to 5 for
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general fatigue. At 7.5 minutes, and encompassing all 4 tests, the range of values for VAS 
breathlessness and general fatigue was 17-88 and 25-62 respectively. For the Borg CR10 
scale at 7.5 minutes, the range of values for breathlessness and general fatigue was 1-8 and 
1-7 respectively. These ranges highlight the fact that CHF patients perceive symptoms 
quite differently despite exercising at similar intensities. While the Borg CR10 scale has 
been shown to be used over a limited range in other studies (Wilson and Jones, 1989) and 
Grant et al; (1992), a number of the CHF patients in this study used the upper part of the 
scale. While this study and the studies of Wilson and Jones and Grant asked the subjects 
to exercise submaximally, the relative intensity of the CHF patients was much higher than 
that of the other two studies. As the CHF patients were working near maximum, it is not 
surprising that the verbal anchors did not impose a limitation on the CHF patients.
8.4.9. SUMMARY.
Overall the VAS tended to be more reproducible than the Borg CR10 scale for 
breathlessness and general fatigue. There was no visit effect for any of the scales. There 
was a wide range of values for the perception of breathlessness and general fatigue, using 
both scales for the submaximal and maximal tests.
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CHAPTER 8 
SECTION FIVE.
SYMPTOMATIC AND PHYSIOLOGICAL RESPONSES TO SUBMAXIMAL 
EXERCISE IN CHRONIC HEART FAILURE.
8.5. PHYSIOLOGICAL VARIABLES.
8.5.1. PEAK VALUES.
The peak VO2  values of 20.6 ml.kg"^.min"^ are similar to other studies which have 
tested CHF patients in NYHA classification 1 and 2. (Lipkin et al; 1986b) and Cohen- 
Solal et al; (1991) reported scores of 19.7 and 20.5 ml.kg.‘^.min'^ respectively. There 
was no significant increase in Peak VO2  between Test 1 and Test 2. These findings are 
not in agreement with Elbom et al; (1990) who concluded that at least two tests are needed 
to establish representative maximum baseline measures for CHF patients. Two 
incremental tests were given in an attempt to find a "representative" maximum. In 8 out 
10 subjects the first test produced the higher score. This finding indicates that the subjects 
were unlikely to produce a much longer time or a higher peak VO2  in a third incremental 
test It may be that the thorough treadmill familiarisation carried out before the maximal 
tests in this study produced this finding.
8.5.2. RANGE OF RELATIVE INTENSITIES - CONSTANT WORKRATE 
TESTS.
The mean VO2  relative intensity of 89% was the overall value calculated for all tests. The 
relative intensities for VO2  ranged from 80 to 99% of Peak VO2 . Thus, most subjects 
were working very close to their maximum as determined by the incremental test. The 
relative intensities in this study are high in comparison with the values (68% and 79%) of 
Sullivan et al; (1988) but similar to that of Kiilavouri et al; (1993) of 85%. The endurance 
times in this study are also close to that of Kiilavouri et al; (1993) but much shorter than 
that of Sullivan et al; (1988) whose subjects worked for 24 minutes at 79% peak VO^ 
The mean relative peak VO2  of 89% and the fairly wide standard deviation is worthy of
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discussion. Subject 2 had relative intensities of 99, 100, 96 and 98% of the higher Peak 
VO2  score for constant workrate tests 1,2, 3 and 4 respectively. For the same tests the 
relative heart rates were 97, 97, 98 and 99% of maximum and the relative VE was 88, 93, 
81 and 88% of peak. These values highlight the fact that subject 2 attained values in the 
constant workrate test which were very close to the peak scores. Other subjects worked 
close to their peak values obtained in the maximal incremental test or even above them. 
No clear pattern emerges when a comparison of the peak and constant workrate values is 
made. Subject 8 had heart rates in the constant workrate test at or above 100% of the peak 
values and VO2  was 91%, while the VE was on average 112% of the peak values. Subject 
1 had a mean relative VO2  of 81%, 82% for VE and 94% for heart rate.
The fact that some subjects had values on the constant workrate tests at or above 100% of 
the peak values in the incremental test suggests that some subjects did not produce a 
"maximal" effort on the incremental test. This range substantiates the hypothesis that the 
"quality" of maximum test varied. Thus, it would be expected that the submaximal 
workrate (given as a % of Peak VO2  ) would depend on the degree to which the subject 
approached his "true" maximum in the incremental test. Evidence supporting this 
hypothesis is the low maximum RER values of some subjects on the incremental test. The 
mean RER values of the two incremental tests were 1.02 and 0.97 (range 0.85-1.18 and 
0.8-1.2). These maximal values are similar to Riley et al; (1990) who reported a mean of 
0.97 in CHF patients. The mean constant workrate RER at the end of the tests was 0.97. 
It may be that some subjects felt the constant workrate test to be less threatening than the 
incremental test which had a one minute increase in workrate whereas the subject was 
aware that there would be no increase in workrate during the constant workrate test. 
Comparison of the heart rates in the two different types of tests showed that the mean 
values were very similar.
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It is probable that some subjects did not produce a "true” maximum in the incremental 
tests. This speculation is supported by the literature which suggests that it is difficult to 
attain a "true" maximum with CHF patients (Poole-Wilson, 1989a).
These findings suggest that CHF patients can sustain a workrate very close to maximum 
(as described by an incremental test) for between 8-17 minutes. However, the question 
remains - is the maximum attained in a incremental test representative of a "true" 
maximum?
8.5.3. TEST TIME FOR THE SUBMAXIMAL TEST.
One of the aims of this study was to establish a method of predicting a treadmill 
endurance time between 8-17 minutes. In out of 40 tests this aim was achieved on 34 
occasions (85%). Three tests were over 17 minutes and three tests were under 8 minutes. 
The three tests under 8 minutes were between 6 and 8 minutes and the three tests above 17 
minutes were between 18 and 22 minutes. Thus, this method appears to have application 
in a clinical setting.
The method of selecting the constant workrate for each subject is not based on any 
scientific formula. This method was developed on a trial and error basis with a number of 
patients. Prior to the CHF pilot study the attempted use of a ventilatory threshold or an 
arbritary relative intensity gave wide-ranging results. It may well be that there is no 
method based on a scientific formula which will allow an appropriate timescale to be 
selected.
The endurance time had a 76% reproducibility coefficient. This figure excludes the first 
test of subject 6 who stopped after 6 minutes but in the next 3 tests walked for between 17 
and 21 minutes. If this subject is included, the reproducibility coefficient plummets to 
51%. The GLM showed that there was no significant learning effect over the four tests.
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These stable endurance times may provide a baseline which can be of value in evaluating 
the impact of a drug intervention.
Selection of the work rate using 80% of the predicted energy cost has sound clinical 
application. Incremental tests on CHF patients are regularly carried out without gas 
collection. Therefore it is important to establish a method of prescribing a treadmill speed 
and gradient using non ventilatory parameters. Originally, selection of a work rate was 
made by selecting a work rate 2 stages below the final stage. It was found that this 
method had limitations as some subjects achieved only a few seconds into a stage while 
others nearly completed a stage. The use of the diagrammatic aid allows the attainment of 
part of a stage to be considered when work rate selection is made.
Previous studies have attempted to use sub-maximal tests in CHF to a symptom limited 
endpoint A wide range of workrate selection methods and endurance times have been 
reported. Koch and Broustet, (1993) assessed CHF patients by asking them to exercise at 
two stages below the maximum achieved in a 10 watt incremental cycle test. Mean 
endurance times were around 10 minutes but the authors reported a a very large standard 
deviation of 13. Cowley et al; (1986) used stage four of the Modified Bruce protocol to 
determine exercise tolerance in CHF patients. They reported that mean endurance times 
were 6 minutes. Sullivan et al; (1988) selected a workrate 25 watts below the maximum 
workrate achieved in a maximum test to assess the effects of a training programme in CHF 
patients. Test 1 endurance times were 16 minutes and rose to 24 minutes after training. 
The constant workrate represented 79% peak VO2  before training and 68 % peak VO2  
after training. Kiilavuori et al; (1993) used a submaximal endurance test at 85% of peak 
VC>2 to evaluate a 6 month training programme. At week 0 the mean endurance times 
were 15 minutes rising to nearly 30 minutes at 3 months and 6 months. Interestingly, peak 
VO2  values did not show any improvement throughout the training programme.
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8.5.4. EVERYDAY ACTIVITY.
Subjects were asked if the constant workrate selected related to everyday activities. All
subjects were able to cope with the selected workrate but some expressed surprise at the
initial "fast" speed. Several reported that the workrate selected resembled some occasions 
when they were "in a huny". Others indicated that they would not walk at the specified 
speed and gradient in everyday life for more than a short period of time as they realised 
that they could not sustain this pace for very long. Thus, it appears that the selected 
workrate for these CHF patients has some relevance to every day life. A common 
complaint was a dislike of the mouthpiece. As it is possible to carry out the above 
procedures without gas analysis, it would be worthwhile to evaluate the subjective scales 
without gas analysis.
8.5.5. CONCLUSIONS.
The method of selecting the workrate for the submaximal test (to elicit an endurance time 
of between 8-17 minutes is appropriate for most patients.
The intensities elicited by the test reflected some aspects of everyday life. The CHF 
patients found the test procedures to be acceptable. The use of the above exercise protocol 
with the VAS scale can offer a useful means of evaluating symptoms in CHF.
8.5.6. FURTHER RESEARCH.
As many CHF clinical tests are carried out without gas collection, it is suggested that this 
study is replicated without gas collection.
The test protocol should be evaluated using larger numbers.
An examination of the sensitivity to change in CHF patients would be of value. A method 
has yet to be established to improve the status of the patients to assess the sensitivity of 
subjective scales and endurance time to any intervention. As many variables are involved, 
the selection of an "appropriate" intervention is likely to prove to be a problem.
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CHAPTER 8 
SECTION SIX.
SYMPTOMATIC AND PHYSIOLOGICAL RESPONSES TO SUBMAXIMAL 
EXERCISE IN CHRONIC HEART FAILURE.
8.6. THE RELATIONSHIP OF SYMPTOMS AND PHYSIOLOGICAL
VARIABLES.
8.6.1. BREATHLESSNESS AND GENERAL FATIGUE.
Both scales showed a good relationship with heart rate where correlations were around 
0.84 with the VAS (breathlessness and general fatigue) and 0.80 for the Borg CR10 
(breathlessness and general fatigue). It has been shown that abrupt increases in right 
ventricular strain resulted in immediate and proportional increases in VE (Jones et al; 
1982). Wasserman and Cassaburi, (1988) have suggested that it would be expected that 
CHF patients would have right ventricular pressure elevation which would provide an 
increased stimulus to breathe and a feeling of breathlessness. The immediate increase in 
VE following the artificially induced, abrupt increase in blood flow through the heart, is 
suggestive of a linkage between the cardiovascular and respiratory systems (Jones et al; 
1982). These findings could be a possible explanation for the high correlations between 
heart rate and the VAS and Borg CR10 (breathlessness) scales.
For VO2  , there was a good correlation (around 0.79) with VAS (breathlessness and 
general fatigue) whereas for the Borg CR10 scale the correlations were around 0.67. 
These findings are not in full agreement with the Grant et al; (1992) study in normals 
which found that VE, V(>2 , VCO2  and heart rate had correlations over 0.9 with the same 
subjective scales. In the "normals" study, there was a small increase in work rate 2 
minutes into the exercise bout. This feature of the protocol may have had the effect of 
"pulling out" the relationship between the physiological variables and the subjective scales 
resulting in higher correlations for the Grant et al; (1992) study.
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Several factors may explain the poor relationship between the respiratory variables and the 
subjective scales in this study with CHF patients. There are probably multifactorial causes 
of breathlessness and general fatigue in CHF. Thus, it may be simplistic to attempt to 
establish links between subjective scales and physiological variables which respond to a 
variety of inputs.
8.6.2. BREATHLESSNESS AND RESPIRATORY VARIABLES.
The cause of breathlessness in CHF is unknown. It has been postulated that the causes of 
breathlessness in CHF include; a ventilation/perfusion mismatch (Buller and Poole- 
Wilson, 1989); weakness in the inspiratory and expiratory muscles, reduced blood flow to 
the respiratory muscles (McParland et al; 1992, Hammond et al; 1990) and respiratory 
muscle deoxygenation (Mancini et al; 1991). McParland et al; (1992) found a good 
correlation between inspiratory muscle weakness and breathlessness experienced during 
daily activities (r = 0.89). They suggested that weakness in inspiratory muscles 
necessitates a greater inspiratory motor output to produce a given increase in dynamic 
inspiratory muscle pressure and VE. The magnitude of breathlessness experienced is at 
least partly determined by the perception of the outgoing central motor command to the 
muscles involved in inspiration (Cockcroft and Guz, 1987).
While CHF patients require a disproportionately large increase in VE during exercise, one 
recent study indicated that breathlessness is not merely a sensing of VE. Davies et al; 
(1993) examined the relationship between VE and VAS (breathlessness) during a constant 
workrate test at 70% peak VO2  in CHF patients. They concluded that the temporal 
dissociation between the VAS scores and VE indicated that breathlessness in CHF is not 
simply an awareness of total ventilation. Thus, it may not be surprising that there was a 
poor relationship between the respiratory variables and the subjective scales 
(breathlessness). In this study subjective scale scores increased over nearly all of the 
timepoints but VE, frequency of breathing, VO2  and heart rate increased over the first 
three timepoints. Thus, the comparison of a stable VE with a rise in the subjective scales
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as in the Davies et al; (1993) study was not possible in the present study. Therefore, it is 
difficult to make a meaningful conclusion about any interaction between the subjective 
scales and physiological variables.
The conclusions of Clark et al; (1993) cast doubt on the value of the VE/VCO2  ratio as a 
meaningful measure of impairment and a marker of physiological dead space. They 
showed that the VE/VCO2  ratio was a function of the exercise protocol and it was not 
possible to compare values between studies utilising different exercise protocols. Clark et 
al; (1993) showed that the increase in VE/VCO2  ratio was faster with a one minute 
incremental protocol compared with a three minute incremental protocol. Therefore, the 
VE/VCO2  ratio of around 38 in this study may not provide a meaningful comparative 
figure to the range suggested by Fink et al; (1986) and may not be of value in assessing the 
extent of "excess" ventilation due to an increased physiological dead space.
8.6.3. BREATHLESSNESS, GENERAL FATIGUE AND PERIPHERAL
ABNORMALITIES.
Recent evidence confirms that there are a range of peripheral abnormalities in CHF which 
may contribute to breathlessness and general fatigue. Abnormalities in peripheral 
circulation (Magnuson et al; 1993), skeletal muscle structure Volterrani et al (1993), 
skeletal muscle function (Derman et al; (1993) have been shown to contribute to a 
decreased work capacity and probably promote a feeling of general fatigue. Wilson et a l ; 
(1984) demonstrated that CHF patients developed fatigue when muscle underperfusion 
reached a critical level. The decrease in oxidative capacity and increase in anaerobic 
metabolism may contribute to an increase in VE via bicarbonate buffering of lactate and 
stimulation of the peripheral chemoreceptors. In addition, the high levels of arterial K+ in 
CHF during submaximal exercise may contribute to an increased VE and could play a role 
in fatigue (Barlow et al, 1994). The wide range of abnormalities found within a 
"homogeneous" group may result in a variety of factors involved in the promotion of 
breathlessness and general fatigue with little degree of commonality among the subjects.
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The individual use of the scales may be another factor. Some subjects scored low on the 
subjective scales compared to others despite exercising at similar relative intensities.
The reason why the patients stopped exercising in the submaximal tests is unclear. The 
patients stated that they stopped exercising because of breathlessness, general fatigue or 
leg fatigue. Most subjects stopped around the maximum heart rate attained in the 
incremental test.
8.6.4. SUMMARY.
The highest correlations (around 0.8) were for heart rate on all four scales. It was not 
possible to relate symptoms to any respiratory markers in any meaningful way using a 
constant workrate protocol in CHF patients. Correlations were low (except for VO2 ) for 
the respiratory variables and the subjective scales (breathlessness and general fatigue). 
These results indicate that there is no direct relationship between respiratory variables and 
the subjective scales.
It is hypothesised that the use of an incremental protocol may result in a high correlation 
between respiratory variables and subjective scales but whether this would be a causal 
relationship remains debatable. The fact that sensory input may vary depending on the 
severity of impairment, may also create further difficulties in establishing a meaningful 
relationship between the perception of symptoms and physiological variables. The 
individualistic way of using the subjective scales may also lead to difficulties in 
establishing a link between the physiological variables and the scales.
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CHAPTER 8 
SECTION SEVEN.
AN EVALUATION OF THE STEXT PROTOCOL.
8.7.1. SUBJECTIVE SCALES.
8.7.2. MEASUREMENT OF BREATHLESSNESS - REPRODUCIBILITY.
Reproducibility for the VAS and Borg CR10 scales was low at minute 3 (48% and 23% 
respectively) but by minute 7 had increased to 77% on both scales. Thereafter, 
reproducibility was consistently high to maximum. The reproducibility coefficients in the 
mid 70's for the Borg CR10 and low 80'S for the VAS compare favourably with the 78% 
for the VAS and 50% for the Borg CR10 scale at minute 8 in the comparison of the VAS 
and Borg CR10 scales during steady state exercise (Grant et al; 1992). However, in this 
previous study there was a trend for the VAS to be better than the Borg CR10, and at one 
timepoint the VAS was significantly more reproducible than the Borg CR10 scale. In the 
STEXT study the reproducibility coefficients were very similar for both scales and the 
95% confidence intervals showed a wide overlap. It is difficult to explain why the 
absolute reproducibility coefficient values (after the first two timepoints) for the Borg 
CR10 scale were much higher in the STEXT study compared with the "steady state " 
values (Grant et al; 1992). The subjects in both studies were similar, and the only obvious 
differences are the number of tests and the markedly different exercise protocols.
8.7.3. MEASUREMENT OF BREATHLESSNESS - SENSITIVITY.
While sensitivity coefficients were significant between 9 and 15 minutes, the ratios were 
low compared with the VAS Borg CR10 comparison during steady state exercise (Grant et 
al; 1992). In the "steady state" study sensitivity was 2.7 for the VAS and 2.0 for the Borg 
CR10. The highest ratios in the STEXT study were 1.25 for the VAS and 1.1 for the Borg 
CR10. There were no significant differences between the scales for sensitivity unlike the 
previous comparison in normals (Grant et al; (1992) where the VAS was significantly 
better than the Borg CR10 scale at two out of the three timepoints.
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8.7.4. MEASUREMENT OF GENERAL FATIGUE - REPRODUCIBILITY.
Both scales showed a very similar picture throughout all timepoints. The reproducibility 
coefficients were high for both scales from 11 minutes onwards. There were no significant 
differences between the scales which is the same finding reported by Grant et al; (1992) 
who reported that the VAS scores tended to be higher.
8.7.5. MEASUREMENT OF GENERAL FATIGUE - SENSITIVITY.
There was a significant sensitivity effect from minutes 9 to 15 on both scales. There were 
no significant differences between the scales. This finding contrasts with the Grant et al; 
(1992) study which showed that the Borg CR10 scale was significantly more sensitive 
than the VAS at 6 minutes but at 8 minutes there was no significant difference despite a 
trend in that direction. The sensitivity ratios were lower in the STEXT study (1.6 for VAS 
and 1.7 for Borg CR10) compared with the "steady state" study of Grant et al; (1992) 
which produced ratios of 2.4 and 3.0 for VAS and Borg CR10 scales respectively.
8.7.6. VAS and BORG CR10 SCALES.
Both scales for all but the first two timepoints showed good reproducibility. There were no 
differences between the scales for reproducibility or sensitivity. These results indicate that 
there was no meaningful difference between the scales using the STEXT protocol in 
normals. The STEXT protocol starts at a very low energy cost with small energy cost 
increments in the first few stages. It may be that this protocol enables subjects to estimate 
breathlessness and general fatigue in a reproducible manner after the first few minutes as 
the gradual progression in work rate enables subjects to estimate breathlessness and 
general fatigue throughout "a full range".
For the first three timepoints in all scales apart from the first timepoint in the VAS 
breathlessness scale there was no significant active treatment effect This finding is not 
surprising as the subjects were exercising at very low relative intensities in the early 
stages.
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8.7.7. RANGE OF SCALES.
As might be expected with a test which begins at an energy cost of 8.0 ml.kg'^.min'^to 
a maximum of around 56.5ml.kg"^.min'^ (for most subjects) the subjective scales were 
used in most instances over a full range. In the submaximal test of Grant et al; (1992) it 
was anticipated that the upper part of the scales would not be used, especially the Borg 
CR10 scale which has verbal restrictors. In the STEXT study, subject 10 consistently 
scored low for all four scales. Despite low symptomatic scores he maintained that he had 
given maximum effort. Subject 8 scored very high on all scales even at low levels of 
exercise. These examples demonstrate how subjective scales are used in an individualistic 
manner and highlight the fact that it is not possible to make meaningful inter-subject 
comparisons.
8.7.8. VISIT EFFECT.
All four scales showed a visit effect i.e. over time the scores for all the scales increased. 
For all scales test 1 was significantly lower than tests 4-8. There were no significant 
differences among tests 2-8. This finding demonstrates that during the "run-in" period 
(i.e. tests 1-2) the subjects reassessed their perception of symptoms over time. The "run- 
in" period was effective in promoting stability in the subjective scale scores. Interestingly, 
the direction of the visit effect was opposite to that of the Grant et al; (1992) study. In the 
STEXT study the scores increased over time whereas scores decreased in the previous 
study. The therapy effect was much larger than the visit effect for all the scales except the 
VAS breathlessness which showed a very large increase in scores between test 1 and test 
5.
The subjects in this study were regular exercisers and consisted almost totally of 
university students and staff. Thus, it must be stressed that these results may not be 
generalisable to other populations. However, the subjects reported that they found the 
instructions to be clear and could carry out the operation of recording scores easily.
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8.7.9. SUMMARY.
Reproducibility was high for the VAS and Borg CR10 for breathlessness and general 
fatigue. Both scales were sensitive to change through a range of timepoints for 
breathlessness and general fatigue. It is concluded that there were no meaningful 
differences between the VAS and Borg CR10 scales for reproducibility and sensitivity in a 
group of physically active males using the STEXT protocol. The "run-in" period was 
effective in providing stable values for the intervention part of the study.
8.7.10. FUTURE RESEARCH.
The STEXT protocol may be of value in the evaluation of symptoms in CHD patients. 
The use of an incremental protocol which encompasses a wide range of work rate energy 
costs in a reasonably short timescale can be administered to a group of wide ranging 
fitness and obviates the necessity of determining an individual steady state or using a 
specific protocol to accommodate the capabilities for each subject.
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CHAPTER 8 
SECTION EIGHT.
AN EVALUATION OF THE STEXT PROTOCOL.
8.8. PHYSIOLOGICAL VARIABLES.
8.8.1. VO2  max.
A VO2  max mean score of 56.5 ml.kg'^-.min'^  is typical of physically active young to 
middle aged male subjects. VO2  max was reduced by propranolol from 56.5 ml.kg"1.min'1 
to 45.8 ml.kg'lmin‘1 at the third timepoint (tests 5 & 6) and from 57.6 ml.kg r^min 
to 46.3 ml.kg"l.min"l at the fourth timepoint (tests 7 & 8). These findings are 
consistent with a number of studies which have demonstrated a range of reduced VO 2  
max scores using either trained or normal subjects. These decreases of 19% and 20% 
respectively are greater than those studies which have used subjects with a VO2  max of 
around 50-63 m l.kg'l. min"* . Pooled data from these studies (Tesch and Kaiser (1981), 
Mac Farlane et al; 1983) Hughson et al; (1984) and Joyner et al (1986) show that VO2  
max was decreased on average by 10.3%. In trained subjects with VO2  max values of 65 
ml.kg"-kmin"l Anderson et al; (1985) showed a decrease of 13% in VO 2  max with 
the same level of propranolol as this study. In his review Tesch (1985) stated that VO2  
max is typically decreased by 10 to 15% when heart rate is lowered by at least 30%. In 
their review Allen et al; (1984) reported that acute beta blockade on VO2  max ranged 
from a decrease of 11 to 21% and that they found that the magnitude of decrease in heart 
rate and VO2  max was dose related i.e. increasing doses had a greater effect but they 
found a marked variation in drug susceptibility among subjects. Somewhat surprisingly 
Wilmore et al; (1985) reported no fall in VO2  max after beta blockade despite a decrease 
of 47 beats, min"-^  in maximum heart rate.
Other studies using untrained or low fitness groups have shown no change in VO2  max 
after beta blockade (Violante et al; 1984, Reybrouck et al; 1977, Sklar et al; 1982) which
216
suggests that there has been complete central and/or peripheral compensation for the 
decrease in maximal heart rate. The decrease in VO2  max after beta blockade in this 
study indicates that the subjects cannot fully compensate for the decreased maximal heart 
rate in order to maintain maximal cardiac output, maximal blood flow and consequently 
VC>2 max. It has been suggested that the increased loss of potassium from the muscles 
with beta blockade may affect membrane excitability, reduce muscle contractility and 
result in increased fatigue (Sjogaard et al; 1985).
The decrease in VO2  max is linearly related to the magnitude of reduction in maximum 
heart rate. However, it has been suggested that non-selective beta blockade will reduce 
VC>2 max to a greater extent. The maximum heart rate in this study was lowered on 
propranolol by 34.2% and 31.6% at timepoint 3 and timepoint 4 respectively. It is 
hypothesised that the greater decrease in maximum heart rate found in this study is partly 
the explanation for the greater magnitude of decrease in VO2  max found in this study 
compared with Tesch and Kaiser, 1981, Mac Farlane et al; 1983, Hughson et al; 1984) and 
Joyner et al; (1986). Tesch, (1985) stated that the increased A-VO2  difference can 
partially compensate for a decreased cardiac output during modest beta blockade but in 
this study it appears that it cannot compensate for a fall in maximum heart rate of 30%.
8.8.2. VE/VCO2  max.
VCO2  max was reduced with propranolol compared with placebo in this study, and the 
study of MacFarlane et al; (1983) who found that the decrease in VCO2  was in direct 
proportion to the fall in VO2 . The decreased VE max values with propranolol were 
probably a reflection of reduced stimuli i.e. a reduced work intensity and VCO2 . Joyner 
et al; (1987) suggested that the decreased VCO2  max indicates a fall in maximum CO2  
flow to the lung so that any chemically mediated drive to breathe should be lower at 
maximum during beta blockade. A decrease in maximum work rate could also lower the 
contribution of the "central command" to exercise hypemea under beta blockade (Joyner 
et al; (1987). A lowered VE max could also be as a result of inhibition of the beta 2
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mediated dilation of the bronchioles. However, in subjects with a healthy bronchial 
system, blockade of beta 2 adrenoieceptors does not impair VE during exercise probably 
because bronchodilation during exercise results mainly from the withdrawal of resting 
vagal tone (Warren et al; 1984).
8.8.3. FREQUENCY OF BREATHING.
There was a decrease in the frequency of breathing at VO2  max under beta blockade. 
This finding contrasts with Joyner et al; (1987) who found no difference in the frequency 
of breathing. They speculated that the same level of frequency of breathing with and
without beta blockade suggested a "compensatory increase".
8.8.4. RELIABILITY AND SENSITIVITY OF V 02 max.
In the "non beta blocker" tests there were no significant differences in the six tests and the 
reproducibility coefficient was high. These findings indicate that the V 02 max tests were 
reproducible. Davies et al; (1970) investigated the effects of repeated continuous exercise 
to maximum. Eight maximum tests were given at 2 day intervals. There was a significant 
increase in V 02 max in tests 3 and 4 compared with the other tests. There was no change 
in VE max or maximum heart rate. Taylor et al; (1955) reported a correlation coefficient 
of 0.95 between 28 duplicate V 02 max tests.
8.8.5. TREADMILL TIME.
Treadmill time decreased at timepoint 3 from 16.73 minutes to 15.1 minutes (9.7%) and at 
timepoint 4 from 16.81 minutes to 15.31 minutes (9.0%). It is not possible to compare the 
magnitude of change in treadmill time with other studies because different exercise 
protocols have been used. However, using beta blockade, exercise time has been 
significantly reduced in a number of studies (Tesch and Kaiser, 1983).
8.8.6. CONCLUSION.
V 02 max was found to be highly reproducible in the "non beta blocker" tests. Beta 
blockade resulted in a decrease in maximum values for V 02, VC02, VE, heart rate, tidal 
volume and a reduction in endurance time.
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8.8.7. SUBMAXIMAL PHYSIOLOGICAL VARIABLES OF THE STEXT
PROTOCOL.
It is the first time that the STEXT protocol has been used to evaluate the effect of beta 
blockers on normal subjects. Twentyman et al; (1981) caution that it may be inappropriate 
to compare studies when the type of exercise, work rate and measurement times differ.
8.8.9. EFFECT OF PROPRANOLOL.
8.8.10. HEART RATE.
A clear reduction in heart rate was found throughout the complete range of submaximal 
heart rates with propranolol compared with the other "treatments". This finding has been 
reported in other studies of similar design (Petersen et al; 1983, Pearson et al; 1987). The 
increase in heart rate normally associated with exercise is blunted by beta blockade as is 
the normal augmentation of myocardial activity. Most studies have shown that cardiac 
output is decreased by about 10% during submaximal exercise with an increase in stroke 
volume. The decrease in cardiac output of around 5-15% during beta blockade is 
counteracted by an increase in oxygen extraction from the blood (Van Baack, 1988). A 
wider discussion of the effects of propranolol on haemodynamics during submaximal 
exercise is given in Section 8.2.2.
8.8.11. VE.
The decrease in VE with beta blockade at one timepoint fairly early in exercise is in 
agreement with Violante et al; (1984) and Pearson et al; (1987) but some studies have 
reported no effect of beta blockade on VE early in exercise (Pearson et al; 1979, Leitch et 
al; 1980). It has been shown that beta blocking drugs have a direct effect on the chemical 
drive to breathing. It is suggested that propranolol can cause a small decrease in the VE 
response to CO2  (Patrick et al; 1978). Propranolol has a small but consistent effect in 
depressing the ventilatory response to CO2  inhalation. A central action depressing either 
the medullary chemoreceptors or respiratory centres are the likely explanation for the 
effects of propranolol on CO2  response. It is possible that beta blockers depress some
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other source of respiratory drive during exercise after beta blockade. Twentyman et al;
(1981) postulated that the reduction in VE which they found in the early part of exercise 
was a result of delayed cardiovascular responses following beta blocker drugs. The low 
energy cost starting level of the STEXT protocol and small energy cost increments early 
in the protocol may explain why propranolol had little impact on VE in the early stages of 
exercise. While rates of cardiovascular adjustment could be an important influence on 
VE, it should be noted that VO2  was depressed over the whole protocol with VE only 
decreased at minute 8.
On beta blockade Twentyman et al; (1981) and Pearson et al; (1987) reported an increase 
in VE at the highest levels of exercise as in this study where VE was significantly higher 
at minute 14 and 15 compared with the other "treatments". The increase in VE at minutes 
14 and 15 could be as a result of greater anaerobiosis and metabolic acidosis and/or an 
increased tendency to pulmonary venous congestion with beta blocker drugs (Younes and 
Burke, 1985). It is to be anticipated that the greater magnitude of work rate increments in 
the later stages of the STEXT protocol would result in an increase in anaerobic 
metabolism.
8.8.12. V 02 and RER.
V 02 was significantly lower throughout the exercise protocol on propranolol compared 
with the other treatments. From minutes 10 to 15 the RER was significantly increased on 
propranolol compared with the other "treatments". Pearson et al; (1979) reported that 80 
mg of propranolol decreased VO2  by 3.5% over the whole range of their incremental test. 
Twentyman et al; (1981) reported a small but intermittent reduction in VO2  after beta 
blockade during an incremental test while Petersen et al; (1983) found no significant 
change in VC>2 after beta blockade during incremental exercise. The above examples 
confirm the statement of Tesch (1985) that the studies of VO2  during submaximal 
exercise with beta blockade have produced inconsistent results. Pearson et al; (1979) 
hypothesised that the decrease in VO2  was a consequence of a decreased blood flow as a
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result of a decreased cardiac output leading to a greater energy production from anaerobic 
metabolism. It may be however, that changes in cardiac output may not be directly related 
to proportional changes in skeletal muscle blood flow as compensatory changes in 
regional circulation may also have a role to play. Twentyman et al; (1981) postulated that 
propranolol may have a direct effect on peripheral circulation because it potentiates the 
normal increase in circulating catecholamines during exercise and blocks beta receptors 
involved in vasodilation.
The increased RER from 10-15 minutes in this study is suggestive of an increase in
glycolysis and decreased lypolysis. Assuming a greater reliance and usage of glycolytic
precursors as fuel a small decrease in VO2  would be expected as carbohydrate utilisation 
gives approximately 10% higher energy yield per litre of O2  compared with fat.
8.8.13. VC02
With propranolol, VCO2  was increased at minutes 8 and 15. The increase in VCO2  at 
minute 15 is probably as a consequence of greater anaerobic metabolism, buffering of 
lactic acid and subsequently greater CC>2 production. The increase in VCO2  at minute 8 
was unexpected and cannot be easily explained.
8.8.14. FREQUENCY OF BREATHING/TIDAL VOLUME.
Frequency of breathing and tidal volume increased significantly at minutes 14 and 15 on 
beta blockade compared with the other "treatments". These increases were in tandem with 
a greater VE. Pearson et al; (1987) and McLoed et al; (1985) reported that atenolol 
produced larger tidal volumes but no change in tidal volume after propranolol. It is 
unlikely that propranolol will influence airway resistance in healthy subjects (Warren et 
al; 1984). Joyner et al; (1987) showed a small decrease in tidal volume resulting in a 
compensatory increase in frequency of breathing after propranolol. They suggested that 
the contribution of airway beta receptors (particularly type 2) which promote airway 
dilation is decreased during beta blockade.
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8.8.15. VE/V02
The VE/V02 ratio was significantly higher from minutes 10 to 15 on propranolol 
compared with the other "treatments". Petersen et al; (1983) also reported an increase in 
VE/VC>2 on beta blockade on an incremental protocol compared with placebo.
8.8.16. VE/VC02
The VE/VC02 ratio was unaffected on beta blockade up to minute 11. From minutes 12- 
15 there was an increase with no change at minute 16 or maximum. Petersen et al; (1983) 
showed that the VE7VC02 relationship was unaffected by propranolol. They reported that 
the stability of the end tidal C 02 suggests that the fall in tidal volume did not have 
sufficient impact on the dead space/tidal volume ratio to cause a significant reduction in 
alveolar ventilation and change C 02 tension.
8.8.17. VISIT EFFECT.
There were no significant visit effects for any of the physiological variables. These 
findings indicate that the "run-in" period would appear to be unnecessary to attain stable 
values in the physiological variables before any intervention. The therapy effect was 
significant for all variables.
8.8.18. SUMMARY.
V 02 and heart rate were significantly lower at all timepoints on beta blockade compared 
with other treatments. On beta blockade several physiological variables (VE, frequency 
of breathing and tidal volume) showed increases at minutes 14 and 15. There were also 
increases in VC02 , tidal volume, RER, VE/V02 , and VE/VC02 at some 
timepoints.
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CHAPTER 8 
SECTION NINE.
AN EVALUATION OF THE STEXT PROTOCOL.
8.9. RELATIONSHIP BETWEEN THE PERCEPTION OF SYMPTOMS
AND PHYSIOLOGICAL VARIABLES.
8.9.1. BREATHLESSNESS.
The overall group correlations for VE and VCO2  were all over 0.8 for both the VAS and 
Borg CR10 scales. Apart from VE/VO2  and VE/VCO2  all other correlations were over 
0.7. The range of the pooled individual correlations was wide with minimum and 
maximum correlation values between -0.76 to 0.99. The individual visit correlation range 
was -0.87 to 1.0 There were no meaningful differences between the scales and any 
physiological variable. Other studies have reported high correlations between subjective 
scales and VE using incremental protocols. Wilson and Jones, (1991a) reported median 
correlations between VE and Borg CR10 scale (breathlessness) of 0.85 (range 0.7 to 0.95). 
In 1989, the same authors found mean correlations for VE/VAS (breathlessness) of 0.68 
and 0.75 for VE/Borg CR10 scales. Muza et al; (1990) reported a correlation of 0.85 
between VE and VAS (breathlessness).
8.9.2. GENERL FATIGUE.
As for breathlessness, both scales for general fatigue showed high overall group 
correlations of over 0.8 for VE and VCO2 . The range of pooled individual correlations 
was wide, ranging from -0.76 to 0.99 and the individual subject visit correlations from - 
0.88 to 1.0.
In other studies, correlations between VE and RPE have shown a wide range (0.54-0.92) 
(Carton and Rhodes, 1985). Edwards et al., (1972) reported high correlations between 
RPE and several physiological variables in both continuous and intermittent exercise.
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Correlations between RPE and VO2 , heart rate and VE were around 0.9 but the correlation 
between RPE and frequency of breathing was only 0.67.
The authors suggested it may be possible to predict physiological variables in field 
experiments on previously "calibrated" subjects.
8.9.3. BREATHLESSNESS AND GENERAL FATIGUE.
Overall group correlations for the subjective scales and the physiological variables were 
not so high on the STEXT protocol compared with the "steady state" study. These lower 
correlations may be explained by the different exercise protocols. It may have been 
expected that the progressive nature of the increase in energy cost would result in a high 
correlation between the subjective scales and the physiological variables. It was 
anticipated that subjects would score 0 for breathlessness and general fatigue at 7.5 
ml.kg"l.min"l (the energy cost of minute one on the STEXT protocol) with a mean 
aerobic power of 57 ml.kg'^.minr^In almost all subjects, there was no movement in the 
subjective scales over the first few stages but there was a small increase in most of the 
physiological variables. During the first few minutes, there was a decrease in VE/VO2  
and VWVCO2 . Thus, the above factors would be expected to adversely influence the 
correlations. Correlations were calculated using the subjective scales and physiological 
variables from 9 minutes onwards. This procedure resulted in a small increase in almost 
all correlations.
It may have been expected that correlations would have been higher in the STEXT 
protocol compared with the "steady state" study. In the "steady state" study, there was a 
sharp increase in the subjective scales and physiological variables between timepoint 1 
and timepoint 2. From timepoint 2 to timepoint 3 there was a significant increase in the 
subjective scales but there was no significant increase in almost all the physiological 
variables. However, the upward trend throughout the "steady state" protocol in the
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subjective scales and the physiological variables may be one possible explanation for the 
very high correlations in the "steady state" study.
It may be unrealistic to expect a good relationship between subjective scale responses and 
physiological variables. Subjects have varying sensitivities to sensory inputs provoking 
the sensations of breathlessness and general fatigue. The manner in which the subjects 
interpret and use the scales is likely to vary and responses could be influenced by the 
experimenter.
The findings of other studies in this area have already been reported in Section 8.3. 
SUMMARY.
These results showed good overall group correlations between VE, VO2 , VCO2  frequency 
of breathing, heart rate, tidal volume, RER and VAS/Borg CR10 scales (breathlessness 
and general fatigue). There were no meaningful or systematic differences between the 
scales.
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CONCLUSIONS.
The above studies have shown a slight tendency for the VAS to be more reproducible than 
the Borg CR10 scale for breathlessness and general fatigue. For sensitivity, there was no 
meaningful difference between these scales. The degree of reproducibility has varied 
among the studies. This finding may be due to the use of different subjects and number of 
subjects. The higher sensitivity ratios in the "steady state" study compared with the 
STEXT protocol may be a result of less impact of propranolol with the STEXT protocol as 
the subjects worked for a shorter period of time at high intensities during the STEXT 
protocol.
The results from the "steady state," CHF and STEXT studies indicate that subjective 
scales can be used in a meaningful way to assess the symptoms of breathlessness and 
general fatigue. All three studies have shown that subjective scales can reproducibly 
measure the symptoms of breathlessness and general fatigue. In two of the studies, 
subjective scales have been able to detect the effect of drug intervention. It must be 
conceded that assessment of the sensitivity of the scales was carried out in the "wrong 
direction" i.e. the subjects were made to feel worse. However, it has been shown that 
physiological changes after beta blockade have been reflected in differences in the 
perception of symptoms.
In the "steady state" study there was a very good correlation between some physiological 
variables and the subjective scales whereas in the CHF study correlations were generally 
low. In the STEXT study a good relationship between some physiological variables and 
the subjective scales was found. It has already been stressed that the relationship between 
the subjective scales and physiological variables may not be causal.
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The impact of beta blockade on physiological variables in the "steady state" and STEXT 
studies was similar to that reported in other studies. Maximal physiological values have 
been shown to be reproducible using the STEXT protocol. These findings indicate that the 
STEXT protocol can be used to assess aerobic fitness reproducibly. Subjective scales 
have also been shown to be reproducible and sensitive to change using the STEXT 
protocol. These results demonstrate that the STEXT protocol can be of value in assessing 
physiological values and symptoms using subjective scales.
It has been shown that subjective scales can be incorporated in to a submaximal test to 
evaluate symptoms with CHF patients. Both the subjective scales and endurance time are 
reproducible. The establishment of a clinically acceptable length of endurance treadmill 
times and the selection of an appropriate work intensity indicates that this method has 
potential for the evaluation of symptoms in a situation which resembles everyday life.
FUTURE RESEARCH.
It would be of value to use the CHF submaximal test to evaluate an intervention with CHF 
patients. Thus, the sensitivity of the subjective scales could be assessed and the effect on 
endurance time measured.
It seems logical to apply the STEXT protocol format used in this study to a group of 
angina patients to evaluate a drug intervention. Using a population of wide ranging 
fitness levels, it may be possible to predict VO2  max from endurance time attained on the 
STEXT protocol.
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APPENDIX A.
CHF PILOT STUDY.
A COMPARISON OF THE REPRODUCIBILITY OF VISUAL ANALOGUE AND 
BORG CR 10 SCALES IN CHRONIC HEART FAILURE.
A.1.1. OBJECTIVES OF PILOT STUDY.
A pilot study was undertaken to:
1) determine the reproducibility of VAS and Borg CR10 scales in CHF 
patients.
2) determine a method of establishing appropriate submaximal 
intensities during the exercise test
3) determine the suitability of test instructions and the subject's 
responses to the test
4) evaluate the practicality of the test procedures.
A.2.1. METHODS.
A.2.2. SUBJECTS.
Six subjects participated in the study. Subjects were male between the ages of 53-75 
years. All subjects had chronic heart failure (NYHA 1 and 2) and all were taking some 
form of diuretic. Subjects gave informed consent to this study which had been approved 
by the West Ethical Committee.
A.2.3. RESEARCH DESIGN.
A.2.4. PRELIMINARY EXERCISE PROTOCOLS.
Subjects reported to the laboratory at the same time of day and with the same timing of 
medication on each occasion. Subjects underwent two maximal incremental treadmill 
tests (see Appendix C) at least four days apart. Before the maximal test the subjects were 
familiarised with the treadmill and the use of the subjective scales (see below). At the end 
of the test the subjects were asked to quantify their perception of breathlessness and 
general fatigue.
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A.2.5. SUBMAXIMAL TESTS.
On the third visit, subjects were given a submaximal test which incorporated workrate 
stages of 60% upwards of the previously determined peak VO2  (higher score of the two 
tests). Estimation of the relative workrates was made using the American College of 
Sports Medicine energy cost tables (ACSM, 1986). Each stage lasted 6 minutes. No 
scales were given during this test but the subjects exercised through a range of relative 
intensities and this procedure provided the following information:
The progressive stages gave some indication of what the patient was capable of and 
enabled workrates to be selected so that the patient could hopefully complete three stages 
in the subsequent tests.
At week one, week two, week four and week six after the second maximal test the subjects 
performed a submaximal exercise test. This test incorporated a range of relative 
intensities (workrate selection was based on the subject’s performance of the preliminary 
submaximal test) and each stage lasted six minutes. Subjects were asked to continue for 
as long as possible. Most subjects performed three stages on each occasion. Patients 
responded to the subjective scales at 2 minutes 30 seconds and 5 minutes 15 seconds for 
each stage.
A.2.6. EQUIPMENT - TREADMILL, ECG AND GAS ANALYSIS.
Expired air was collected using a Hans Rudolph 2700 valve with a mouthpiece which was 
attached by tubing to the metabolic cart. All subjects wore a noseclip. Respiratory 
variables were determined during exercise by an automated gas analysis system (Beckman 
metabolic measurement cart; classic exercise model system 2). Before each test the 
oxygen and carbon dioxide sensors were calibrated with a standard gas mixture containing 
16% oxygen 4% carbon dioxide and 80% nitrogen. Volume was checked using standard 
procedures. Heart rate was taken from the electrocardiogram during the last 10 seconds of 
each minute. A marquette MAC2 and ECG console were used for the treadmill test.
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A.2.7. EQUIPMENT - SUBJECTIVE SCALES.
Each scale was administered by a computer (BBC Master) and displayed on a colour 
television screen in front of the subject while he exercised on the treadmill. The subject 
recorded his response by means of finger controls (see below) and the information was 
stored in the computer. An audible prompt was given each time a new scale appeared on 
the screen. On each occasion the subjects had to move the lever before the cursor 
appeared on the screen, i.e. before any score was displayed (thus the previous score was 
not visible when the new scale was presented). The subjects were introduced to the 
subjective scales between the treadmill familiarisation and the first maximal test. Firstly, 
the subjects were shown how to operate the scales and they were allowed to practise until 
they could carry out the procedures with no difficulty. Thereafter, instructions were read 
to the subjects. The following instructions were also read to the subjects before each 
submaximal test Details of the equipment used are given in Appendix B.
A.2.8. SUBJECTIVE SCALES - INSTRUCTIONS TO SUBJECTS.
A.2.8.(a) BREATHLESSNESS.
Breathlessness was described as "breathless, out of breath, air hunger, unable to breathe 
enough".
Subjects were told,
"Based on these descriptions, quantify your sensation of breathlessness by referring to 
your common experience of an uncomfortable awareness of breathing". Avoid simply
observing that your level of breathing has increased - think of "an uncomfortable need to
breathe". "Disregard other sensations like leg fatigue or general fatigue".
A.2.8.(b) GENERAL FATIGUE.
General fatigue was described as "overall tiredness", overall fatigue". "Based on these 
descriptions and by referring to your common experience of general fatigue you are asked 
to quantify your sensation of general fatigue. Disregard other sensations like leg fatigue 
and breathlessness."
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The subjects again practised with the scales and were asked to think about the range of the 
scales and their past experience in relation to breathlessness and general fatigue.
The subjects were asked if they understood the instructions. It was suggested to the 
subjects that zero on the scales may relate to their feelings at rest and at the upper end of 
the scales, subjects were asked to think of previous experiences which may relate to the 
upper ranges of the scales. It was also suggested to them that their perception of 
sensations at the end of the maximum tests may help them with their judgement of the 
range of the scales. Any questions from the subjects were answered. Subjects were 
randomly assigned to a VAS/Borg CR10 or a Borg CR10/VAS sequence of presentation.
During the test the subjects were asked to respond to the scales when they appeared on the 
TV monitor.
A.2.8.(c) DESCRIPTION OF SCALES.
The scales had a heading of either breathlessness or general fatigue. The following scales 
were used:
A.2.8.(d) VISUAL ANALOGUE SCALE.
The visual analogue scale (see appendix F) consisted of a horizontal line. At the left hand 
side of the scale the word "none" was labelled and at the far right the word "very severe" 
was placed. Subjects indicated their level of breathlessness or general fatigue by moving 
the lever on the treadmill which adjusted the line on the TV monitor. Once the subject 
had chosen the desired score, he pressed the button to record this in the computer. At this 
point another scale appeared.
A*2.8.(e) BORG CR10 SCALE.
The Borg CR10 scale (see Appendix F) consisted of a vertical scale labelled 0-10 with 
verbal descriptors at various numbers on the scale. Operation of the lever and button (see 
above) on the treadmill allowed the subjects to select the appropriate number.
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A.2.9. PROCEDURES.
The subject’s feet were placed on the side of the treadmill. At a given signal the subject 
walked on the treadmill and held on to the support bars for a few seconds until the subject 
had gained balance. Thereafter, the subject walked without support. At two and half 
minutes and 5 minutes 30 seconds for each stage, the subjects responded to the subjective 
scales which appeared on the TV monitor. The subjects were asked to walk as long as 
possible. During all tests gas collection and analysis were continuous and respiratory 
values for every 30 seconds were given on a print-out. Heart rate was monitored 
continuously and recorded for 10 seconds at the end of each minute.
A.3. STATISTICAL METHODS.
A generalised linear model (GLM) was applied to the data to include the possible effects 
of visit, subject, time and natural (or error) variability. Reproducibility was quantified as 
the proportion of total variance (i.e. between plus within subject variance) explained by 
the between subject variance.
A.4. RESULTS OF PILOT STUDY.
Table A1 summarises the results of the pilot study. Reproducibility coefficients are given 
for each scale for each workrate. Generally, the higher the relative intensity, the better the 
reproducibility. There were no significant differences between the scales. The VAS 
tended to be more reproducible than the Borg CR10 scale.
Table A l.
Reproducibility coefficients for the Visual Analogue (VAS) and Borg CR10 Scales 
(Breathlessness and General Fatigue) at three relative intensities.
Relative Intensity
Breathlessness 
VAS BorgCRlO
General Fatigue 
VAS BorgCRlO
(% Peak V 02) 
65% 78% 43% 55% 39%
74% 63% 65% 67% 60%
83% 82% 72% 81% 71%
There were no significant differences between the scales for breathlessness or general 
fatigue at any timepoint.
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A.5.
1.
2.
3.
4.
5.
6. 
7.
CONCLUSIONS OF PILOT STUDY.
In general, the higher the relative intensity of the test, the more 
reproducible the scores were for breathlessness and general fatigue.
Generally, the VAS tended to be more reproducible than the Borg CR10 
scale for breathlessness and general fatigue.
The necessity of carrying out a submaximal test to establish what the 
patient was capable of at submaximal intensities was considered to be time 
consuming and unsuitable for clinical practice.
The test instructions were easily understood by the subjects.
The results indicated that a similar form of test may prove to have value in 
assessing symptoms.
It was decided to investigate the possibility of finding a simpler and faster 
method of determining an "appropriate" work intensity to evaluate patient 
symptoms.
An attempt would be made to establish a work intensity which resulted in a 
subject determined cessation of exercise between 8 and 17 minutes.
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APPENDIX B.
DETAILS OF EQUIPMENT USED IN THE STUDY.
B.1.1.
Marquette treadmill.
The marquette treadmill was made in the USA by: 
Marquette Electronics Inc.
Milwaukee,
Wisconsin.
U.S.A.
B.1.2.
Marquette console and ECG system. 
These items were made in in the USA by: 
Marquette Electronics Inc.
Milwaukee,
Wisconsin.
U.S.A.
All Marquette equipment was supplied by: 
Dolby House,
Anderson Street,
Dunblane F K 15 9A.
B.1.3.
Horizon Sensor Medics metabolic cart
The Horizon Sensor Medics was made in in the USA by:
Sensor Medics,
MMC Horizon System,
Annaheim,
Caifomia.
The metabolic cart was supplied by: 
Cardiokinetics Ltd.,
2 Kansas Avenue,
Salford M5 2 GL.
B.1.4.
BBC Master computer.
The BBC Master computer was made in in the UK by: 
British Brodcasting Corporation.
The BBC master was supplied by: 
The Computer Depot,
205 Buchanan Street,
Glasgow G12 JZ
B.1.5.
Subjective scales programme.
The subjective scales programme was made by: Mr Jim Christie, 
Medical Physics,
Western Infirmary,
Glasgow.
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APPENDIX C.
CHF INCREMENTAL PROTOCOL.
INCREMENTAL TEST.
STAGE SPEED GRADIENT
(Mins) (mph) (%)
1 1.4 0
2 1.5 0
3 1.7 0
4 1.7 1.0
5 1.7 2.0
6 2.0 2.0
7 2.0 3.0
8 2.0 4.5
9 2.0 5.5
10 2.0 7.0
11 2.0 8.5
12 2.3 8.5
13 2.3 10.0
14 2.6 10.0
15 2.7 11.0
16 3.0 11.0
17 3.4 11.0
18 3.75 11.0
19 3.4 13.0
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APPENDIX D.
DIAGRAMMATIC AID FOR WORKRATE SELECTION.
The diagrammatic aid (see Figure ADI) was used to determine the workrate for the 
submaximal tests. For example, a subject who had an endurance time of 13 minutes on 
the incremental test could have a submaximal workrate of 2.3 mph 6.5% gradient or 2.5 
mph 5.5% gradient. The speed selected was normally around that at which the subject 
walked at the end of the test. If the subject expressed a desire for a lower speed than that 
selected by the experimenter, an increased gradient with a reduced speed was selected.
The workrate selected was 80% of the predicted energy cost of the workrate attained at the 
end of the incremental test (American College of Sports Medicine, 1986).
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I
e  ad  i
Diagrammatic Aid for Submaximal Workload Estimation
STAGE
12 13 14 15 16 17 18 19
O
ci
0 6 10 122 84
GRADIENT (%)
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APPENDIX E. 
STEXT PROTOCOL
STAGE SPEED GRADIENT
(Mins) (mph). (%)
1. 1.5 0
2. 2.0 0
3. 2.0 1.5
4. 2.0 3
5. 2.5 3
6. 2.5 5
7. 2.5 7
8. 3.0 7
9. 3.0 9
10. 3.0 11
11. 3.5 11
12. 3.5 13
13. 3.5 16
14. 4.2 16
15. 5.0 16
16. 5.6 16
17. 6.3 16
18. 7.1 16
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APPENDIX F 
SUBJECTIVE SCALES.
Examples of the Subjective Scales, Visual Analogue Scale, Breathlessness Borg CR10 
Scale, General Fatigue Likert Scale Breathlessness.
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LIKERT SCALE
BREATHLESSNESS
□ Not at all breathless
□ Slightly breathless
□ Moderately breathless
B Realiy quite breathless
□ Very breathless indeed
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Visual Analogue Scale  
Breathlessness
VERY
NONE SEVERE
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Borg CR10 scale. 
General Fatigue
0 □  ' Nothing at all
0.5 □ Very, very slight
1 □ Very slight
2 □ Slight
3 □ Moderate
4 □ Somewhat severe
5 □ Severe
6 H
7 □ Very severe
8 □  '
9 □ Very, very severe
10 □ Maximal
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APPENDIX G.
UNITS OF MEASUREMENT.
List of Units.
Minute Ventilation
Oxygen Consumption
Volume of Carbon 
Dioxide Produced
Frequency of Breathing
Heart Rate
Tidal Volume
GLASGOW
UNIVERSITY
LIBRARY
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litres, min-1 
litres.min"! 
litres, min'-^
breaths, min"-^  
beats, min'^ 
litres
